Disease gene identification through next generation sequencing by Gilissen, C.F.H.A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/92728
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
DISEASE GENE IDENTIFICATION THROUGH
NEXT GENERATION SEQUENCING
Een wetenschappelijke proeve op het gebied van de
Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op het gezag van de rector magnificus prof. dr. S.C.J.J. Kortmann,
volgens besluit van het college van decanen
in het openbaar te verdedigen op vrijdag 13 januari 2012
om 10.30 uur precies
door
Christian Fransiscus Hendrika Andreas Gilissen
geboren op 13 april 1980
te Geleen
Promotor: Prof. dr. H.G. Brunner
Copromotor: Dr. ir. J.A. Veltman
Manuscriptcommissie:
Prof. dr. M.G. Netea (voorzitter)
Prof. dr. G. Vriend
Prof. dr. N.V.A.M. Knoers
Copyright c© 2011 by Christian Gilissen, Nijmegen, The Netherlands
Printing of this thesis was financially supported by the Department of Human Genetics,
Radboud University Nijmegen Medical Centre, the Netherlands.
Cover: Inspired by Conway’s "Game of Life"
Cover design: Ruben Maalman
Thesis layout: Typeset by the author in LATEX 2ε
Printed by: Ipskamp Drukkers, Nijmegen
ISBN: 978-94-6191-130-8
Contents
Contents 3
Chapter 1 General introduction 5
Chapter 2 Massively parallel sequencing of ataxia genes after array-based
enrichment 31
Chapter 3 Next generation sequencing of a 40 Mb linkage interval reveals
TSPAN12 mutations in patients with familial exudative vitreoretinopathy 41
Chapter 4 Targeted next generation sequencing of a 12.5 Mb homozygous region
reveals ANO10 mutations in patients with autosomal recessive
cerebellar ataxia 51
Chapter 5 De novo mutations of SETBP1 cause Schinzel-Giedion syndrome 61
Chapter 6 Exome sequencing identifies WDR35 variants involved in
Sensenbrenner syndrome 67
Chapter 7 Exome sequencing identifies truncating mutations in human SERPINF1
in autosomal-recessive osteogenesis imperfecta 75
Chapter 8 A de novo paradigm for mental retardation 87
Chapter 9 Next generation genetic testing for Retinis Pigmentosa 99
Chapter 10 Disease gene identification strategies for exome sequencing 113
Chapter 11 Unlocking Mendelian disease using exome sequencing 125
Chapter 12 General discussion 137
3
Supplementary Figures 151
Supplementary Tables 177
References 203
List of Figures 229
List of Tables 233
List of Acronyms 237
List of Publications 239
Curriculum Vitae 243
Summary 245
Samenvatting 249
Acknowledgements 253
4
1
General introduction
Abstract
The concept of heritability - the passing on of traits to offspring - has since long been known.
Heritability acts through a carrier present in almost all living cells, known as Deoxyribonucleic
Acid (DNA) that contains the instructions for the normal development and functioning of an
organism. In 1959 it was first established that changes in DNA can elicit disease (i.e. Down
syndrome). Finding the exact genetic cause of a disease offers many benefits to patients,
their family members and society in general:
1) Patients may be accurately diagnosed which allows for predictions of disease progression
and risk of inheritance to offspring.
2) Knowledge of the genetic cause may provide targets for treatment.
3) Embryos may be screened preventively through prenatal diagnostics or preimplantation
diagnostics.
4) Gaining insight into the function of specific genetic loci may facilitate further research into
the causes of heritable diseases.
Currently, more than 1,700 Mendelian disorders are known for which the molecular basis is still
unresolved. This thesis describes the application of a new technology called Next Generation
Sequencing (NGS) to identify the genetic causes of disease. The first chapter is a general
introduction and consists of three parts, the first of which deals with the fundamentals of
genetics. The second part is a brief summary of established technologies that are used to
identify variation in the DNA, followed by a short overview of how these are currently applied
in different strategies for disease gene identification. The third part of the introduction explains
the concepts of NGS with a specific focus on the inherent large role of bioinformatics and the
application of NGS for disease gene identification.
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Genetics
Genetics is a discipline in biology that aims at understanding heritability and variation in living
organisms. Heritability in living organisms acts primarily through the DNA.
DNA
DNA is a long molecule with a helix-like structure, present in the nucleus of almost every
single cell of an organism and which contains the instructions for its normal development
and functioning (Figure 1.1). DNA acts as a blueprint and determines characteristics such as
gender and eye color. In humans these instructions are "written" in a language based on only
four letters (nucleotides): Adenine (A), Cytosine (C), Guanine (G), and Thymine (T). This
may seem a very limited dictionary to describe the complete story of the development and
functioning of a human being, but this is remedied by the size of the book: the human DNA
molecule contains more than 3 billion nucleotides (present as base pairs). In order to store
this molecule efficiently, it is bundled into 46 packages called chromosomes which (under
the right circumstances) can be directly observed under a microscope.
Figure 1.1: Stylist impression of DNA
This figure shows a cell with a nucleus containing DNA which is, via solenoid loops within chromatids, packaged
into 46 chromosomes. Within the solenoids, the DNA is wrapped around nucleosomes. The DNA is composed
of four base pairs (A,C,T,G) which, in a certain order, form genes. (Image adapted from the National Human
Genome Research Institute)
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Of these 46 chromosomes, 22 are present in two copies (the autosomes). These autosomes
are supplemented with either two X-chromosomes for females or an X and Y chromosome for
males, (the sex-chromosomes). The fact that humans have two copies of each chromosome
(except for the sex-chromosomes) makes them diploid organisms. DNA is inherited from
parents to offspring where each child receives half of its genetic material from the father and
half from the mother. One of the two copies in a child is inherited from a single parent and
such a chromosome is a merger of fragments of the two original chromosome copies present
in that the parent.
Apart from nuclear DNA every human cell also contains mitochondrial DNA which is inherited
from the mother. Although the mitochondrial DNA is only ∼16.5 kilobases (kbs) in size, it is
present in thousands of copies.
Genes
Only a small part of the DNA (1-2%) consists of protein coding regions; regions in which the
nucleotide sequence specifically codes for a sequence of amino acids that make up a protein
(Figure 1.2). These regions are called genes and have a typical structure consisting of non-
coding parts (introns), coding parts (exons) and regions that, although transcribed, are not
translated into protein (Untranslated Region (UTR)). First, an entire gene is transcribed into
a complementary copy of the DNA (pre-messenger Ribonucleic acid (mRNA)), after which the
intronic sequences are "spliced"-out. The resulting mRNA is transported out of the nucleus
to the ribosomes where the coding parts (the exons) are translated into amino acids that
make up a protein. The UTRs protect the mRNA against a process called nonsense mediated
decay which breaks down incomplete or incorrect mRNA.
The translation of the coding sequence is performed using strict rules where combinations of
three base pairs (codons) translate into one of twenty possible amino acids. A start codon
marks the beginning of translation while a stop codon marks the end of translation. The non-
coding bases flanking exons are called splice sites and indicate which regions should be kept
for translation. The size of the splice sites differs but in general the first 2 bases (the canon-
ical splice site) are considered most important. Except for genes, the DNA contains many
other functional elements such as promoter and enhancer sites that regulate the expression
of genes and non-coding Ribonucleic Acid (RNA) elements that influence the expression of
genes at the mRNA level. However, the exact function (if any) of the majority of the DNA is
still largely unknown.
Genetic variation
Single Nucleotide Variants
Although the actual DNA of any two individuals is more than 98% identical, there remain many
differences in both the composition and the structure of the DNA between individuals1 (see
Table 1.1). A locus at which the nucleotide composition is known to vary among more than 1%
of the normal population is called a polymorphism. Variations affecting only a single base
pair are referred to as Single Nucleotide Polymorphisms (SNPs) and they are the most
prevalent class of genetic variation among individuals.2 A certain make-up at such a variable
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Figure 1.2: Transcription and translation of genes
The top panel shows the structure of a gene at the DNA level. A gene is transcribed according to the direction
of its reading frame from the 5’ to the 3’ end, resulting in a pre-messenger RNA (not depicted). Splice acceptor
and splice donor sites determine the retention of exonic sequences in the mRNA (middle panel). This mRNA is
subsequently translated into a protein consisting of amino acids (bottom panel).
position is called an allele and the frequency of that allele within a population is the allele
frequency. The human genome contains an estimated 15 million SNPs,1 with a Minor Allele
Frequency (MAF) of over 1%. This comes down to every two haploid human genomes differ-
ing 1 nucleotide per 1,331 bp.3 Every individual will have approximately 3 million nucleotide
differences with any other individual of which at least 20,000 changes occur within the coding
regions of genes.1 However, the exact amount of variation differs per population. For example,
populations with African ancestry show the highest amount of variation compared to all other
ethnic populations and all populations harbor unique genomic variations not found in other
populations.1,4 Next to common variants there is also variation that is rare or even unique
within a population or even an individual. A base pair variant in the DNA with a population
allele frequency of less than 1% is called a Single Nucleotide Variant (SNV) or rare variant.
SNPs are a subclass of SNVs. When the same variant exists on both copies of a chromosome
we call it homozygous, while a variant on only one of the copies is called heterozygous.
Except for nucleotide substitutions, a nucleotide can also be deleted or inserted within the
DNA (Figure 1.3). Small insertions or deletions (indels) are the second most frequent poly-
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ATTGGCCTTAACCC - - - CCGATTATCAGGAT
ATTGGCCTTAACCCGATCCGATTATCAGGAT
ATTGGCCTTAACCCCCGATTATCAGGAT
ATTGGCCTTAACCTCCGATTATCAGGATSingle nucleotide variant
Insertion-deletion variant
Inversion variant
Copy number variant
Block substitution
ATTGGCCTTAACCCCCGATTATCAGGAT
ATTGGCCTTAACAGTGGATTATCAGGAT
ATTGGCCTTAACCCCCGATTATCAGGAT
ATTGGCCTTGCCCCCAAATTATCAGGAT
ATTGGCCTTAGGCCTTAACCCCCGATTATCAGGAT
ATTGGCCTTA - - - - - - - - ACCCCCGATTATCAGGAT
Figure 1.3: Classes of human genetic variants
Single nucleotide variants are DNA sequence variations in which a single nucleotide (A, T, G or C) is altered.
Insertion-deletion variants (indels) occur when one or more base pairs are present in some genomes but absent
in others. They are generally composed of only a few bases but can be greater than 80 kb in length. Block
substitutions describe cases in which a string of adjacent nucleotides varies between two genomes. An inversion
variant is one in which the order of the base pairs is reversed in a defined section of a chromosome. Copy number
variants occur when identical or nearly identical sequences are repeated in some chromosomes but not others.
Adapted from Frazer et al.2
morphism,5 with an estimated number of 700,000 to 950,000 per individual genome.1 Indels,
however, are typically more difficult to detect than substitution variants, thus these numbers
are likely to be an underestimate of the true amount.6
A variant that occurs within the coding region of a gene is expected to change the amino acid
composition of the translated protein. However, due to the degeneracy of the genetic code
(i.e. multiple combinations of three base pairs (codons) code for the same amino acid), many
variants have no actual effect on the protein composition.7 Variants within the coding regions
that do not alter the encoded amino acid are synonymous (or silent) variants as opposed to
non-synonymous variants.
Copy number variations and inversions
The genome does not only vary by these nucleotide differences but also by genomic inser-
tions or deletions of thousands to millions of consecutive base pairs. Such larger genomic
duplications or deletions (> 1 kb) are referred to as Copy Number Variations (CNVs) as they
effectively change the DNA copy number.8 Recent studies suggest that CNVs account for
up to 20% of all genetic variants in humans and encompass more than 70% of the variant
bases. Altogether, for any given individual, structural variants constitute between 9 and 25 Mb
of the genome (approximately 0.5 to 1%).2,8 The number of structural variants identified in any
individual genome has increased dramatically as the resolution of the technologies has im-
proved. The first genome-wide studies identified ∼10 variants per individual;9,10 later studies
have identified hundreds of variants in individuals.11–13 Copy number variants are arise mainly
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Table 1.1: Different kinds of genomic variation
Type of variation Description Size
Chromosomal aberrations and translocations Deletions, duplications of whole or parts
of chromosomes as well as rearrange-
ments
> 5 Mb
Copy number variation Deletion and duplication of DNA regions > 1 kb and < 5 Mb
Inversions Genomic inversions not affecting copy
numbers
> 1 kb and < 5 Mb
Small Indels Nucleotide level deletions or insertions <1 kb
Block substitutions Multiple nucleotide changes <1 kb
Single nucleotide variants One base pair nucleotide change 1 bp
by four mechanisms: Non-allelic Homologous Recombination (NAHR), Non-homologous End
Joining (NHEJ), retrotransposition, and Fork Stalling and Template Switching (FoSTeS).14–19
Other variation, such as genomic inversions, or translocations, do not necessarily change the
genomic content, but only affect the relative positioning of the DNA. Such balanced changes
can, however, have an effect when they occur within a coding region, or by a positional effect.19
Evolutionary conservation
Although the genetic content of individuals varies by millions of base pairs, percentage-wise
the vast majority of the DNA is the same. Surprisingly, this holds true also when comparing the
genomes of other mammals to that of humans. For instance chimpanzees and humans share
more than 98% of their DNA sequence.20,21 The comparison of DNA sequences between
different species revealed many homologous genes, i.e., genes of which the sequence has
not changed very much across species and of which the function has been largely preserved.
This led to the hypothesis that these conserved sequences are under specific selection by
evolution and that changes in these sequences would be non-beneficial for the reproductive
fitness of the organism and are, therefore, selected against. A total of 5% of the bases in the
genome can be confidently identified as being under evolutionary constraint in mammals.22
Interestingly, the majority of constrained bases resides within the non-coding portion of the
human genome.22–24
Mendelian inheritance
Children inherit 23 pairs of chromosomes from their parents. Each pair consists of one chro-
mosome from each of both parents, which is a merger of the two original chromosomes
present in that parent. This process of merging pieces of chromosomes into one, is called
recombination (Figure 1.4) and occurs during meiosis, a special type of cell division that pro-
duces gametes. The unit of inheritance is thus not the chromosome itself but rather so-called
haplotype blocks, DNA pieces of varying size derived from two original parental chromo-
somes that are merged into a single new chromosome. Linkage Disequilibrium (LD) refers to
the fact that particular alleles at nearby sites can co-occur on the same haplotype more often
than is expected by chance.25,26 This correlation structure between variants on the same hap-
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lotype, however, varies in a complex and almost unpredictable manner across the genome
and between different populations.2
A phenotype (or trait) is defined as any observable characteristic or trait of an organism
(such as eye-color), but it can also relate to a phenotype that is not directly observable. The
phenotype is determined by a combination of two factors: the genotype and environmental
factors.27 The genotype of an organism is the make-up of the genetic material and usually
refers to the specific nucleotide composition at a specific location within the genetic material.
Environmental factors for traits like for example intelligence include educational attainment,
income and health.28 Heritability is thus defined as the proportion of phenotypic variation in a
trait that is due to underlying genetic variation.29 The fundamental rules that dictate the relation
between genotype and phenotype where derived in the 19th century by Gregor Mendel, an
Austrian monk conducting hybridization experiments in garden peas.30 The fact that each
of the autosomes is present in two copies within each human cell allows for dominant and
recessive traits. A dominant trait is due to a variant on a single chromosome. In contrast, a
recessive trait requires two changes, each on one of the two chromosomal copies.
Not all traits are inherited in accordance to Mendelian rules. Examples are traits for which
the responsible gene is located on the X-chromosome (e.g. Rett syndrome31), Y-chromsome
(e.g. male sex determination32), mitochondrial chromosome (e.g. Leber’s hereditary optic
neuropathy33), or traits that are caused by parental imprinting of genes.34 Even more com-
plex inheritance patterns occur when a trait is not determined by a single genetic locus, but
by a combination of different loci that give rise to a continuous phenotypic spectrum. Such
inheritance is called complex.
Maternal 
chromosomes
Paternal 
chromosomes
Maternal
allele
Paternal 
allele
Inherited
chromosomes
Figure 1.4: Recombination and inheritance of DNA from parents to offspring occurs by haplo-
type blocks
A child inherits 23 pairs of chromosomes, each pair made up of one chromosome from each parent. The inherited
chromosomes are a recombination of the two original chromosomes of each parent.
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Finding the genetic cause of disease
The occurrence of new variation and the inheritance of (recombined) existing variation is part
of the evolutionary mechanism to select a gene pool that gives rise to an organism that is
best suited to its environment and, consequently, has the highest chances of passing on the
gene pool to its offspring. Unfortunately, variation occurs in part randomly and can also affect
the fitness of an individual in a negative way, for example by predisposing to disease. For
many years researchers have been trying to identify the specific genetic defects that cause a
certain disease with the goal of improving the diagnosis, prognosis, and eventually treatment
of patients. Currently there are more than 2,500 human genes for which inherited disease-
causing mutations have been described.7
Genetic causes of disease
Dominant monogenic disorders
For many diseases there is a single locus within the genome which, when disrupted, gives
rise to a specific disorder. In most cases such a locus is a single gene, coding for one spe-
cific protein which is involved in a specific developmental process. Such a disease caused by
changes in only a single specific gene is called monogenic or Mendelian (Figure 1.5). At this
time at least 1,800 diseases have been reported to be monogenic.35 The most straightforward
way by which mutations can cause disease is when they result in the introduction of a prema-
ture stop codon which leads to nonsense mediated decay of the transcribed mRNA.36 In such
a case no protein is produced from the allele containing the mutation. An insertion or deletion
of bases can cause the codons to become "out-of-frame", meaning that the reading frame is
shifted by either one or two bases. A shift of the reading frame will quickly introduce a stop
codon and also lead to nonsense mediated decay. Hence stop mutations and out-of-frame
mutations are collectively called truncating mutations. In other cases a mutation leads to
the substitution of an amino acid within the protein (a missense mutation), which can prevent
it from folding into its correct 3-dimensional structure, and prohibit its normal functioning.37
A dominant monogenic disorder is hypothesized to underlie a dosage mechanism in which
the reduction of the amount of protein (haploinsufficiency) due to the loss of a single copy,
causes the disease.38 Alternatively, a dominant mutation can change the function of the result-
ing protein (gain-of-function effect), which then interferes with normal biological processes39
or can give rise to a dominant-negative effect, i.e., an effect whereby one mutated allele in-
terferes with the proper function of the wild-type (normal) allele and effectively leads to the
dysfunction of both gene copies.37
Recessive monogenic disorders
A recessive monogenic disorder requires both genes on each copy of the chromosomes to
be disrupted, effectively inhibiting any normal protein production; hence two mutations are re-
quired. The mutations can either be exactly the same, being a homozygous mutation, or there
can be two different (heterozygous) mutations, each of which disrupts the proper function of
the gene in its own way (compound heterozygous) (Figure 1.5). Homozygous variants are
frequently found in the offspring of consanguineous marriages.35
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Sex-linked monogenic disorders
When a mutation for a recessive disease occurs on the X-chromosomes this will cause distinct
sex-specific patterns in the sense that females will be rarely affected (having one "rescue"
copy of the X-chromosome) while males will be always affected (as they have only one copy
of the chromosome). For example Intellectual Disability (ID) more frequently affects males
than females due to several genes associated with ID syndromes that are located on the X-
chromosome (e.g. FMR1 for fragile-X syndrome).40 A similar pattern holds for mutations on
the Y-chromosome, which only give rise to disorders in men, most notably infertility.41
Genetically heterogeneous monogenic disorders
For some diseases different genotypes give rise to the same phenotype. One can imagine
two proteins that need to interact and form a crucial protein complex. Loss of function of either
one of the genes is sufficient for the loss of interaction and the manifestation of disease. A
disease where any of multiple disrupted genes gives rise to the same phenotype is genetically
heterogeneous and is sometimes referred to as a complex monogenic disorder (Figure 1.5).
For example, Retinis Pigmentosa (RP) is an ocular disease that results in progressive retinal
degeneration and for which mutations in more than 45 genes have been implicated so far.42,43
Genomic disorders
The term "genomic disorder" refers to a disease that is caused by an alteration of the ge-
nome that results in complete loss, gain, or disruption of the structural integrity of one or more
dosage sensitive genes. In most of the common chromosome deletion/duplication syndromes,
the rearranged genomic segments (CNVs) are flanked by large (usually >10 kb), highly homol-
ogous Low Copy Repeat (LCR) structures that act as substrates for NAHR.15,19 Well-known
examples of CNVs and conveyed genomic disorders are Williams-Beuren syndrome44 (a dele-
tion on 17q11.23), Smith-Magenis syndrome45 (a deletion on 17p11.2), DiGeorge syndrome46
(a deletion on 22q11.2), and many others.14
Many of these genomic disorders represent contiguous gene syndromes, meaning that they
are caused by the combined effect of the loss or gain of dozens of genes. However, for some
genomic disorders only a single gene is responsible for the clinical phenotype and nonsense
(stop) mutations in this gene cause the same disorder.13,14 For example Kleefstra syndrome
was originally found to be caused by a deletion of a region at 9q34.3.47 Later it was found that
non-sense point mutations in the EHMT1 gene, that is located within the deletion region, give
rise to the same syndrome.48
Digenic disorders
In the case of a recessive monogenic disease it is clear that two mutations affect the same
gene and together disturb its normal function in such a way that it leads to a disease. At a
higher level it is possible that two genes contribute to the same biological process or pathway.
A mutation in one of the genes may not impact the process sufficiently to result in disease,
but mutations in two genes of the same pathway sometimes do. Diseases in which mutations
in two different genes (but not in only one of them) lead to a disease, are called digenic dis-
13
eases (Figure 1.5). Alternatively, when mutations in one gene change the phenotype caused
by mutations in another gene it is also considered digenic, and the second gene is called a
modifier.49 As an example, mutations in the CTFR gene were identified early on as the cause
for Cystic Fibrosis (CF). Mutations in CFTR almost always cause the CF phenotype but owing
to modification effects by other genetic factors, the presence and nature of mutations at the
CFTR locus cannot predict what the phenotypic manifestation of the disease will be. There-
fore, although CF is considered a Mendelian recessive disease, the phenotype in each patient
depends on a discrete number of alleles at different loci.49,50
Complex disorders
For many very commonly occurring diseases (common diseases) no clear inheritance pat-
tern has been established and it is thought that the phenotypic variation may be quantitative.
Examples are metric traits such as height and weight. This type of variation is thought to be
based on the cumulative interaction of common alleles of several genes and the environment
(Figure 1.5).51 Diseases where no single change, but different combinations of many different
common variants are thought to give rise to the same phenotype are called complex disor-
ders. This model is referred to as the common disease, common variant hypothesis.52 An
alternative model suggests rare variants as the underlying cause of common disease, such
that similar phenotypes result from any one of thousands of different mutations in any one of
multiple different genes, but all the implicated genes encode proteins in related pathways.53,54
Non-genic causes of disease
Although the vast majority of genetic causes for disease can be ascribed to the coding re-
gions of genes, there are also several causes that involve other genomic elements. A large
part of these consists of variants within the non-coding parts of genes. Nearly 10,000 differ-
ent pathogenic intronic variants have been reported to occur in consensus donor and acceptor
splice sites and their flanking sequences.7 Mutations also occur within the 5’ and 3’-UTR re-
gions of genes which are of major importance for translational regulation, stability/degradation
nuclear export and sub-cellular localization.7 Outside of genes mutations can occur within pro-
moters or non-coding RNAs.55 Besides causes pertaining to the DNA there are also genetic
causes underlying the epi-genome i.e., involving modifications of the DNA or its associated
nucleosomal proteins (histones; Figure 1.1) that do not change the genetic code.7
De novo mutations
The occurrence of pathogenic mutations in a patient with a Mendelian disorder can occur
in two logical ways: (1) The mutation was inherited from a parent. In case the parent is
unaffected this implies that the disease is not dominant, and that a second mutation of some
kind is likely present in the patient. (2) The mutation has newly arisen in the patient and is not
present in any of the two parents. Such De novo mutations are introduced by mistakes during
the process of meiosis which gives rise to either sperm cells in males or egg cells in females.
The per-generation mutation rate has been estimated between 7.6 × 10−9 and 2.2 × 10−8
implying that an average newborn acquires 50 to 100 new mutations in his or her genome,
resulting in approximately 0.86 new amino-acid-altering mutations.56,57
14
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Recessive monogenic 
(homozygous)
Dominant monogenic
Recessive monogenic 
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Complex
Figure 1.5: Genetic causes of disease
This figure depicts seven different genetic disease models. From bottom to top: dominant monogenic (one gene
on one allele affected), recessive monogenic (one gene on both alleles affected in the same way), recessive
monogenic (one gene on both alleles affected in different ways), complex monogenic (one of multiple genes
affected on one allele), digenic (two different genes affected), and complex (many genes affected). The size of
the box is indicative of the strength of the effect of the mutation.
Detection of genetic variation
The availability of techniques to interrogate variation in the genome has determined the differ-
ent genomic variations that we currently distinguish (see Table 1.2). These techniques have
evolved in two ways: (1) from the detection of SNVs in small genomic regions towards ge-
nome wide detection and (2) from the genome wide detection of large chromosomal variation
towards smaller CNVs.
Karyotyping
Karyotyping is a technique that entails the staining of chromosomes to make them visible un-
der a normal microscope and to, subsequently, visually identify chromosomal aberrations
such as large (> 5Mb) deletions, duplications, or rearrangements of (parts of) the chromo-
somes.58–61 This has lead to the successful identification of many genetic causes of disease,
most notably the duplication of chromosome 21 as the genetic cause of Down syndrome.62
In most cases, however, karyotyping by itself is unable to identify the exact gene responsible
for a disease, due to its limited resolution, but provides crucial evidence as to its location; for
example in the case of the identification of the DMD gene for Duchenne Muscular Dystrophy.63
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Genomic microarrays
With the development of genomic microarrays in the mid-nineties, the resolution at which
aberrations could be detected was lowered from the megabase to the kilobase level. With this
technique patient and control DNA are labeled using different fluorescent dyes and hybridized
onto a microarray on which large-insert clones (e.g. Bacterial Artificial Chromosome (BAC)
clones) or oligonucleotide probes were robotically spotted. The ratio of both fluorescent sig-
nals for each spot can then be measured, and by that, relative gains or losses of DNA can be
detected.64,65 The size of the CNVs that can be detected is determined by the amount and
genomic spacing of the probes, as well as by the experimental noise.60,61,66,67
The adoption of oligonucleotide-based arrays10,68 and SNP oligonucleotide-arrays69,70 for ge-
nome-wide detection of genomic copy numbers increased the resolution from 100kb down to
as low as 1 kb for detecting CNVs. These SNP microarrays can be used for measuring two
different kinds of genomic variation. Each individual probe measures the genotype of a known
Single Nucleotide Polymorphism (SNP), whereas the signal of multiple probes can again be
used to measure the relative abundance of a genomic locus in a patient. However, SNP
microarrays only generate a signal for a single individual and copy numbers are determined
based upon signals of healthy control individuals under the assumption that the majority of the
genome is diploid. Contrary to karyotyping, SNP microarrays only detect genomic variation
that affects the copy number of a genomic region. Thus balanced genomic rearrangements
such as inversions remain undetected.70 Furthermore, in case of copy number gains the
exact location of additional copies on the genome is unknown.8 Because copy numbers are
determined relative to a control cohort, determining the exact number of copies becomes
increasingly more difficult at higher copy numbers because the relative intensity differences
become smaller. Some arrays, called CNV arrays are especially designed for detecting CNVs
and do not necessarily interrogate known SNPs, but rather random sites in the genome.
Sanger sequencing
In the early 1970s Sanger and Coulson pioneered a method for rapidly determining the con-
tents of the DNA at the nucleotide level. The target sequence is flanked by primers and then
amplified by Polymerase Chain Reaction (PCR). Subsequently, cycles of template denatura-
tion, primer annealing and primer extension are carried out. After each cycle fluorescently
labeled dideoxnucleotides are incorporated.71,72 Current instruments deliver read lengths of
up to 1000 bases, high raw accuracy (>99.999%) and allow for 384 samples to be sequenced
in parallel generating 24 bases per instrument second.73 This method has become the gold
standard for determining the exact DNA content on a nucleotide resolution. Since 1977, a
total of approximately 10 × 1011 bases has been determined with Sanger’s chain termination
sequencing method.73,74 Although this technique obtains the utmost resolution of a single
base pair, it is unfortunately limited by its throughput. The construction of the sequence of
a single human genome in 2002, which was performed mainly by this technique, took more
than 20 years to finish.74,75
16
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Table 1.2: Techniques for detecting genomic variation, modified from Feuk et al.76
Technique Type of variation Advantages Disadvantages
Karyotyping Chromosomal aber-
rations • Genome wide• Detects rearrangements
• Limited resolution
• requires special training
SNP microarrays SNP, CNV • Genome wide
• Genotype information
• Single nucleotide resolution for
SNPs
• Limited resolution for CNVs
• Biased to known variants
• No balanced rearrangments
CNV microarray CNV • Genome wide
• High resolution
• No genotype information
• No balanced rearrangements
Sanger sequencing SNV, indel • Unbiased to knowledge of ge-
nomic content
• Base pair level resolution
• Expensive
• Not genome wide
Disease gene identification strategies
The search for disease causing genes, in its simplest form comes down to finding a certain
variation that only occurs in patients and not in healthy individuals. Such a variation is then
called a mutation, provided the causality can also be proven by other means. Determining the
DNA sequences that cause a specific phenotype in the intact organism remains particularly
difficult in human genetics for which experimental interventions are unavailable.77 This has
led to the development of different strategies (see Table 1.3) of which the application depends
on (1) the inheritance pattern of the disease (2) the availability of techniques for identifying
genomic variation (3) the availability of family information.
Candidate gene approach
The most straightforward approach is hypothesis-based candidate gene selection. Genes
are selected on the basis of evidence that they might affect disease risk.51 This evidence
can come from previously implicated genes, genes associated with similar diseases, or on
the activities of protein products that seem relevant to the physiology of the disease.77 This
approach has been successful in the past, identifying genes involved in for example hyperten-
sion.78 It has also had its more recent successes, usually identifying additional genes involved
in particular syndromes such as for example Joubert syndrome for which the RPGRIP1L gene
was selected for mutation analysis by Sanger sequencing, based on similarities with a known
Joubert disease gene.79
A candidate gene approach has some clear advantages: (1) it requires no additional labo-
ratory experiments except for straightforward Sanger sequencing of candidates, (2) it works
equally well for any kind of (complex) monogenic disease, (3) it requires in principle only a sin-
gle patient. This approach is, however, severely biased towards the current biological knowl-
edge and testing only a single gene can be very time intensive. Furthermore, the functional
interpretation of rare coding variants can be challenging.51,77
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Positional cloning
One of the most powerful methods for the identification of disease genes is positional cloning,
which aims at identifying genomic loci that are likely to be related to the disease. Through po-
sitional cloning, genes controlling Mendelian traits or diseases are identified and isolated only
using knowledge that the phenotype is inherited. Significantly, no knowledge of the biology
of the disease or trait, beyond a secure assessment of the phenotype, is required. Identifica-
tion of the gene leads immediately to knowledge of the relevant protein or proteins and, often
for the first time, any understanding of the molecular and physiological basis of the disease
phenotype.77 The identification of loci for cloning was traditionally done by linkage or chromo-
some analysis,80,81 but in the last decade has also been done by various other methods such
as homozygousity mapping,82 CNV analysis,83 or Genome Wide Association Study (GWAS).
Several of these approaches are often tested as one can rarely predict beforehand whether
a disease is caused by mutations at the nucleotide or at the chromosomal level. In addi-
tion, these mapping approaches commonly do not reduce the number of candidate genes
sufficiently for straightforward follow-up by Sanger sequencing, especially if applied to only a
single patient or family, and, therefore, an additional candidate gene approach is required.
Positional cloning using linkage analysis
Linkage analysis utilizes Linkage Disequilibrium (LD) within families with segregating disease
phenotypes to identify co-segregating haplotype blocks using microarrays containing a set of
genetic markers (SNPs).26,77,80 Once a region that segregates with the disease within a family
has been identified, candidate genes can be selected for Sanger sequencing to screen for
potential mutations. This strategy has proven to be very successful and has led, among many
others, to the identification of the genes underlying lactose intolerance,84 X-linked muscular
dystrophy,85 Fanconi anemia,86 cystic fibrosis,80,87 and Leber Congenital Amaurosis (LCA).88
Notwithstanding the enormous successes of this method, there are also some limitations:77
(1) The disease that is studied needs to be heritable (i.e. fecundity should not be affected).
(2) Either multiple small families or a single large family in which the disease phenotype seg-
regates needs to be available. In the more usual case of multiple families, the assessment of
the phenotypes has to be made with minimal ambiguity (to identify a single candidate locus).
(3) Even if one has an unlimited supply of closely linked, genomic markers, the limit of reso-
lution remains the number of meioses in which crossovers might have occurred. In favorable
cases (such as cystic fibrosis), the pattern of crossovers in the region of the gene among the
cohorts studied leaves only a few predicted genes, all within about approximately 1 Mb, as
likely candidates. In less favorable cases, there may be as many as a few hundred candidate
genes for which follow-up by Sanger sequencing is costly and time-consuming.
Positional cloning using homozygosity mapping
In a consanguineous family or highly inbred population one can assume that recessive dis-
ease is caused by a true homozygous mutation (meaning that both alleles share the same
genotype as opposed to one allele being deleted). Due to consanguinity, a single heterozy-
gous variant for a recessive disease has a very high chance of becoming homozygous among
offspring and causing disease.82 Again by using polymorphic genetic markers on SNP mi-
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croarrays, one can identify such large regions of homozygosity (i.e., both genomic copies are
exactly the same). This method is particularly suitable in populations where marriages among
close relatives are common, and many of the rare recessive diseases are found only in such
populations. Any two affected siblings from a consanguineous marriage, will share many ho-
mozygous regions.82,89 After identifying sufficiently small homozygous regions the approach
follows that of linkage analysis, in the sense that candidate genes are selected from the iden-
tified homozygous regions and screened for mutations by Sanger sequencing. Homozygosity
mapping has the advantage that relatively few individuals are required and that genetic het-
erogeneity, although still a problem, is mitigated by the reality that each set of closely related
affected individuals is very likely to carry the identical mutation.77 This approach has become
the method of choice for rare recessive disorders and has allowed the identification of genes
for Fanconi anemia,90–92 Charcot-Marie-Tooth disease,93–95 LCA,96 and RP.97 The limitations
of homozygosity mapping are similar to those of linkage analysis, with the additional restriction
that it can only be applied to recessive disorders.77
Positional gene discovery using copy number analysis
With the implementation of high resolution microarray-based copy number analysis it has
become feasible to screen patients for pathogenic copy number variants and to use these loci
for further cloning. Many CNVs are identified in each patient, and consequently maps of CNVs
from cohorts of apparently healthy individuals can be used to discriminate between benign and
pathogenic variants. Excluding CNVs from further consideration on the basis of their presence
in these "control" maps allows the prioritization of potentially clinically-relevant variants.13,18
Identifying individuals with overlapping CNVs and similar phenotypic features is often critical
for confirming a causal role.13 However, individual pathogenic CNVs are often rare, which
makes proving their causal role challenging. Additionally, because differences in copy number
are part of the normal variation spectrum8,10,14 simply comparing the copy number regions
between healthy individuals and patients is not sufficient evidence for causality. A strong
inidicator that a CNV is causally related to a sporadic disease is its de novo occurrence in a
patient.13,98 In this way the method differs from typical positional cloning approaches in which
the inheritance of the disease is key. Successful applications of this approach include the
identification of CHD7 as the cause of CHARGE syndome,83 EHMT1 as the cause of Kleefstra
syndrome48 as well as many others.60,66 A disadvantage of this method is, as mentioned
before, the inability to detect balanced rearrangements, and the limited resolution, which does
not allow the detection of base pair level insertions or deletions. For some syndromes like
Noonan syndrome (PTPN11 gene) or achondroplasia (FGFR3 gene), which are caused by
a gain-of-function or dominant-negative effect, copy number analysis will be unable to detect
the cause.99
Positional gene discovery using genome wide association
Genome-wide linkage analyses have also been carried out for many common diseases and
quantitative traits, but with limited success.51,100 Owing to weak linkage signals due to lower
relative risk, positional cloning is of limited use in the identification of disease-associated vari-
ants.77 GWAS studies are more suited for the identification of genetic variants associated with
common disease under the assumption of the common-disease common variant hypothe-
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Table 1.3: Strategies for disease gene identification
Strategy Applies to Advantages Disadvantages
Candidate gene ap-
proach
Any disease Easy to perform Biased to known biological in-
formation
Karyotyping Any disease Easy to perform, no familial
cases required
Very limited resolution
Linkage analysis Monogenic
diseases
Easy to perform Requires large family cohorts,
identifies large loci
Homozygosity mapping Recessive
monogenic
diseases
Small families can be used Identifies large loci, most useful
for consanguine families
Copy number analysis Monogenic
diseases
No familial cases required, can
potentially identify small loci
Genome wide associa-
tion study
Complex dis-
eases
No familial cases required,
identifies relatively small loci
Very large patient-control co-
horts required, functional inter-
pretation is often difficult
sis.52 GWAS studies use SNP microarrays to genotype many common genetic variants within
large cohorts that are informative for a trait of interest. The aim is to map susceptibility effects
through the detection of (statistical) associations between genotype frequency and trait sta-
tus.101,102 Large international consortia have been able to convincingly associate genomic loci
with common diseases such as diabetes type 1,103–105 diabetes type 2,104,106–109 rheumatoid
artritis110 and many other diseases,101 but also with common traits such as height111–114 and
body mass.115–117
The obvious disadvantage of this type of study, to obtain and genotype very large case-control
cohorts, has been overcome by establishing large collaborative consortia. Recently, issues
have been raised about the value of these studies as hithero associated variants explain
only a small fraction of the heritability and have (arguably) not led to many new biological
insights.102,118,119
Next Generation Sequencing
The advent of a new technology, boldly entitled as "Next Generation Sequencing (NGS)"
promises to overcome all the limitations of the current disease gene identification strategies
as outlined above.
Although the Sanger sequencing technology provides the ultimate resolution for detecting
genetic variation, the technique is difficult to scale, generally allowing only 96 or 384 reactions
in parallel. This makes the technique time-intensive and also expensive, at a cost of roughly
$500 per Mega base (Mb).71,72,120 Technological break-throughs of the last 5 years have led to
the development of an assortment of so-called NGS or Massive Parallel Sequencing (MPS)
instruments. This "next-generation" distinguishes itself by the ability to sequence millions of
DNA fragments in a highly parallel fashion. Equally important, NGS had the potential to detect
all kinds of genomic variation in a single experiment.
The specific instruments differ in many aspects, but the main workflows are conceptually simi-
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lar.121 DNA is randomly fragmented followed by ligation of adapter sequences. The DNA frag-
ments are then clonally amplified and clustered together to serve as the sequencing feature.
Sequencing is then performed by alternating cycles of Cyclic Reversible Termination (CRT)
and imaging.120–122 CRT uses reversible terminators to incorporate (fluorescently) labeled
nucleotides, which are then imaged and later cleaved off. Alternatively, to generating inde-
pendent reads, all sequencers can generate two reads at an approximately known distance
in the genome using two disparate sequencing strategies to generate reads from both sides
of a DNA segment (the insert). Mate pairs are created using size-selected genomic inserts
that are circularized and linked using an internal adapter. These circularized fragments are
randomly sheared and segments containing the adapter are purified. Paired end reads, by
contrast, are generated by the fragmentation of genomic DNA into short (< 300 bp) segments
which are then sequenced at both ends. Paired end reads provide tighter insert-size distribu-
tions, whereas mate-pairs have the advantage of larger insert sizes.123,124
Three NGS technologies have by now been widely adopted by the community.122 Although
there exist other (second generation) sequencing technologies, none have manifested them-
selves as prominent as the Roche/454 GSFlex,125,126 Illumina Genome analyzer or HiSeq,127,128
and Life technologies SOLiD.129 In the last two years these instruments have gone through
rapid improvements, such that not one instrument currently resembles the first instrument that
was released under the same name, except for the underlying basic sequencing chemistry.130
There are six main criteria by which the performance of a NGS instrument may be evaluated,
which are all intrinsically related:71,120,121,131
(1) Throughput. The total sequencing throughput of a single run and the time required to set
up and perform a single run determine the amount of bases that can be sequenced within
an arbitrary unit of time.
(2) Read length. The average length of the fragments that are sequenced determines the
usability of the sequence for various applications. Longer reads have a higher chance of
being unique within the genome and are thus more easy to use in the reconstruction of
the unfragmented DNA. Longer reads can more easily bridge genomic repeat regions or
deletions.
(3) Accuracy The accuracy of the generated sequence has implications for the reliability of
detecting DNA variants and thus for the required sequencing depth necessary for reliable
variant calling.6
(4) Robustness. The ability to complete a full sequencing run depends on the ease of labora-
tory protocols, robustness of the chemistry and the instrument. The first instruments and
corresponding protocols that were brought to market were notoriously lacking robustness.
(5) Available applications. The diversity of applications that can be performed on a single
instrument determines its usability for specific research purposes. The availability of pro-
tocols for barcoding/multiplexing for example is an important factor for targeted resequenc-
ing of large cohorts.
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(6) Cost. The costs for sequencing 1 Gb of DNA will determine the large scale implementation
of, for example, medical whole genome resequencing. Although the costs have dropped
significantly, we have not yet reached the magical number of $1000 per genome.132
Secondary criteria include the availability of software, support contracts and the potential of
the technology to improve on any of the before mentioned criteria.
In recent years many other applications, besides the sequencing of genomes, have been
developed to interrogate various aspects of molecular cellular features such as the transcrip-
tome, epigenome, proteome and interactome.133,134
Genomic enrichment for NGS
In many cases one is not necessarily interested in knowing the contents of the entire genome.
Moreover the costs of sequencing an entire genome might outweigh the additional benefit of
detecting variants genome-wide, especially because the function of the majority of the ge-
nome is still unknown. In such cases, DNA enrichment or genomic partitioning is required
to select or target a specific region of interest.135,136
In general there are four ways in which genomic regions can be enriched.135–137 (1) Multiplexed
PCR, which uses several primer pairs in a single reaction, generating multiple amplicons.
(2) Capture by circularization. Molecular Inversion probes consisting of a universal spacer
region flanked by target-specific sequences are designed for each amplicon. These probes
anneal at either side of the target region, and the gap is filled by a DNA polymerase and
a ligase. Genomic DNA is digested, and the target DNA is PCR-amplified and sequenced.
(3) Solution based hybrid selection. Adaptor-modified genomic DNA libraries are hybridized
to target-specific probes in solution. Background DNA is washed away, and the target DNA
is eluted and sequenced. (4) Array-based hybrid selection. This is in principle the same as
solution-based hybrid selection, except that the hybridization is performed on a microarray
surface.
The performance of these DNA enrichment technologies can be captured in metrics of (1) tar-
get specificity: the ability to capture only the DNA targets. (2) uniformity: the equal capture of
all the targets. (3) completeness: the ability to capture all targets. (4) allelic bias: the equal
capture of two alleles of a heterozygous variant (5) multiplexity: the ability to combine multiple
samples in a single experiment while still being able to separate them after sequencing (i.e.
sample barcoding). (6) input requirements: the amount of input DNA material that is required.
(7) scalability: how easy the procedure scales to larger sample volumes (i.e. the possibility
of automation). (8) cost : the costs associated with performing an enrichment for a single
sample.
Although many different methods for targeted capture have been described, only few have
been extended to target the human exome (i.e., all coding regions within the human genome).
These methods belong to the hybridization type and include array-based hybridization and
liquid-based hybridization. The term "whole human exome" can be defined in many different
ways, but is usually based upon the human Consensus Coding Sequence (CCDS) regions,138
which cover approximately 29Mb of the genome.137 However, the CCDS set is by no means
complete and more recently studies have started to use larger, more inclusive gene sets.139
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Bioinformatics
With the large scale introduction of microarrays it already became obvious that computer sci-
ence skills offered advantages in data handling and analysis, although small scale studies
could still be managed on a normal desktop computer. But a trend was established in the
sense that computer science skills were used for handling and analyzing biological data.130
Next generation sequencing now generates unprecedented amounts of data with which an
ordinary computer can no longer cope.140,141 Although all-in-one data management and ana-
lysis solutions for some platforms exist, any non-trivial task pertaining to these data will require
a person with at least some skills in computer science. In the future software companies and
instrument suppliers will develop programs that do not necessarily require computer science
skills to analyze sequencing data, but these will confine any user to the pre-defined functional-
ity of the software.141 Furthermore, a meaningful analysis of experimental data depends upon
the incorporation of existing relevant information. To integrate the amount of experimental
data, as well as the amount of information available in on-line databases, obviously requires
computer science skills.
Data management
Data handling or management is inherently different from data analysis in that it requires
no knowledge of the actual meaning or content of the data. Storage and management of
sequencing data is a large issue. The principal needs are threefold: (1) scalable, highly
dense, and inexpensive disk systems for massive online growth; (2) high-performance disk
systems that place the data near to the pipeline algorithms; (3) and archival storage of the
data that are required to be kept by the institution.141
Storage
The rate of growth of the sequences that are generated by subsequent upgrades of instru-
ments is exponential and exceeds that of the improvements in the field of computer science
that allow for faster computation (Moore’s law) and higher disk storage capacities.140 An im-
portant consideration for the online, massive storage environment is the length of time neces-
sary to retain data. In most analyses, data are converted from raw image files into series of
called bases. These sequences or reads are then subjected to an assembly or alignment pro-
cess that determines how they all line up with each other and, usually, a reference genome.
Throughout the process, many intermediate files are created, copied and shared between
researchers.142 A group that understands the institutional requirements of the various sets of
data (images, intensities, base pairs, and alignments) can develop reasonable data retention
policies. In some cases, the cost of the DNA sample does not relate to the cost of DNA stor-
age of data such that it will be cheaper to rerun than to store. However, in a clinical setting
the DNA sample itself may be unique and therefore priceless, necessitating the need to store
much of the upstream data.141
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Figure 1.6: Historical trends in storage prices versus DNA sequencing costs
The solid squares describe the historic cost of disk prices in megabytes per US dollar. The long-term trend (solid
dark line, which is a straight line here because the plot is logarithmic) shows exponential growth in storage per
dollar with a doubling time of roughly 1.5 years. The cost of DNA sequencing, expressed in base pairs per dollar,
is shown by the triangles. It follows an exponential curve (light line) with a doubling time slightly slower than disk
storage until 2004, when next generation sequencing (NGS) causes an inflection in the curve to a doubling time
of less than 6 months (rightmost line, starting 2004). These curves are not corrected for inflation or for the ’fully
loaded’ cost of sequencing and disk storage, which would include personnel costs, depreciation and overhead.
Adapted from Stein (2010)140
Computation
The computational capacity required for performing even relatively simple tasks on this data
is high due to its large amount. More importantly, many common tasks such as short-read
sequence assembly are non-trivial and computationally complex.143–147 There is a limit to the
computational capacity of any single computer, which can only be surpassed by combining
multiple computers together. This option, however, creates a new problem in that the task at
hand needs to be split in (preferably equal) subtasks and that the results after computation
need to be merged again.141,142 The analogy with fragmentation and assembly of DNA is
striking. Thus for the analysis of next generation sequencing data within a reasonable amount
of time, ordinary computers are no longer sufficient and many of the current algorithms and
software programs must be modified for use.141
Data analysis
The data analysis of next generation sequencing is very similar across the different platforms
and applications, although there are some typical features concerning the data of each specific
platform. Any data analysis includes at least three steps148 (1) Base calling (2) Sequence
assembly, and (3) Variation detection.
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Figure 1.7: Growth of public database dbSNP from 2002 to 2010
Exponential growth in submissions following the first genome sequenced on next-generation sequencing tech-
nology (Watson) in 2007. Adapted from Koboldt (2010)148
Base calling
Every single NGS technology relies on the detection of illumination signals indicating a certain
event within a specific time-frame.∗ The speed and accuracy at which this conversion from
an analogue signal to a digital one can be done is one of the main analysis bottlenecks of
the current generation of sequencers. This dependence on imaging, however, also poses a
bottle neck in the sense that it results in large quantities of very high resolution images that
require large storage capacity.141 Additionally, the automated analysis, i.e., the conversion
of digital images to meaningful data, is computationally quite intensive. As a first step, the
location of interesting features (e.g. beads) needs to be identified resulting in a map with the
feature positions. Secondly, all images are aligned and features are extracted to be stored
in intermediate files. The signal intensities can be used for the calculation of base quality
values or, as with the Roche/454 platform, to estimate multiple incorporation events (i.e. ho-
mopolymers).130 Base call quality values are typically calculated based upon the base calling
metrics of a calibration dataset of which the correct calls are known.150 Finally, the intensity
information that is extracted from the different slides is combined into single sequence reads,
which are optionally filtered based on any kind of quality metric (e.g. read length).
The actual sequencing is a stochastic process governed by large numbers. For individual
reads, however, many types of random errors may occur, depending on the specific techno-
logy used. Common errors on all platforms are out-of-phase errors when a signal is detected
while there was no corresponding base incorporation, or vice versa. In case it is unclear which
nucleotide was actually incorporated, the final sequence read will contain a N or . character
instead of a nucleotide character.
∗With the exception of the IonTorrent technology149
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Figure 1.8: Basic workflows for next-generation sequencing
(A) Sequencing and alignment. Libraries constructed from genomic DNA or RNA are sequenced on massively
parallel instruments (e.g. Illumina or SOLiD). The resulting NGS reads are mapped to a reference sequence.
Mapped and unmapped reads are imported into SAM/BAM format and marked for PCR/optical duplicates. B)
Post-BAM downstream analysis. The FLAG field of the BAM file indicates the mapping status for each read.
Mapped, properly paired reads (or mapped fragment-end reads) are used for SNP/indel detection and copy
number estimation. Aberrantly mapped reads, in which reads in a pair map with unexpected distance or ori-
entations, are mined for evidence of structural variation. Finally, de novo assembly of unmapped reads yields
predictions of structural variants and novel insertions. Adapted from Koboldt et al.148
Some technologies incorporate an additional error-correction step before the reads are used
for assembly. This is different from the read filtering steps in the sense that no sequence is lost
by rejection or trimming. Instead, the actual sequence of a read is changed to conform to a
majority k-mer voting system. By generating a spectrum of subsequences of a certain length
(k-mers) from the reads, it is possible to identify likely errors within the reads and correct them.
For most technologies this is an awkward step as one might "correct" actual variants present in
low abundant reads. For the SOLiD platforms the two-base encoding system makes it easier
to distinguish a color space error from an actual polymorphism as a true polymorphism will
yield two consecutive color changes.151
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Assembly
The requirement of all technologies to shear the original DNA into many small random frag-
ments eventually becomes a problem when the pieces need to be fit back together to ob-
tain the global picture of biological information of interest.144 This assembly or reconstruc-
tion of an entire DNA molecule from the sequence of individual (short) reads alone is al-
most impossible and cannot be solved by traditional local alignment algorithms130,146 such as
BLAST152 or BLAT.153 Several new algorithms have been developed that all face the same
challenges:130,143–148,154
1. The task of mapping billions of sequences to a mammalian-sized genome calls for ex-
traordinary efficient algorithms.
2. All technologies produce reads of lengths much shorter than even the smallest genomes.
This limitation is overcome by over-sampling the target genome with short reads from
random positions. However, shorter read lengths decrease the likelihood that a read
can be mapped to a single unique location which increases the mapping complexity
given the complicated repeat structures of mammalian genomes and, may cause mis-
assemblies.
3. Reads from NGS platforms are of imperfect quality, containing sequencing errors.155,156
Even a relatively high accuracy of 99.9% would yield an error rate of one in thousand
and would imply many errors considering the large amount of sequence data that is
generated. When this error rate is too high and no additional information on the type of
errors is available, assembly becomes very difficult especially in the light of sequence
variation between chromosome copies.
4. Many regions of the DNA are inherently difficult to sequence (e.g. GC rich regions).
This is also dependent on the biases introduced by the specific sequencing platform.
Obviously, regions that were not sequenced cannot be assembled and will yield gaps in
the assembly.
5. Many genomes consist of multiple copies of chromosomes (two for humans). These
copies are only nearly identical and can differ both structurally as well as in the exact
nucleotide sequence. For assembly this means that one has to reconstruct two slightly
different jigsaw puzzles from one set of pieces.
6. Even under the best circumstances samples are contaminated with bacterial and viral
DNA or even DNA from lab workers.157 These additional pieces from a different puzzle
further complicate the assembly.
Assemblies can be improved by using data from complementary sequencing techniques that
give more long-range or structural information. Such data could come from mate-pair sequen-
cing, BAC clones or fosmid maps.143 An alternative method to ease the burden of assembly
is to use a previously finished sequence that closely resembles the DNA that is being se-
quenced.158 The method of assembly relying on a reference sequence is called mapping
or reference/comparative assembly as opposed to assembly not guided by any reference,
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referred to as de novo assembly. Reference assembly can, however, bias the results es-
pecially when the reference differs greatly from the actual genome being sequenced.143 Cur-
rently many different software tools have been developed for sequence assembly for specific
applications.145,148,159,160
Variant detection
Variant detection attempts to reliably detect differences in the sequence of an individual com-
pared to a reference sequence. The results depend strongly upon the quality of the assembly,
as wrongly aligned sequences will yield false positives while non-aligned sequences might
lead to false negatives. Next-generation sequencing however has the potential to detect all
kinds of genomic variation in single experiment,148 and even detect genome wide inversions,
a type of variation that has been difficult to detect by most other techniques.161
SNVs
The detection of SNVs has been shown to be possible at high accuracy provided there is at
least 10-15 fold coverage at the SNV position and a reasonable sequencing error rate.1,162
Most algorithms for SNV detection utilize a Bayesian approach, computing the conditional
likelihood of the nucleotides at each position159,163–165 based upon, for example, the number
of independent reads supporting the variant, base call quality scores and others.130,154
Sequencing errors, which are more prevalent for NGS platforms than traditional capillary-
based methods, can lead to false positive variant calls. While sequencing errors are often
random, certain platform-specific and platform-independent trends have become evident. On
the Illumina/Solexa platform, sequencing errors are positively correlated with read positions;
errors tend to occur near the ends of reads. In contrast, errors on the Roche/454 platform are
not dependent on read position, but tend to cluster around homopolymeric sequences that
are under- or over-called during 454 pyrosequencing.148 Among high-throughput strategies
SOLiD seems preferable for this purpose, since its color-space system can discern sequen-
cing errors from genuine variations.130
Indels
Detection of small insertions and deletions in NGS data has proven more difficult, particu-
larly due to the relatively short-read length typical of most platforms. Particularly single-base
events suffer from high false positive rates due to alignment artifacts and sequencing errors.
Localized de novo assembly improves the performance of indel detection, though not nearly
to levels of sensitivity and specificity that are achievable for SNVs, and at a high computational
price.6,148,154
CNVs and large inversions
The first methods to accurately identify structural variations used paired-end or mate-pair
sequencing data.11,12,123,166,167 This approach extends seminal work on end-sequence profil-
ing of BACs168,169 in which mate-pair or paired-end reads are generated at an approximately
known distance in the genome. The reads are mapped to a reference genome, and pairs
mapping at a distance that is substantially different from the expected length, or with anoma-
lous orientation, suggest structural variants.123 A single mate pair is typically not sufficient
to predict a structural variation due to several reasons: (1) the true insert size is only known
approximately, (2) miss-aligned mate pairs create the appearance of structural variants, (3) a
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small fraction of all mate pairs is chimeric. Instead, mate pairs are clustered, with multiple
mate pairs required to support each putative event.154,166 Methods for structural variation de-
tection with mate pairs cannot identify insertions larger than the insert size or identify the exact
borders of the variation.
An alternative method for identifying copy number variation relies on the "depth-of-coverage"
signal.160,170,171 Assuming that the sequencing process is uniform, the number of reads map-
ping to a region follows a Poisson distribution and is expected to be proportional to the number
of times the region appears in the genome.123 The assumption is that sequence is distributed
equally over the genome. Regions that seem to contradict this assumption are candidates
for copy number changes. One confounding factor, however, is the sequencing biases of the
underlying platforms, more specifically a (non-linear) bias from GC-content.127,171 In addition,
mis-mapped reads in for example repeat-rich regions, further complicate CNV discovery. Con-
sequentially, depth-of-coverage methods are more suitable for calling larger CNVs over which
the various biases would average out.154,160 Other studies determine CNVs by directly com-
paring relative sequence coverage of two genomes, akin to arrayCGH-based methods.172,173
In a recent study the "depth-of-coverage" strategy was combined with the mate pair strategy
to more accurately predict CNVs.174
A third method uses "split-reads" to detect breakpoints of CNVs.154,175 The method is based
on the principle that reads spanning a CNV breakpoint will not align properly onto a reference
genome. Reads that cannot be aligned are split in two parts in such a way that each part
aligns to different loci on the genome. The distance between these parts is then indicative
of CNVs or inversions. As with the mate pairs strategy, a single event is not sufficient for
the prediction of a breakpoint and multiple events are clustered. This method relies critically
on the read length, as sequences smaller than 25bps are likely to be non-unique within the
genome.154
Aim of this thesis
With the introduction Next Generation Sequencing (NGS) in September 2008 within our insti-
tute, both the laboratory skills, as well as the bioinformatics related to this technology were
completely new. In terms of applications we decided that disease gene identification and ge-
netic diagnostics would be our main focus. As such:
The aim of this thesis was the development and application of bioinformatic strategies
for disease gene identification and clinical diagnostics using NGS technology.
This aim can be subdivided into:
1. Evaluation of the possibilities of NGS for the identification of known pathogenic muta-
tions in single genes in individual patients (Chapter 2)
2. Exploration of the possibilities of targeted NGS for the identification of novel disease
genes by:
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(a) Using linkage analysis to identify a dominant mutation for a complex monogenic
disorder (Chapter 3)
(b) Using homozygosity mapping to identify a recessive mutation for a complex mono-
genic disorder (Chapter 4)
3. Development of strategies for the the identification of disease genes from unbiased
whole exome resequencing data in case of:
(a) a dominant monogenic disorder (Chapter 5)
(b) a recessive complex monogenic disorder (Chapter 6 and Chapter 7)
(c) a dominant complex monogenic disorder (Chapter 8)
4. Evaluation of the possibilities of NGS for clinical diagnostics in genetically heteroge-
neous diseases (Chapter 9)
Chapter 10 then reviews the different disease gene identification strategies for exome rese-
quencing while Chapter 11 reviews the impact of their recent findings on our views of the
underlying genetics of Mendelian diseases.
The final Chapter 12 provides a general discussion of the future implications of next-generation
sequencing technologies.
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Abstract
Massively parallel sequencing has tremendous diagnostic potential but requires enriched tem-
plates for sequencing. Here we report the validation of an array-based sequence capture
method in genetically heterogeneous disorders. The model disorder selected was Autosomal
Recessive (AR) ataxia, using 5 subjects with known mutations and 2 unaffected controls. The
genomic sequences of seven disease genes, together with two control loci were targeted on
a 2Mb sequence-capture array. After enrichment, the patients’ DNA samples were analyzed
using one quarter Roche GS FLX Titanium sequencing run, resulting in an average of 65Mb
of sequence data per patient. This was sufficient for an average 25-fold coverage/base in all
targeted regions. Enrichment showed high specificity, on average 80% of uniquely mapped
reads were on target. Importantly, this approach enabled automated detection of deletions
and hetero- and homozygous point mutations for 6/7 mutant alleles, and greater than 99%
accuracy for known SNP variants. Our results also clearly show reduced coverage for se-
quences in repeat-rich regions, which significantly impacts the reliable detection of genomic
variants. Based on these findings we recommend a minimal coverage of 15-fold for diagnostic
implementation of this technology. We conclude that massive parallel sequencing of enriched
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samples enables personalized diagnosis of heterogeneous genetic disorders and qualifies for
rapid diagnostic implementation.
Introduction
Complex monogenic disorders are characterized by substantial genetic and allelic hetero-
geneity and include some of the most common genetic disorders for which genetic diagnosis
is sought, e.g. inherited breast cancer, mental retardation, ataxia, congenital sensory disor-
ders and inherited muscle disorders. In order to identify causative mutations in such disorders
it may be necessary to analyze up to 1000 genes. Mutation screening by conventional Sanger-
based DNA sequencing approach is not a scalable technology in the diagnostic setting as the
length of time to complete an analysis and the quality assurance requirements for the various
components of the procedure increases exponentially with increasing genetic complexity. As
a result genetic and prenatal services are unavailable for many patients with complex mono-
genic disorders
Recent advances in sequencing technologies have dramatically increased the speed and
throughput capacities of DNA sequencing and, as a corollary, reduced the costs per nu-
cleotide.71,120,176–178 For most diagnostic applications targeted analysis of candidate genes
is preferred at present, as this will reduce the number of sequencing errors, facilitate func-
tional interpretation of sequence variations, and overcome limitations in computational power
as well as ethical restrictions. Medical resequencing of selected genes requires an enrich-
ment step prior to the sequencing process itself, irrespective of the methodology chosen for
sequencing. Several papers have described the feasibility of microarray-based enrichment
procedures.179–185 Alternatively, approaches have been developed for enrichment in solu-
tion186,187 or on nitrocellulose.188 None of these methods has been extensively tested on
clinical samples so far.
Here we present the results of a proof of principle study of the application of next genera-
tion sequencing to mutation screening in the diagnostic context, using autosomal recessive
ataxia189 as a prototypical complex monogenic disorder. We performed enrichment by hy-
bridization on NimbleGen sequence capture arrays, followed by sequencing with Roche 454
Titanium shotgun sequencing
Materials and Methods
Array design
The array included a total of 385,000 oligonucleotide probes. Three features were targeted by
the array design. The principal feature was the complete genomic sequence (coding and non-
coding regions) of seven genes, mutations in which are known to cause autosomal recessive
ataxia (APTX, ATM, FXN, SACS, SETX, SYNE1 and TDP1). These seven genes have a
combined total of 279 exons (of which 269 were coding, and 10 upstream non-coding exons),
representing 62kb of genomic sequence. With the inclusion of all intronic sequences plus an
additional 5 kb of sequence up- and downstream of each gene the total DNA targeted was
886kb. Two further design features were also included on the array to explore the enrichment
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efficiency of the technique. The first of these targeted only the coding regions of the SYNE2
gene (each exon target expanded to at least 500 bp), whilst the other targeted a large control
region of 1.3 Mb of unique genomic sequence. In total 1,962,354 bases were represented on
the array which were selected using the most stringent settings for probe design (uniqueness
tested by Sequence Search and Alignment by Hashing Algorithm (SSAHA)).190
DNA samples
The DNA samples studied were from five subjects with previously characterized mutations
in the represented AR ataxia genes together with two negative control samples. DNA was
isolated from peripheral blood leucocytes following standard techniques. This study was ap-
proved by the Medical Ethics Committee of the Radboud University Nijmegen Medical Centre.
Sequence Capture
A schematic workflow is provided as Supplementary Figure S1. Array based sequence capture
was performed following the manufacturer’s instructions. In brief an input amount of twenty
micrograms of genomic DNA per sample was used in the preparation of DNA for sequence
capture hybridization. A final amount of 5µ per sample was hybridized to the customized
array, subsequently eluted and amplified by ligation mediated (LM-) PCR. Approximately 3µg
of amplified enriched DNA was subsequently used as input to generate ssDNA libraries for
massively parallel sequencing, using a Roche 454 GS FLX sequencer with Titanium series
reagents.
Read mapping and variant analysis
Sequence reads were mapped against the human reference genome (hg18) with the Roche
Newbler software (version 2.0.01.12) using the default software settings. Additional mapping
and coverage statistics were extracted from the mapping output files using custom software.
Sequence variations were automatically detected during mapping and annotated with known
gene (refSeq genes from http://genome.ucsc.edu/) and SNP information (dbSNP129
from http://genome.ucsc.edu/). Variations were categorized as high quality differences
(HCDiffs) when; 1) the variation was present in at least 3 non-duplicate reads which included
at least one forward and one reverse read, or 2) the variation was seen in at least 5 reads with
quality scores over 20.Variant annotation was supplemented with scores for evolutionary con-
servation based upon the University of California, Santa Cruz (UCSC) database (vertebrate
PhyloP and PhastCons191–193).
Results
The principle goal of this study was to determine the sensitivity and specificity of massive
parallel sequencing of enriched samples for the identification of pathogenic mutations. Auto-
somal recessive ataxia was chosen as a model disease and 5 patients with known pathogenic
mutations in ataxia disease genes as well as 2 unaffected controls were selected for this
study. Enrichment of these diagnostic samples for known disease genes was performed by
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Table 2.1: Coverage statistics per patient
Patient
1
Patient
2
Patient
3
Patient
4
Patient
5
Control
1
Control
2
Average
Run 14
1
4
1
4
1
4
1
4
1
4
1
4
1
4
Bases sequenced 91,154,273 48,891,585 64,037,196 73,646,644 69,660,798 55,777,722 50,754,080 64,846,043
Bases mapped 90,289,534 48,290,853 62,987,829 73,092,415 68,840,696 55,107,013 50,021,123 64,089,923
% mapped 99.05% 98.77% 98,36 99.25% 98,82% 98.80% 98,56% 98.80%
Mapped bases in regions 79.76% 68.93% 62.62% 87.09% 67.81% 84.14% 85.11% 76.49%
Mapped bases near region (500bp) 3.93% 3.24% 3.94% 3.95% 4.04% 3.97% 3.69% 3.82%
Mapped bases outside region 16.31% 27.83% 33.44% 8.97% 28.16% 11.88% 11.20% 19.68%
Target bases covered 98.20% 96.17% 98.26% 98.66% 98.44% 98.57% 98.02% 98.05%
Target bases with > 5x coverage 93.97% 84.69% 90.95% 93.99% 91.86% 92.50% 90.87% 91.26%
Target bases with > 10x coverage 87.99% 68.51% 78.24% 87.36% 81.16% 83.11% 79.85% 80.89%
Target bases with > 30x coverage 58.55% 13.26% 18.99% 53.41% 31.32% 32.34% 26.58% 33.49%
Target region bases not covered 1.80% 3.83% 1.74% 1.34% 1.56% 1.43% 1.98% 1.95%
hybridization onto custom NimbleGen sequence capture arrays, followed by sequencing with
Roche 454 Titanium shotgun sequencing.
Sequencing output, enrichment and obtained coverage
In all cases one quarter of a GS FLX Titanium run was used which generated an average of
65Mb of high quality sequence data per sample (range 49-91Mb, Table 2.1). Approximately
99% of the sequence data mapped back to unique regions of the human genome (hg 18).
On average 76% of these unique reads mapped to the targeted regions. In addition a small
proportion (on average 4%) mapped to regions flanking the targeted regions, i.e. within 500bp
proximity. The remaining 20% of reads mapped outside the targeted regions, mainly to satel-
lite repeats. On average 2% of the targeted regions per sample were not covered by any
sequence data.
A mean sequence depth of 25-fold (range 17 to 37-fold) was attained in the targeted re-
gions. This depth of coverage could be further resolved into 31-fold coverage for the coding
sequences of the disease genes, whilst non-coding sequences were covered to an average
depth of 24-fold. Individual disease genes showed an approximately 2-fold variation in cover-
age of the coding sequence, ranging from 17-fold for FXN to 45-fold for SACS (Supplementary
Table S1, Supplementary Table S2). No sequence reads were obtained for the first coding exon
of the FXN gene and the second coding exon for the SACS gene in any of the 7 samples
tested. On average only seven coding exons were covered less than 10-fold (i.e. 2.6% of all
coding exons) and 18 exons had less than 15-fold coverage (6.7%), Supplementary Figure S2).
The 50 exons with the least coverage harbored a total of 36 repeat elements in their immedi-
ate vicinity (100 bp upstream and downstream of each exon), compared with only 6 of these
elements in the equivalent regions of the 50 disease gene exons with the greatest coverage.
In addition, the average GC content for the 50 best covered exons was 37.6%, compared with
an average GC content of 39.6% for the 50 worst covered exons. The two exons without any
coverage contained a very high GC-content, with 76.1% for the 2nd coding exon of SACS and
63.6% for exon 1 of FXN.
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Mutation detection
To explore whether disease mutation detection is possible, we inspected all mapped se-
quence data from the samples with known mutations (Table 2.1, and Figure 2.1, Figure 2.2).
Multiple mutation types were targeted, including deletions, insertion-deletions and basepair-
substitutions, both in the homozygous and heterozygous states. The trinucleotide repeat
expansion present in the Friedreich’s ataxia patients was not represented in the array design
in order to avoid over-representation of repeat sequences and was therefore excluded from
the analysis. All but one of the known mutations could be identified by direct inspection of
the sequence data. For the two homozygous changes, the per-base coverage of the mutation
position was 33-fold (patient 1) and 25-fold (patient 5) respectively, with all reads confirming
the mutation. For the two patients with compound heterozygous changes, mutations were
detected for allele one in 16 out of 24 and for allele two in 36 out of 47 reads for patient 2 and
similarly in 19 out of 34 and 10 out of 17 reads for patient 3. Thus for the studied samples
the proportion of reads showing the mutant allele of a heterozygous mutation was in a range
56-77%. The heterozygous FXN mutation in patient 4 was not detected in the initial analysis
as no sequence read mapped to the affected exon. To exclude read mapping problems due to
repeats an indepth analysis of all unmapped reads was performed, but none of these mapped
back to this exon. When we used the same enriched material and performed an additional
3/4 run on the Roche sequencer the mutation was detected in 2 out of 9 reads. The Roche
software automatically detected 6 of the 7 mutant alleles and included these in the High Con-
fidence Differences (HCdiffs) output with standard software settings. The FXN mutation in
patient 4 was not automatically reported because of low sequence coverage.
SNP genotyping comparison
A comparison was performed between the number of SNP genotypes identified in the 7 sam-
ples using an Affymetrix 6.0 array and those called in the sequenced genotypes (on average
3867 SNP markers). This comparison showed a clear correlation between sequence cover-
age depth and genotyping accuracy. Whilst a minimum coverage of 10-fold resulted in 0.94%
conflicts for heterozygous calls, and 0.12% for homozygous calls, this improved to 0.55% and
0.10% for a minimum 15-fold coverage and 0.28% and 0.06% for markers covered at least
20-fold. Thus minimum of 15-fold sequence coverage was sufficient to achieve greater than
99% genotyping accuracy.
On average 284 SNPs (range 205 to 338) per sample were called by both methods as being
different from the reference allele in the target region, of which 96% were in agreement (Table
2.2). For the 19 conflicting SNPs Sanger sequencing was performed to determine which of
the two methods was correct and to establish the cause of the artifact. This analysis showed
that the majority of the conflicts (58%) could be attributed to lack of sufficient sequence cov-
erage, explaining why the variant allele was either not sequenced at all, or sequenced at
an insufficient frequency (when frequencies between 0.2 and 0.8 are considered as heterozy-
gous alleles). Local sequence misalignment was identified as another major cause of conflicts
(37%), of which 5% were due to nearby homopolymer stretches. An additional 5% of conflicts
were due to incorrect calling of the Affymetrix SNP-array platform. After corrections for these
effects more than 99% of the SNP calls were in agreement between the sequence data and
the SNP array for all samples.
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Figure 2.1: Array-based sequence enrichment of disease genes and mutations detection by
massive parallel sequencing
A) An overview of targeted disease genes. Targeted regions are depicted in a genome browser view, showing
the targeted region, the tiled region, that is, the sequences represented on the enrichment array, the RefSeq
gene track, and the RepeatMasker track. B and D) Show detailed results for patient 1 with a homozygous
mutation in the ATM gene, whereas C and E show results for patient 3 with a heterozygous mutation in the SETX
gene. The coverage histogram is shown in B and C, with zoom-in of the exon carrying the mutation in D and E.
The tracks display genomic position, coverage histogram (y-axis showing the fold coverage), target region, tiled
region, RefSeq gene and RepeatMasker track.
Mutation interpretation
An average of 912 genomic variants per sample were categorized as HCdiffs for the seven
targeted disease genes. Among these variants 148 were present in all 7 samples, and rep-
resented the minor allele of a SNP in the reference assembly, at least when considering
individuals of European ancestry.
In order to identify disease causing mutations among the HCdiffs we applied following 3 step
procedure. The first stage screened for mutations that could give rise to premature protein
truncating mutations i.e. stop mutations, variants at potential splice sites and exonic dele-
tions/insertions potentially resulting in frameshifts. Next we considered all unknown (i.e. non-
SNP) exonic missense variants where they represented at least 20% of reads, which reduced
the number of variants to an average of 7 per sample (Supplementary Table S4). Finally variants
were ranked based upon evolutionary conservation of the affected nucleotide using vertebrate
PhyloP and PhastCons scores. The use of this procedure resulted in all known pathogenic
mutations being ranked in the top position (Supplementary Table S4). When this procedure was
applied to the single mutation which was only detected manually as a result of low coverage it
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Figure 2.2: Summary of sequence enrichment and mutation detection
For each mutation allele two panels are shown. Left: UCSC genome browser view, with genomic position,
coverage histogram of the sample carrying the mutation at this position, target region, tiled region, RefSeq gene,
Exon number, and RepeatMasker. Right: Individual read alignment of the mutation position.
was also ranked in the highest position among variants present in that sample.
Discussion
Research studies have shown that massive parallel sequencing has the potential to become
the method of choice for diagnostic laboratories that seek to identify mutations in families
with complex monogenic disorders. In order for this to happen however the performance
of the technology in the diagnostic setting has to be determined. This paper identifies and
quantifies the strengths and limitations of this technology in a group of patients presenting
with AR ataxia, a clinical classification with heterogenous genetic causes. Below we will
discuss the critical components of this approach and improvements required for diagnostic
implementation.
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Table 2.2: (a) Characteristics of the known mutations. (b) Variants discovered in the target
sequence. (c) Comparison of sequence variations with SNP 6.0 array data
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Control 1 Control 2
a) Known variants
Known mutations ATM,
c.[del7875-876insGC]
+
[del7875-7876insGC]
SACS,
c.[del 5998-6002]
+ [12160C>T]
SETX,
c.[6017C>T] +
[del6831-6836]
FXN,
c.264-1G>A
APTX,
c.[837C>T] +
[837C>T]
NA NA
Genomic position (hg18) Chr11:107,708,785 Chr13:22,810,013;
22,803,855
Chr9:134,161,169;
134,143,284
Chr9:70,857,875 Chr9:
32,964,493
NA NA
PhyloP mutation-basepair 4.64 4.40 6.58 5.38 3.41 3.93 4.26 5.28 NA NA
Coverage of the known mu-
tations bp (HC diffs cover-
age)
33x (22x) 24x (16x); 47x
(25x)
34x (22x); 17x
(11x)
0x (-); 9x∗ 25x (20x) NA NA
Number reads with vari-
ant(HC diffs coverage)
33 (22) 16 (9); 36 (16) 19 (12); 10 (7) 0 (-); 2∗ 25 (20) NA NA
b) Variant details for dis-
ease gene variants
n n n n n n n
Variants 870 471 973 1140 972 992 966
Non-SNP variants 85 42 77 127 122 140 128
Intronic 820 437 926 1081 929 942 926
5bp intronic 2 1 2 2 3 2 3
Exonic 48 33 45 57 40 48 37
Exonic non-SNP 9 4 4 7 2 3 3
Exonic deletions 5 2 2 1 0 5 4
Exonic insertions 1 0 1 0 1 0 0
Exonic substitutions 44 31 42 58 39 43 33
Exonic translated variants 32 26 36 35 26 31 21
Synonymous 16 12 15 16 12 12 8
Non-synonymous 16 14 21 19 14 19 13
c) SNP array comparison -
whole 2Mb stretch
SNP called by both methods 280 205 289 338 NA 278 314
Heterozygous conflicts 8 5 5 6 NA 4 7
Homozygous conflicts 3 2 3 1 NA 10 9
Conflicting SNPs 3.93% 3.41% 2.77% 2.07% NA 5.04% 5.10%
∗ when considering reads from additional 3/4 454 run.
∗∗ not in HC diffs due to missing reverse read.
Coverage
In this study 80% of unique reads mapped to or near the targeted regions, a figure which is
significantly higher than that reported in an earlier study which used a similar approach.184
This may be explained by recent improvements in probe density, array design algorithms
and sequencing methods, but also by the ease with which longer sequencing reads can be
mapped. We observed a higher coverage for the coding sequences (31-fold) of the disease
genes, compared to non-coding sequences (24-fold). This difference is most likely due to a
greater level of unique sequence in coding sequences, and not to array design issues, as only
targeted bases were considered for these calculations. The local sequence architecture ap-
pears to have a strong effect on the efficiency of DNA enrichment for individual exons. Those
exons which are located near repeat rich regions in general show lower coverage, consistent
with recent observations by Nikolaev and colleagues.185 It may be that co-hybridization with
human Cot1 DNA suppresses hybridization to repeat sequences but also the adjacent exonic
sequences, so reducing the coverage in these regions. The negative effect of extreme GC
contents, as seen in our study for the exons with null coverage is also consistent with earlier
observations that extremely high GC content has strong influence on capture efficiency.186,187
The number of exons for which enrichment failed completely following the first round of se-
quence capture array design was as low as 0.7%. This figure is comparable or better than
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the PCR failure rates of 3% (2 out of 63 amplicons) reported following the first round of PCR
design for multiplex-PCR based diagnosis of peripheral neuropathies.194 Whilst overall 20% of
all targets had less than 10-fold coverage (Table 2.1), only 2.6% of coding disease gene exons
had that low coverage. We speculate that improved depth of sequencing associated with cod-
ing sequences can be explained by the higher degree of uniqueness of coding sequences.
This effect favors diagnostic applications that focus on sequencing the coding sequence of
known disease genes.
Mutation detection
In general these results show that mutation detection is possible provided sufficient sequence
coverage has been obtained. Six out of 7 known mutation alleles were identified through
the use of just a quarter sequence run in an unbiased fashion. The detection of a mutation
in the FXN gene turned out to be most problematic as could be expected from the lower
sequence coverage obtained for this gene. The detection frequency of heterozygous mutation
alleles shows that there is no obvious bias against mutation alleles, during hybridization or
sequencing.
By comparing SNP genotypes from massively parallel sequencing with SNP genotyping mi-
croarray results we concluded that SNP detection accuracy in next-generation sequencing
data is mainly limited by sequence coverage and sequence misalignment, rather than by se-
quencing errors. This is similar to findings made with other enrichment techniques and utilizing
different sequencers.187
Mutation interpretation
One of the main challenges of next-generation sequencing applications will be the interpreta-
tion of the enormous numbers of genomic variants. Fast and reliable identification of causative
variants is crucial for the implementation of this technology into the diagnostics of complex
monogenic disorders. Our results confirm that sequence conservation can be of great value
in prioritizing causal variants. Furthermore, the growing body of publicly available sequence
data from healthy individuals will permit the exclusion of benign variants more easily and im-
prove prioritization of causative variants in the near future. Large scale sequencing project as
the 1000 genomes project (http://www.1000genomes.org), will also give insights into eth-
nic differences and ultimately allow interpretation of sequencing data irrespective of the ethnic
background.
Diagnostic implementation
Our results show that the combination of array-based sequence capture and Roche 454 Ti-
tanium sequencing can be used for the parallel screening of multiple disease genes and to
successfully identify disease causing mutations. This is an important proof of principle study
for diagnostic implementation of massively parallel sequencing. The results also highlight the
importance of coverage for reliable mutation detection in medical next-generation sequencing
approaches, as has been discussed by others.195 Our results indicate that 15-fold sequence
coverage (comparable to a PHRED quality score of 20) is required for reliable detection of
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heterozygous mutations, which was achieved for 93.3% of all coding exons in this proof of
principle study. This kind of information is important for clinical interpretation, especially in
case of negative results, and can easily be provided in diagnostic reports.
We evaluated general characteristics of the enrichment procedure and therefore placed a
large genomic locus as well as the total genomic content of 7 disease genes on the sequence
capture array. This resulted in a total of 2Mb of genomic DNA for which enrichment was per-
formed and sequencing data was obtained. For diagnostic procedures, it is possible to limit
analysis only to the coding and upstream non-coding exons of known disease genes. This
will significantly reduce the amount of sequence to be enriched and sequenced, thereby in-
creasing the coverage required for reliable mutation detection. The 279 exons of the 7 ataxia
genes for example only occupied 62 kb of targeted coding sequence on the array. For diag-
nostic applications we will develop a second-generation enrichment array containing targets
for the coding sequence of all 70 genes that have been linked to ataxia (1324 coding exons,
Table 2.2). The coding sequence of these genes will still only occupy 320 kb. The density
of array probes per target can therefore be increased, resulting in even higher enrichment
specificity. Because of the reduced target region only 1/8th Roche 454 sequence run will be
sufficient to reach even better coverage compared to the current study while simultaneously
lowering costs per patient. Especially targets which are difficult to enrich can benefit from the
increased coverage by being targeted by more probes, although it remains to be seen if this
improvement will allow enrichment of all exonic regions. It may still be required to investigate a
limited number of these targets by traditional Sanger sequencing in cases where no causative
mutation is identified by next generation sequencing.
Genomic coverage can also be improved by simply increasing the amount of sequence data
per sample, as was shown for patient 4 in our study. The massive amount of sequence data
that can be generated by short-read sequencing platforms may allow for this. Although the use
of short-read sequencing after target enrichment has been recently demonstrated,178,184,185
the ability to cover repeat-rich genomic regions appears even more problematic. Also it has
been argued that the accuracy of next generation sequencing technology needs to increase
before it can be reliably applied clinically.71 Our data however indicate that this is no major
bottleneck for targeted disease gene studies.
Conclusion
These results show that massively parallel sequencing of enriched samples for diagnostics of
complex monogenic disorders is possible in the diagnostic laboratory context. This approach
is expected to have a profound effect on the diagnosis and genetic counseling of patients with
complex monogenic disorders. Next generation sequencing of the coding region of known
disease genes shows highest feasibility at this moment. Our limited knowledge on the clinical
interpretation of genomic variants needs to improve dramatically before more genome-wide
approaches can enter the diagnostic arena.
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Abstract
Familial Exudative Vitreoretinopathy (FEVR) is a genetically heterogeneous retinal disorder
characterised by abnormal vascularisation of the peripheral retina, often accompanied by reti-
nal detachment. To date, mutations in three genes (FZD4, LRP5 and NDP) have been shown
to be causative for FEVR. In two large Dutch pedigrees segregating autosomal dominant
FEVR, genome-wide SNP analysis identified a FEVR locus of 40 Mb on chromosome 7. Mi-
crosatellite marker analysis suggested similar at risk haplotypes in patients of both families.
To identify the causative gene, we applied next-generation sequencing in the proband of one
of the families, by analyzing all exons and intron-exon boundaries of 338 genes, in addition
to microRNAs, non-coding RNAs and other highly conserved genomic regions in the 40-Mb
linkage interval. After detailed bio-informatic analysis of the sequence data, prioritization of
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all detected sequence variants led to three candidates to be considered as the causative ge-
netic defect in this family. One of these variants was an alanine to proline substitution in the
transmembrane 4 superfamily member 12 protein, encoded by TSPAN12. This protein has
very recently been implicated in regulating the development of retinal vasculature, together
with the proteins encoded by FZD4, LRP5 and NDP. Sequence analysis of TSPAN12 in total
revealed two mutations segregating in five out of eleven FEVR families, indicating that mu-
tations in TSPAN12 are a relatively frequent cause of FEVR. Furthermore, we demonstrate
as one of the first groups, the power of targeted next-generation sequencing technology to
identify novel disease genes in linkage intervals.
Introduction
Familial exudative vitreoretinopathy (FEVR; MIM 133780) is a well characterised hereditary
ocular disorder that was first described by Criswick and Schepens.196 The pathologic features
of the disease initiate from the abnormal retinal development due to the incomplete vasculari-
sation of the peripheral retina and/or retinal blood vessel differentiation.197 The latter can lead
to various complications, such as retinal neovascularization and exudates, vitreous haemor-
rhage, ectopia of the macula, retinal folds, and retinal detachment.198 FEVR is genetically
heterogeneous and shows autosomal dominant, autosomal recessive, and X-linked recessive
modes of inheritance.196,199–204 Mutations in the genes coding for frizzled 4 (FZD4, located
on 11q14.2 [MIM 604579]) and low density lipoprotein 5 (LRP5, located on 11q13.2 [MIM
603506]) which act as Wnt co-receptors, and Norrin (NDP, located on Xp11.3 [MIM 300658]),
a ligand for these Wnt receptors, have been shown to result in FEVR. A consistent feature is
the aberrant retinal vascular development caused by the impaired action of the Ndp/β-catenin
signaling pathway which, amongst others, orchestrates eye organogenesis and blood sup-
ply.199,202,205–207
Materials and Methods
To unravel the genetic causes underlying FEVR, patients and their relatives were included in
our study. An informed consent adhering to the tenets of the Declaration of Helsinki was ob-
tained from all patients and their participating relatives. In 11 families with autosomal dominant
FEVR, we excluded mutations in FZD4 and LRP5 via sequence analysis of all coding exons
and intron-exon boundaries (unpublished data). In those families in which X-linked inheritance
could not be excluded based on the pattern of inheritance, mutations in NDP were excluded
via sequence analysis. In the two largest families (families A and B) that did not carry exonic
mutations in FZD4 and LRP5, detailed analysis of microsatellite markers surrounding these
two genes excluded them to be causative for FEVR. Patients in both families invariably show
a peripheral avascular area, the most typical feature in FEVR (Figure 3.1). The visual acu-
ity varies considerably (normal to light perception) due to secondary defects such as retinal
detachment and retinal exudates. Subsequently, eight individuals from family A, and fifteen in-
dividuals from family B (Figure 3.2) were genotyped on the Infinium II HumanLinkage-12 Panel
(Illumina, San Diego, CA, USA) that contains 6,090 Single Nucleotide Polymorphism (SNP)
markers. Genome-wide linkage analysis using the GeneHunter 2.1r5 program in the easyLink-
age v5.052beta software package208 revealed a 40.5-Mb genomic region on chromosome 7
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Figure 3.1: Fundus photograph showing part of the avascular periphery of patient IV:2 from
family A
Temporal periphery of the left fundus in patient IV:2 from family A (numbering according to the pedigree presented
in Figure 3.2). The retinal vasculature (at the left side) ends in small aberrant ramifications in the equatorial area
of the fundus. The peripheral retina (at the right side) is avascular; only choroidal vessels are present in this
area.
suggestive for linkage (LOD-score 2.34) in family A (Figure 3.2, left panel), whereas in family
B, a significant LOD-score of 3.31 was obtained for a 16.7-Mb genomic region on chromo-
some 7 (Figure 3.2, right panel), completely contained within the 40.5-Mb region detected in
family A (Figure 3.3). Moreover, the affected individuals in both families shared the same SNP
and microsatellite alleles for a region of at least 10 Mb. These results strongly suggested that
the region on chromosome 7 is likely to contain a gene causative for FEVR. Two obvious
candidate genes within the shared linkage intervals were WNT2 [MIM 147870] and WNT16
[MIM 606267], since the canonical Wnt signaling pathway has been implicated in regulating
the formation of intraretinal capillaries.209 Sequence analysis of the exons and intron-exon
boundaries of these two genes in probands III-7 (family A) and II-5 (family B) however did not
reveal any sequence variant causative for FEVR.
Due to the high number of genes in the region, and the lack of other obvious candidate genes,
we decided to apply array-based sequence capture followed by next-generation sequencing to
simultaneously analyze all genes in the region. The complete 40.5 Mb region on chromosome
7 suggestive for linkage in family A (Figure 3.3, upper panel) was used for sequence cap-
ture. The array design included all known exons, untranslated regions, microRNAs and highly
conserved regions (PhastCons Conserved Elements, 28-way Mammal Multiz Alignment, lod
score > 100), complemented with the complete genomic sequence of WNT2 and WNT16.
For all exons, an additional 30 bp were added at each side to detect splice site mutations.
Targets smaller than 250 bp, which is based on our experience the minimum size for the DNA
capture protocol, were enlarged by extending both ends of the region. In total, 3,048 exons
from 338 RefSeq genes and 313 UCSC genes as well as 14 microRNAs and 23 non-coding
RNAs were targeted (Supplementary Figure S3). Together with the UTR regions and regions of
high conservation, 2,366,514 bp were selected. For reasons of efficiency the array included
targets for another linkage region representing 352 Kb on chromosome 17. After stringent
probe selection by NimbleGen (Roche NimbleGen, Madison, WI, USA) (uniqueness tested by
Sequence Search and Alignment by Hashing Algorithm-SSAHA),190 in total 2,528,988 bases
were represented on an array with 385,000 oligonucleotide probes targeting the region of
interest as well as the additional region on chromosome 17.
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Figure 3.2: Pedigree structure and genome-wide linkage analysis for FEVR families A and B
A) Pedigree structure of those parts of families A and B that were selected for Illumina 6k SNP genotyping
analysis. Individuals of which the clinical status is uncertain are depicted in grey. Probands are indicated with an
arrow. Eight members of family A and fifteen individuals of family B, indicated with asterisks, were genotyped.
B) Genome-wide LOD-score calculations using the 6K SNP array genotyping data. In family A, two peaks are
visible, on chromosomes 7 and 8, respectively. In family B, only one clear peak is visible on chromosome 7, with
a genome-wide significant LOD-score of 3.31. Interestingly, the two peaks on chromosome 7 in families A and
B, indicated by red arrows, represent the same genomic region.
Sequence capture was performed following the manufacturer’s instructions (Roche Nimble-
Gen, Madison, WI, USA). In brief, 20 µg of genomic DNA of the FEVR proband from family
A was used in the preparation of DNA for sequence capture hybridization. A final amount
of 5 µg DNA was hybridized to the customized array, subsequently eluted and amplified by
ligation mediated-PCR. Three microgram of amplified enriched DNA was used as input to
generate a ssDNA library for massive parallel sequencing, using a Roche 454 GS FLX se-
quencer with Titanium series reagents. The sample was sequenced using one quarter lane
of a Roche sequencing run yielding 48.6 Mb of sequence data. Approximately 94.5% of the
sequence data mapped back to unique regions of the human genome (hg18, National Center
for Biotechnology Information (NCBI) Build 36.1) using the Roche Newbler software (version
2.0.01.12). Of all mapped reads, 90.5% was located on or near the targeted regions (i.e.
within 500 bp proximity). This was sufficient to reach an average of 13.2-fold coverage of all
target regions and more specifically an average 14.7-fold coverage of the targeted exons on
chromosome 7. For the region of interest, only 5.2% (112,319 bp) of all targeted sequences
were not covered, while 39.2% (1,099,873 bp) of the target sequence was covered less than
10 times (Supplementary Table S7).
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Results
The Roche software detected a total of 1,915 variants on chromosome 7. We used a custom-
made data analysis pipeline to annotate detected variants with various kinds of information,
including known SNPs, amino acid consequences, genomic location, and evolutionary con-
servation. With this analysis 1,749 variants were found to correspond to known SNPs or
overlapped with a known polymorphic region (dbSNP130). After excluding non-exonic (145),
synonymous (4) and putative homozygous variants (variation percentage < 80%) (3), 14 vari-
ants remained (Table 3.1). From these, three promising candidates were selected (in the
PTCD1, ZAN [MIM 602372] and TSPAN12 [MIM 613138] genes) since they were detected in
at least four non-duplicate reads and had a high score for evolutionary conservation (verte-
brate PhyloP).191–193
The missense variant detected in PTCD1 changes an arginine to a cysteine, whereas the vari-
ant in ZAN alters an arginine to a histidine residue. Both arginine residues are not completely
conserved throughout vertebrate evolution. In addition, the presumed physiological roles of
the proteins encoded by PTCD1 and ZAN, namely controlling leucine tRNA levels in mitochon-
dria210 and regulating the adhesion of sperm cells to the zona pellucida,211 respectively, do not
support their involvement in causing FEVR. Finally, PTCD1 and ZAN are both located outside
the smaller linkage interval in family B, and will therefore definitely not be causative for FEVR
in that family. The TSPAN12 gene however is located within the shared linkage interval, and
the variant detected via next-generation sequence technology substitutes a proline residue for
a highly conserved alanine residue, with the highest PhyloP conservation score (Table 3.1). In
addition, very recently, TSPAN12 was found to regulate retinal vascular development in coop-
eration with the proteins encoded by FZD4, LRP5 and NDP.212 Therefore, the variant detected
in TSPAN12 was considered to be the mutation causative for FEVR in family A.
TSPAN12 contains eight exons for which exons two to eight are protein-coding, plus an al-
ternative non-coding exon for a different isoform (Figure 3.3). All exons of TSPAN12 were
covered by sequence reads from the targeted next-generation sequencing experiment (Figure
3.3). The missense variant that was detected by this approach (c.709G>C; p.Ala237Pro) is
located in exon eight. This exon was covered by more than 30 sequence reads (Figure 3.3).
The mutated nucleotide (at position 120,216,091) was covered by 20 unique sequence reads.
In 10 reads, the reference allele was detected, whereas in the other 10 reads the mutant allele
was observed (Figure 3.3), indicating that the mutation is present in a heterozygous state.
Conventional Sanger sequencing confirmed the mutation to be present in the proband of
family A, as well as in the proband of family B that shared the at risk haplotype for the region
containing TSPAN12. Furthermore, the mutation was present in all relatives that were clearly
affected with FEVR in both families (Supplementary Figure S4). In three other relatives of which
the clinical status was uncertain (III:1 in family A; III:15 and IV:2 in family B) and in one healthy
individual (III:8 in family B), the mutation was also present, which points to non-penetrance,
a feature that is also often observed in FEVR families with mutations in FZD4, LRP5 and
NDP.198
To determine the prevalence of TSPAN12 mutations as a cause of FEVR, 9 additional FEVR
probands from unrelated families were selected for sequence analysis of the complete gene
(primer sequences are listed in Supplementary Table S7). In two other families, the same
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Table 3.1: Overview of all non-synonymous sequence variants not present in dbSNP
Position refer-
ence allele on
chromosome 7
Reference
allele
Variant
allele
# of
reads
# of
variant
reads
% varia-
tion
Reference
amino
acid
Variant
amino
acid
Gene PhyloP
score
92570705 T C 7 3 43 D G SAMD9 1.56
98870495 G A 26 16 62 R C PTCD1 3.06
99835402 C T 13 6 46 P L PILRA 1.75
100122289 - CCT 5 3 60 EQ ERQ GIGYF1 3.98
100209410 G A 15 8 53 R H ZAN 1.81
100473466 A G 38 13 34 T A MUC17 0.60
105066159 TC - 19 3 16 E X ATXN7L1 4.92
113306419 C T 15 6 40 S N PPP1R3A 1.05
115411632 C T 14 5 36 D N TFEC -0.45
119702880 T C 29 3 10 C R KCND2 5.00
120216091 C G 20 10 50 A P TSPAN12 5.32
120555712 T C 10 3 30 L S C7orf58 3.00
128099699 C G 7 5 71 I M FAM71F2 0.42
128221650 T C 13 3 23 L P CCDC136 1.26
After initial filtering of the 1,915 variants based upon overlap with dbSNP (build 130) and amino acid conse-
quences, only 14 candidate variants remained. Variants marked in bold and indicated with an arrow were se-
lected after further prioritization based upon the number of variant reads and evolutionary conservation. The
position of the reference base pair is based on UCSC genome build hg18. The table lists the reference allele
and the variant allele for that position, the total number of high confident sequence reads for this position, and
the number of times a variant was read. The percentage of variation indicates how often a variant was read
compared to the total number of reads. The amino acid of the reference and mutant alleles are indicated as well
as the gene in which the variant was detected. In the right column, the vertebrate PhyloP score for evolutionary
conservation is presented.191–193
Table 3.2: Overview of the missense mutations identified in TSPAN12
Family Proband # of affected
relatives with
mutation
# of unaffected
relatives with
mutation
Mutation
(cDNA level)
Mutation (pro-
tein level)
Frequency in
control alleles
Family A III-7 3 0 c.709G>C p.Ala237Pro 0 / 280
Family B II-5 7 1 c.709G>C p.Ala237Pro 0 / 280
Family C II-2 0 0 c.709G>C p.Ala237Pro 0 / 280
Family D III-2 3 0 c.709G>C p.Ala237Pro 0 / 280
Family E II-1 1 0 c.562G>C p.Gly188Arg 0 / 280
Five families have been identified that carry a dominant missense mutation in TSPAN12. The proband corre-
sponds to the pedigrees depicted in Supplementary Figure S4. For each family, the number of affected relatives
that carry the mutation is listed. In family B, one healthy individual also carried the mutation, suggesting non-
penetrance. None of the two variants was detected in over 280 ethnically matched control alleles.
p.Ala237Pro change was detected to segregate with the phenotype (families C and D, Sup-
plementary Figure S4). Microsatellite marker analysis surrounding TSPAN12 showed that the
affected individuals of all four families showed a shared at-risk haplotype of at least 5.8 Mb
(data not shown). In addition, a second variant was detected in the proband of family E, sub-
stituting an arginine residue for a glycine residue (c.562G>C; p.Gly188Arg). This change was
also present in his affected brother (Supplementary Figure S4). Both changes were not de-
tected in 140 ethnically matched control individuals (data not shown), nor were they present
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in a database containing more than two million variants from various in-house and published
next-generation sequencing projects.178,213,214 An overview of the mutations that were identi-
fied is presented in Table 3.2.
The TSPAN12 protein is a member of the tetraspanin family that share certain specific struc-
tural features that distinguishes it from other proteins that pass the membrane four times.215
The glycine residue at position 188 is located in the extracellular loop between the third and
the fourth transmembrane region and is completely conserved throughout vertebrate evolu-
tion (Figure 3.3). The arginine residue substituting the glycine has a bulky side chain that is
positively charged. In addition, this small and flexible glycine residue precedes a cysteine
residue that is involved in the formation of disulfide bridges (Figure 3.3) and highly conserved
in the complete tetraspanin protein family.216 Therefore, the substitution of an arginine for
this glycine residue is likely to affect TSPAN12 function. The alanine at position 237 resides
within the fourth transmembrane region and is also completely conserved throughout verte-
brate evolution (Figure 3.3). A proline residue has the intrinsic property to induce bends in the
three-dimensional protein structure. Therefore, a proline residue at position 237 is predicted
to disrupt the helical structure of the transmembrane region, which would result in a TSPAN12
protein with a defective confirmation that even might be subject to proteolytic degradation. The
p.Ala237Pro mutation was detected in four unrelated Dutch families. Genealogical analysis
however revealed that the ancestors of families A, B and C were born in the same region in the
eastern part of the Netherlands, with those of families B and C being even born in the same
village. These data, combined with the microsatellite marker analysis that showed a shared
haplotype between all families, suggest that the p.Ala237Pro mutation might be a regional
founder mutation.
The TSPAN12 protein has recently been identified to play a crucial role in the regulation of
the development of the retinal vasculature.212 Mice lacking Tspan12 show a primary vascular
defect in the developing retina between postnatal day 5 and 11, similar to the phenotypes
described for Fzd4, Lrp5 and Ndph mutant mice, genes for which mutations in the human or-
thologues also cause FEVR.207,217,218 In addition, whereas heterozygous Tspan12, Lrp5 and
Ndph single mutant mice did not show any abnormalities, Tspan12/Lrp5 and Tspan12/Ndph
double heterozygous mice demonstrated a retinal vascular phenotype, indicating that these
proteins act in a similar pathway. A series of dedicated experiments revealed that TSPAN12
is required for Norrin-induced β-catenin signaling, by promoting FZD4 multimerization and
clustering of FZD4 via binding to Norrin multimers.212
Discussion
A question that remains is how the heterozygous FEVR-mutations described in this study
affect the function of TSPAN12 and the complex it is associated with. The glycine residue
at position 188 precedes a highly conserved cysteine among tetraspanin family members
involved in the formation of disulfide bridges, and is located in the large extracellular loop
(EC2) between the third and fourth transmembrane region (Figure 3.3). This extracellular loop
is known to harbour most of the protein-protein interaction sites described for tetraspanins.216
As such the substitution of an arginine residue for the glycine at position 188 might disrupt one
of such interactions, for instance with the Fzd4/Lrp5/Norrin protein complex. The alanine to
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Figure 3.3: Genomic structure, next-generation sequencing and mutation analysis of
TSPAN12
A) Upper panel, part of chromosome 7 showing the linkage intervals and the corresponding flanking SNPs for
FEVR families A and B. The linkage interval from family A was enriched for targeted next-generation sequencing
technology. The TSPAN12 gene is located in the shared interval between families A and B. Lower panel, overview
of the genomic structure of the TSPAN12 gene, showing all introns and exons. For all exons as well as a highly
conserved region between exons 7 and 8, the sequence coverage histograms are presented. B) Overview of all
patient reads for exon eight of TSPAN12. In total, more than thirty reads were representing parts of this exon. C)
Sequence traces for the twenty unique reads covering the TSPAN12 heterozygous G to C mutation. For these
twenty reads, ten were representing the reference allele, and ten were showing the mutant allele. At the protein
level, the G to C transition results in the substitution of a proline for an alanine residue (c.709G>C; p.Ala237Pro).
D) Topology of TSPAN12 and the positions of the missense mutions identified in the FEVR families. TSPAN12
shows the characteristic domain structure of tetraspanins including four transmembrane domains (in green).
A cysteine residue preceding transmembrane domain 1 (C9) and another following transmembrane domain 2
(C83) likely are palmitoylated (wavy lines). The second extracellular loop (EC2) contains three a-helices (boxes),
the typical C-C-G- motif characteristic for all tetraspanin proteins, followed by one pair of and two single cysteine
residues. These six cysteines are predicted to form disulphide bonds (stippled lines). The glycine residue that
is mutated into an arginine (G188) precedes one of these cysteines. The alanine residue that is mutated into a
proline (A237) resides within an alpha-helical structure within the fourth transmembrane region. E) Sequence
comparison of a number of vertebrate TSPAN12 proteins. Depicted are parts of TSPAN12 that harbor the amino
acid residues that are mutated. Both the glycine residue at position 188 (upper panel) and the alanine residue
at position 237 (lower panel) are completely conserved throughout vertebrate evolution. Residues identical in all
sequences are black on a white background, whereas similar amino acids are black on a light grey background.
Non-conservative changes are indicated in white on a black background. UniProt accession number of the
protein sequences used for sequence comparison are as follows: human TSPAN12: O95859; bovine TSPAN12:
Q29RH7; mouse TSPAN12: Q8BKT6; chicken TSPAN12: Q5ZIF5; zebrafish TSPAN12: Q7T2G0.
proline change at position 237 is likely to disrupt the three-dimensional structure of TSPAN12.
Both haplo-insufficiency and a dominant-negative effect of the mutant TSPAN12 on the wild-
type protein should be considered as the underlying disease mechanism.
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Tetraspanins are suggested to form so-called tetraspanin-enriched microdomains that act as
specific signaling compartments within the membrane, and might form homomultimers as
well as protein complexes with non-tetraspanin membrane proteins.216,219 In case TSPAN12
indeed forms homomultimers, the two missense mutations that cause FEVR might impair mul-
timerization of the protein and as such act in a dominant-negative fashion. This would be in
line with the absence of any abnormalities in the heterozygous Tspan12 mutant mice.212 Re-
cessive loss-of-function mutations in genes encoding other tetraspanins like TM4SF2 [MIM
300096] and CD151 [MIM 602243], causing X-linked mental retardation and kidney mal-
functions, respectively, would favor a dominant-negative mechanism instead of haploinsuf-
ficiency.220,221 On the other hand, heterozygous loss-of-function mutations in the PRPH2
[MIM 179605] gene encoding the tetraspanin peripherin cause autosomal dominant retinal
photoreceptor degeneration, favoring a model for haploinsufficiency.222,223 Taken together,
further functional studies are needed to determine the effect of the two missense mutations
described here, in order to unravel the pathological mechanism in which dominant mutations
in TSPAN12 are causative for FEVR.
This study shows the power of next-generation sequencing after initial identification of a dis-
ease gene locus. The only other example of this approach so far has been reported on by
Brkanac et al., which led to the identification of IFRD1 [MIM 603502] as a candidate gene
for autosomal dominant sensory/motor neuropathy with ataxia [MIM 607458].184 This tar-
geted resequencing approach may be an attractive alternative to whole genome or exome
resequencing in those families for which disease loci have been defined. Recently, unbiased
genome-wide resequencing of the whole human exome led to the first disease gene identifi-
cation in patients with Miller syndrome.224 The number of potential protein-truncating variants
in their study however was approximately three orders of magnitude higher than those iden-
tified by us. Such a genome-wide approach requires multiple affected individuals to limit the
amount of potential candidate genes, especially when operating under an autosomal dominant
disease model.
Conclusion
In conclusion, we have identified TSPAN12 as a gene causative for autosomal dominant
FEVR. TSPAN12 is only the third autosomal gene described to be causative for FEVR and
is mutated in five out of eleven Dutch families. Based on the function of TSPAN12 in regulat-
ing the development of the retinal vascular system, it is expected that mutations in TSPAN12
will also be causative in FEVR patients from different populations, and as such will facilitate
genetic diagnostics for FEVR. Moreover, we have proven, as one of the first groups ever, the
enormous power of next-generation sequencing technology in combination with array-based
sequence capture, by identifying a single causative base-pair substitution within a 40 Mb-
region containing more than 300 genes. Since for many inherited disorders, several loci have
been published for which the causative gene still awaits discovery, applying this technology
will be instrumental to identify many novel disease genes in the near future.
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Abstract
Autosomal recessive cerebellar ataxias comprise a clinically and genetically heterogeneous
group of neurodegenerative disorders. In contrast to their dominant counterparts, unraveling
the molecular background of these ataxias has proven to be more complicated and the cur-
rently known mutations provide an incomplete coverage for genotyping patients. By combining
SNP array-based linkage analysis and targeted re-sequencing of relevant sequences in the
linkage interval using next generation sequencing technology, we identified a mutation in a
gene and have shown its association with autosomal recessive cerebellar ataxia. In a Dutch
consanguineous family with 3 affected siblings a homozygous 12.5 Mb region on chromo-
some 3 was targeted by array-based sequence capture. Prioritization of all detected sequence
variants led to four candidate genes one of which contained a variant with a high base pair
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conservation score (phyloP score 5.26). This variant was a leucine-to-arginine substitution in
the DUF 590 domain of a 16K transmembrane protein, a putative calcium-activated chloride
channel encoded by anoctamin 10 (ANO10). The analysis of ANO10 by Sanger sequencing
revealed three additional mutations, a homozygous c.1150_1151del (p.Leu384fs) mutation
in a Serbian family, and a compound heterozygous splice site mutation c.1476+1G>T and a
frame shift mutation c.1604del (p.Leu535X) in a French family, respectively. This illustrates
the power of using initial homozygosity mapping with next-generation sequencing technology
to identify novel genes involved in autosomal recessive diseases. Moreover, identifying a pu-
tative calcium-dependent chloride channel involved in cerebellar ataxia adds another pathway
to the list of pathophysiological mechanisms that may cause cerebellar ataxia.
Introduction
Autosomal recessive cerebellar ataxias are a heterogeneous group of rare neurodegenerative
disorders in which progressive spinocerebellar ataxia, due to involvement of the cerebellum,
brainstem and/or spinocerebellar long tracts, is the key feature. Clinically, patients are char-
acterized by gait and balance impairment, upper limb coordination problems, and impairment
of speech, swallowing and eye movements. The overall prevalence is estimated to be around
five to six per 100,000.225 Autosomal recessive cerebellar ataxias are often associated with
other neurological (e.g. polyneuropathy, spasticity) or non-neurological (e.g. cardiomyopathy,
cataract) symptoms and can thus lead to complex phenotypes. Most autosomal recessive
ataxias have an early age of onset, formerly defined as before 20 years of age,226 but some
have been shown to begin much later. In contrast to the rapidly increasing number of genes
involved in the autosomal dominant cerebellar ataxias, the molecular background of the re-
cessive cerebellar ataxias has only partly been elucidated. Many patients with a recessive
ataxia are therefore still left without a molecular diagnosis.
Materials and Methods
Here, we describe the identification of a new gene involved in autosomal recessive cerebel-
lar ataxia, with downbeat nystagmus and involvement of lower motor neurons as additional
clinical features. The gene was identified in a Dutch remotely consanguineous family (Figure
4.1). The current study was approved by the Medical Ethics Committee of the Radboud Uni-
versity Nijmegen Medical Centre. Written informed consent to participate in the study was
obtained from the patients and their participating relatives (and all other patients described in
this paper). All three affected siblings from this family displayed impaired coordination of limbs
and gait with an onset between 20 and 35 years. Neurological investigation revealed a gaze-
evoked downbeat nystagmus with hypermetric saccades, dysarthric speech and brisk knee
reflexes. Mild atrophy of the upper part of the lower limbs with fasciculations was observed
in two of the three affected siblings. These two also had evidence of lower motor neuron in-
volvement on electromyography (Table 4.1). In all 3 affected siblings, brain imaging displayed
marked cerebellar atrophy with normal supratentorial structures (Supplementary Figure S5).
Homozygosity mapping using a 10K SNP array identified five homozygous regions on chromo-
somes 3, 6, 10, 12, and 16. Only the region on chromosome 3 was confirmed by further fine-
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Figure 4.1: Identification of ANO10 mutation in the Dutch family A with autosomal-recessive
cerebellar ataxia
A) Pedigree structure of the Dutch family A. Pedigree for the Dutch family A together with the segregation of
the mutation identified in this family. M1/M1 indicates homozygous carriers of the p.Leu510Arg mutation, M1/+
heterozygous carriers. The proband is indicated by the arrow. Unfortunately DNA was not available for the in-
dividual A:V.2. B) Coverage histogram of ANO10. Upper part: Sequence read histograms uploaded to UCSC
genome browser are displaying the sequencing depth of all exons of ANO10. Tracks displayed: Scale, chro-
mosomal position, read depth histogram per bp (between 0 and 60-fold coverage - higher than 60-fold is not
displayed), RefSeq gene track, highly conserved elements (PhastCons Placental Mammal Conserved Elements,
28-way Multiz Alignment). Lower part: Next generation sequencing read coverage of ANO10 exons 8-10. Tracks
displayed: Scale, chromosomal position, individual 454 sequencing reads, RefSeq gene track. C) Mutation vi-
sualization in the IGV browser. Individual reads overlapping with the mutation are displayed. 17 of 18 reads
show the homozygous mutation at genomic position chr3: 43571913 (the reads are mapped and displayed on
the + strand). D) Verification by Sanger sequencing of missense mutation c.1529T>G (p.Leu510Arg) in ANO10
(accession number NM_018075.3). E) Sequence comparison of the ANO10 protein in different species. The
amino acid which is mutated in the Dutch family is depicted, indicated by the arrow. The amino acid is highly
conserved throughout different species including fruitfly.
mapping by short tandem repeat markers, and showed a locus of approximately 10.5 Mb on
chromosome 3p21.32-p22.3 with a Logarithm of Odds (LOD) score of 3.6 in this Dutch family.
This locus could be further confirmed and fine-mapped by using a 6.0 SNP array (Affymetrix),
interrogating over 900,000 SNPs. The multipoint LOD score calculations and haplotype analy-
sis were performed with GeneHunter (version 2.1 release 5.05) in the easyLINKAGE software
package and Haplopainter software. Within the major locus, more than 80 genes are located
of which 15 candidate genes were sequenced by traditional Sanger sequencing, selected on
the basis of their known function and cerebellar expression. No mutations could be identified
in these genes. Subsequently, we targeted the entire 12.5 Mb region on chromosome 3 as
well as 9 smaller homozygous regions on chromosomes 1, 2, 3, 4 and 14 for array-based
sequence capture followed by next generation sequencing (Supplementary Table S8). The ar-
ray design included all known exons, untranslated regions (UTRs), microRNAs, and highly
conserved regions (PhastCons Conserved Elements, 28-way MostCons Plac Mammal Multiz
Alignment, LOD score > 100) for all homozygous regions.192,227 An additional 30 base pairs
(bp) sequences flanking all exons were added to the regions that were captured on the array
to enable the detection of splice-site mutations. Targets smaller than 250 bp, which is, based
upon our experience, the minimum size for the DNA capture protocol used, were enlarged by
extending both ends of the region. The targeted sequences comprise 1,905,376 bp in total
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Table 4.1: Clinical features of patients with recessive cerebellar ataxia with mutations in
ANO10
Patient A:VII.1 A:VII.2 A:VII.3 B:II.3 B:II.4 B:II.5 C:II.1 C:II.3
Age 50 48 47 42 39 35 60 55
Sex M M F F F M F F
Age of onset (yr) 25 20 32 15 15 13 45 25
Age at assessment 50 48 47 42 39 35 57 49
Mental retardation No No No Yes (mild) Yes (moder-
ate)
No No No
Ocular pursuit Downbeat
nystagmus
Downbeat
nystagmus
Downbeat
nystagmus
Horizontal
and vertical
nystagmus
Horizontal
and vertical
nystagmus
Horizontal
nystagmus
Saccadic pur-
suit, nystag-
mus
Multidirectional
nystagmus
Saccades Hypermetric Hypermetric,
slow (vertical)
Hypermetric Hypermetric,
mild
No Hypermetric,
mild
No Slow sac-
cades
Cerebellar dysarthria Moderate Moderate Mild Moderate Mild Moderate Moderate Moderate
Gait ataxia Moderate Moderate Mild Moderate Moderate Moderate Severe Moderate
Appendicular ataxia Moderate Moderate Mild Mild Mild Mild Moderate Moderate
Tendon reflexes UL Increased Increased Increased Increased Increased Increased tri-
ceps
Increased Increased
Tendon reflexes LL knee Increased Increased Increased Increased Increased Increased Increased Increased
Tendon reflexes LL ankle Increased Normal Increased Increased Normal Normal Increased Increased
Plantar responses Extensor Normal Normal Normal Normal Normal Normal Normal/
Babinski
Other features Cold and blue
toes
Wasting and
fasciculations
proximal leg
muscles,
cold and blue
fingers and
toes
Cold and blue
fingers and
toes
Inspiratory
stridor
Pes cavus Fasciculations
leg muscles.
Inspiratory
stridor and
vocal cord
paresis
Mild lower
limb spastic-
ity, slight rest
tremor, pes
cavus
Episodic
diplopia, pes
cavus
EMG Motor neuron
involvement
Motor neuron
involvement
Not done Not done Not done Motor neuron
involvement
Not done Normal
Cerebellar atrophy on MRI/ CT Severe Severe Severe Severe Severe Severe Not done Severe
Tortuosity of conjunctival vessels Absent Absent Absent Present Present Present Absent Absent
(Supplementary Table S9), and include 1245 exons from 117 RefSeq genes and 187 UCSC
genes, as well as 7 microRNAs and noncoding RNAs. After stringent probe selection by
NimbleGen (Roche NimbleGen, Madison, WI, USA) (uniqueness tested by Sequence Search
and Alignment by Hashing Algorithm-SSAHA), a total of 2,178,492 bases (Supplementary Table
S10) were represented on an array, with 385,000 oligonucleotide probes targeting the regions
of interest. Sequence capture was performed in accordance with the manufacturer’s instruc-
tions (Roche NimbleGen), using the Titanium optimized protocol. In brief, 5 µg of genomic
DNA of the proband (Figure 4.1) was used in the preparation of the DNA library for sequence-
capture hybridization. A final amount of 3µg pre- hybridization LM-PCR-amplified DNA was
hybridized to the customized array, eluted after 72 hours of hybridization and amplified by
post-hybridization LM-PCR. The amplified captured sample was then used as input for emul-
sion PCR amplification and subsequent sequencing using a Roche 454 GS FLX sequencer
with Titanium series reagents.
The sample was sequenced by using one quarter plate of a Roche sequencing run, yielding
83.7 Mb of sequence data. Approximately 95.0% of the sequence data mapped back to
unique regions of the human genome (hg18, NCBI Build 36.1), with the use of the Roche
Newbler software (version 2.3). Of all mapped reads, 93.5% was located on or near the
targeted regions (i.e., within 500 bp proximity) (Supplementary Table S11). This was sufficient
to reach an average of 32-fold coverage for all target regions. For the region of interest, less
than 1% of all targeted sequences were not covered, and only 4.2% of the target sequence
was covered less than ten times (11% was covered less than 15-fold).
The Roche software detected a total of 3,917 high confidence variants, identifying the variant
in at least 3 reads. We used a custom-made data analysis pipeline as described by Hois-
chen et al.228 to annotate detected variants with various types of information, including known
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SNPs, amino acid substitutions, genomic location, and evolutionary conservation. 3,352 vari-
ants were found to correspond to known SNPs and 169 variants overlapped with a known poly-
morphic region (dbSNP130) and were therefore considered not likely to be disease-causing
variants. Of all remaining 396 variants, there were 3 potential splice sites variants, 2 syno-
nymous coding variants and 5 non-synonymous coding variants, of these 10 variants only 4
were called as homozygous variants (i.e. >80% variant reads) (Supplementary Table S11 and
Supplementary Table S12). Of the four remaining candidates only two variants were conserved
during evolution,229 one of which had previously been reported in our internal variant database
in a patient with a different disorder. The remaining single candidate was a homozygous T>G
change in ANO10 which was highly conserved (phyloP score 5.26) and additionally scored
high on the Grantham scale (145) (Supplementary Table S12).
ANO10 consists of 13 exons of which 12 are coding, spanning 2734 base pairs and 660
amino acids (NM_018075.3). All exons of ANO10 were covered by sequence reads from
the targeted next-generation sequencing experiment (Figure 4.1). The homozygous T>G
change at position 1529 that was detected by next-generation sequencing, occurred in exon
10 and is predicted to result in an amino acid substitution of leucine by arginine at codon 510
(p.Leu510Arg). The mutated nucleotide (at position g.43,571,913; hg18, NCBI Build 36.1)
was covered by 18 unique sequence reads. In 17 reads, the mutant allele was detected,
indicating that the mutation is present in a homozygous state (Figure 4.1). The c.1529T>G
(p.Leu510Arg) mutation was confirmed by conventional Sanger sequencing and co-segregated
with the disease in this family (Figure 4.1). The mutation was not present in over 300 control
alleles (Table 4.2). This residue is conserved across multiple vertebrate species (Figure 4.1)
and is located in the DUF590 domain, a domain of unknown function.
Next, we analyzed this gene by conventional Sanger sequencing in a consanguineous family
(B) with three affected siblings of gypsy ethnic origin from Serbia (primer sequences are listed
in Supplementary Table S13). In family B an independent linkage analysis was performed, and
the candidate region overlapped with the whole region in the Dutch family initially studied (data
not shown). A homozygous two base pair deletion (TT) at position 1150 (c.1150_1151del) was
identified, leading to a frameshift (p.Leu384fs) in exon 6 (Table 4.2). This frameshift mutation
co-segregated with the disease in this family (Figure 4.2) and introduces a stop codon at posi-
tion 474. The mutation was not present in the dbSNP130 database, and was not detected in
over 300 control alleles. The affected siblings in this second cerebellar ataxia family also man-
ifested tortuosity of conjunctival vessels and intellectual disability in two siblings (Table 4.1).
Furthermore, ANO10 mutation analysis was performed in a large cohort of 282 index patients
with cerebellar ataxia with presumable autosomal recessive inheritance. In most patients of
this cohort, Friedreich ataxia (FA [MIM 22930]) had already been excluded by mutation ana-
lysis of the FRDA gene. Two compound heterozygous mutations, a splice site mutation in
exon 9 (c.1476+1G>T), and a nonsense mutation in exon 10 (c.1604del: p.Leu535X), were
identified in a single family (C) with 2 affected siblings of French descent (Figure 4.2). The
phenotype of these patients is almost identical to the phenotype of the Dutch family (Table
4.1). An overview of the mutations identified in ANO10 is presented in Table 4.2. So far, we
identified 29 different SNPs in this gene.
In adult tissues, ANO10 has the highest expression in brain as shown by qPCR (Figure 4.3).
Medium expression levels were found in retina and heart and low expression levels in other
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Table 4.2: Overview of the mutations identified in ANO10
Family Proband No. of affected Mutations Mutation Frequency in
siblings with (cDNA level) (protein level) control alleles
Family A VII.1 2 c.1529T>G / c.1529T>G p.Leu510Arg (homo) 0/300
Family B II.5 3 c.1150_1151del / c.1150_1151del p.Leu384fs (homo) 0/300
Family C II.3 2 c.1476+1G>T / c.1604del a/ p.Leu535X (hetero) 0/300
a The effect of the splice-site mutation at the protein level has not been studied
B :I.1 B :I.2 B :I.3
M2/+
B :I.4
B II.2:
+/+
B :II.3
M2/M2
B :II.4
M2/M2
B :II.5
M2/M2
F amily B
B :II.6
M2/+
B :II.I
M2/+
C :I.2
M4/+
C :I.1
C :II.1 C :II.1 C :II.1
M3/M4M3/M4 M4/+
F amily C
Figure 4.2: Pedigree Structure of Two Additional Families, B and C
Pedigrees for family B, from Serbia, and family C, from France, together with the segregation of the mutations
identified in these families. M2/M2 indicates homozygous carriers of the p.Leu384fs mutation, and M2/+ indicates
heterozygous carriers, whereas +/+ indicates individuals with two wild-type alleles. M3/M4 indicates compound-
heterozygous carriers for the c.1476+1G>T and the p.Leu535X mutations, and M4/+ indicates heterozygous
carriers for the p.Leu535X mutation. For family B, the degree of consanguinity is not known. Unfortunately, DNA
was not available for individual C:I.1.
tissues tested. Comparing the ANO10 expression levels between several adult brain areas
showed the highest expression levels in the frontal and occipital cortices and in the cerebellum
(Figure 4.3). In addition, we found that the expression of ANO10 in fetal brain is lower than in
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Figure 4.3: Expression of ANO10 in different human tissues, seen by qPCR
A) Expression of ANO10 in different adult tissues, with the highest expression seen in the brain. B) Expression
of ANO10 in different brain tissues, with the highest expression seen in the adult cerebellum and frontal and
occipital cortices.
adult whole brain, indicating a specific function for ANO10 in adult mature brain and especially
in the cerebral cortex and the cerebellum, rather than in brain development, although a role
of this gene in brain development cannot be excluded. The expression profile is consistent
with the relatively late onset of ataxia. However, ANO10 as well as ANO2 [MIM 610109] and
ANO8 [MIM 610216], were detected with similar distributions in the mantle layer of the neural
tube and in the dorsal root ganglia at E14.5 in murine embryos.230 Furthermore, expression
studies during cephalic development in the mouse seems to show embryonic expression of
ANO10 during brain development.231
Discussion
ANO10, also known as TMEM16K (transmembrane 16K) is a member of the human anoc-
tamin (ANO) family which comprises at least nine other proteins all exhibiting eight trans-
membrane domains and a DUF590 domain of unknown function.232,233 Only very recently, it
has been proposed that some or all of the anoctamin genes code for cell and tissue-specific
calcium-activated chloride channels.234–236 In murine tissues, ANO10 is predominantly ex-
pressed in epithelial cells next to ANO1 [MIM 610108], ANO6 [MIM 608663], ANO7 [MIM
605096], ANO8, ANO9 , while ANO2, ANO3 [MIM 610110], ANO4 [MIM 610111] , and ANO5
[MIM 608662] expression seem common in neuronal and muscle tissues. Based on results
of the functional studies done by Schreiber et al., it appears likely that different anoctamins
interact with each other.234
It is known that calcium-activated chloride channels have important physiological functions,
including, amongst others, regulation of neuronal excitability.237 Whether ANO10 really codes
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for a calcium-regulated chloride channel remains to be confirmed. In the phylogenic tree of
anoctamin genes, ANO1 is the member most distant from ANO10. A total of 25 amino acids
are missing from the region coding for the re-entrant loop between TM5 and TM6 in ANO10,
compared to ANO1,233 possibly blocking the proper formation of a channel. It is also possi-
ble that the ANO10 product can only function in combination with other anoctamins to form
heteromeric channels. Notwithstanding this, it is tempting to speculate that ANO10 indeed
encodes a (subunit of) a calcium-regulated chloride channel. Deranged calcium signaling in
Purkinje cells is one of the major mechanisms causing cerebellar ataxia.238,239 Several prod-
ucts of known ataxia-causing genes, such as calcium pumps, voltage-gated sodium or potas-
sium channels may increase or dampen calcium-signaling pathways in Purkinje cells.240–243 It
could well be that the ANO10 product, which is postulated to be a calcium-dependent chloride
channel, also is a player influencing calcium signaling in Purkinje cells, and a dysfunctional
or absent ANO10 product may cause cerebellar ataxia via this mechanism. The identifica-
tion of a putative chloride channel involved in a relatively pure, non-episodic cerebellar ataxia
may thus shed new light on the pathological mechanisms leading to cerebellar degeneration.
Different molecular pathways, such as mitochondrial and DNA repair dysfunction, are already
known to be involved. As mentioned, in autosomal dominant cerebellar ataxias, involvement of
calcium, sodium and potassium channels has been demonstrated.242,244,245 However, to our
knowledge this would be the first (calcium-activated) chloride channel involved in a cerebel-
lar neurodegenerative disease. Chloride channels are known to be involved in other diseases
such as, Myotonia Congenita [MIM 160800 and 255700], Dent’s disease [MIM 300009], Cystic
Fibrosis [MIM 219700] and Bartter syndrome [602522].87,246–248 At present however, the basic
function of ANO10 is poorly understood and so far most functional studies of anoctamins have
been performed with ANO1.
Dominant mutations in ANO5 (also known as GDD1) have been associated with a rare skele-
tal disorder called gnathodiaphyseal dysplasia (GDD [MIM 166260]).249 Recently, recessive
mutations in ANO5 have been identified in patients with limb girdle muscular dystrophy type 2L
(LGMD2L [MIM 611307]) and distal non-dysferlin Miyoshi myopathy (MMD3 [MIM 613319]).250
So far, no other members of the anoctamin gene family have been associated with genetic dis-
eases in human.
In conclusion, we have identified mutations in ANO10 associated with autosomal recessive
cerebellar ataxia. This report illustrates that the combination of homozygosity mapping to-
gether with targeted array-based sequencing is a powerful tool to identify causative genes for
autosomal recessive diseases. Mutations in ANO10 have so far been identified in three differ-
ent families with a total of eight patients, originating from the Netherlands, Serbia and France.
The phenotype of the patients is fairly similar (Table 4.1). Further functional studies are to
be awaited in order to understand how dysfunction of the ANO10 encoded putative chloride
channel results in cerebellar ataxia.
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Abstract
Schinzel-Giedion syndrome (MIM 269150) is characterized by severe mental retardation,
characteristic facial features and multiple congenital malformations; most patients die before
the age of ten. We sequenced the exomes of four affected individuals and identified het-
erozygous de novo variants in SETBP1. Mutations in 8 additional affected individuals were
identified by Sanger sequencing. All missense mutations clustered to a ultra-high conserved
11 bp exonic region, which suggests a dominant-negative or gain-of-function effect.
Introduction
Schinzel-Giedion syndrome is a highly recognizable syndrome (Figure 5.1) characterized by
severe mental retardation, characteristic facial features, multiple congenital malformations in-
cluding skeletal abnormalities, genitourinary and renal malformations and cardiac defects,
and a higher prevalence of tumors, notably neuroepithelial neoplasia.251,252 Most patients
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A
Figure 5.1: Identification of SETBP1 mutations in Schinzel-Giedion syndrome patients
A) Photos showing Patient 1, 3 and 4 (from left to right). Note the characteristic facial features, prominent fore-
head, bitemporal narrowing, mid-face retraction, hypertelorism, deep groove under the eyes, short upturned nose
and low-set abnormal ears. Written consent was available for all patients shown. B) Evolutionary conservation
of the SETBP1 region that harbors mutated amino acid residues in Schinzel-Giedion syndrome patients (marked
by asterisks, above human protein sequence). All mutated residues (p.Asp868Ala; p.Gly870Ser; p.Ile871Thr)
are completely conserved throughout evolution. Residues identical in all sequences are black on a white back-
ground, whereas different amino acids are black on a gray background. C) Schematic overview of the SETBP1
protein. Overview of known and predicted protein domains in relation to the mutation cluster observed in 12
Schinzel-Giedion patients, the mutated amino acid positions are marked per patient with an asterisks.
die before the age of ten. In almost all subjects, the disease phenotype occurs sporadically
suggesting heterozygous de novo mutations in a single gene as the underlying mechanism.
Rare recurrences may be due to gonadal mosaicism. Traditional disease gene identification
approaches have so far failed to identify the gene for this disease and for the majority of
these rare sporadic disorders. Microarray-based Copy Number Variation screening has been
successful for a number of disorders83 but can fail unless the disease mechanism is haploin-
sufficiency. Recently, whole-exome sequencing was demonstrated to be effective for disease
gene identification224 and was successfully used to decipher Miller syndrome, a recessive
Mendelian disorder.253
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Materials and Methods
We sequenced the exomes (37 Mb of genomic sequences, targeting ∼18,000 genes) of
four unrelated individuals with Schinzel-Giedion syndrome to a mean coverage of 43-fold
(Supplementary Table S14, Supplementary Figure S6 and Supplementary Figure S7). The exomes
of all individuals were enriched using the SureSelect human exome kit (Agilent, Santa Clara,
CA, USA) and subsequently sequenced using one quarter of a SOLiD sequencing slide (Life
Technologies, Carlsbad, CA, USA). A total of 2.7-3.0 Gb mappable sequence data was gen-
erated per patient, with 65-72% of bases mapping to the targeted exome (Supplementary Table
S14). On average 85% of the exome was covered at least 10-fold.
Results
On average 21,800 genetic variants were identified per patient, including 5,351 non-synonymous
changes. A number of prioritization steps were applied to reduce this number and to identify
the potentially pathogenic mutation, similar to what was done by Ng et al.224,253 (Supplementary
Table S15). A comparison with dbSNP130 as well as recently released SNP data from other
groups and in-house SNP data (see Supplemental Methods) showed that more than 95%
of all variants were previously reported as SNPs and cannot explain a dominant disease.
We focused on the 12 genes that contained variants in all four patients, and found that only
two genes had variants at different genomic positions, strengthening the likelihood that these
are causative and not unidentified SNPs. One of these two candidate genes, CTBP2, was
excluded from further analysis as it contained many variants in different in-house exome se-
quencing experiments (data not shown), which may be due to highly homologous sequences
from other genomic loci.
The second candidate was SETBP1, which encodes SET binding protein 1. Validation of
all 4 variants by Sanger sequencing confirmed that these variants were indeed present in a
heterozygous state in all 4 patients (Supplementary Figure S8). Moreover, testing of parental
DNAs showed that all mutations had occurred de novo. Sanger sequencing also confirmed
the presence of SETBP1 mutations in 8 out of 9 additional patients with the clinical diagnosis
of Schinzel-Giedion syndrome. All 13 patients fulfilled the diagnostic criteria suggested by
Lehman et al.252 (Table 5.1 and Supplementary Table S16) and are of European descent, living
in various parts of the world (Europe (n=7), New-Zealand (n=3), Australia (n=2) and the USA
(n=1)). For 6 of the 8 additional cases parental DNA was available and again the mutation was
shown to have occurred de novo. Parentage was confirmed by Short Tandem Repeat (STR)
marker analysis in all patient-parent trios available. None of the mutations were found in 188
control chromosomes. The presence of a second mutation was excluded by sequencing all
coding exons of SETBP1 in all patients. The mutated basepairs are amongst the highest
conserved positions described in the human genome (phyloP 44 species conservation score
up to 7.129). This is in agreement with our earlier observation that basepair conservation can
be used for variant prioritization.254 Remarkably all changes occurred in a genomic stretch of
only 11 nucleotides (g.40,789,905-g.40,789,915; c.2602-c.2612), affecting 3 of 4 consecutive
amino acids (p.868-p.871; Asp, Ser, Gly, Ile). Two mutations were recurrent: c.2602G>A and
c.2612T>C in 4 and 5 patients, respectively.
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Discussion
There are two indications that the mutations may either result in a gain-of-function or have
a dominant negative effect:(1) A gain of function has been described for other syndromes
such as Noonan syndrome with very similar mutation clustering in PTPN11 and SOS1,99 as
well as FGFR3 mutation clustering in achondroplasia, and (2) the phenotype of patients with
partial chromosome 18q deletions affecting the SETBP1 gene256 does not resemble Schinzel-
Giedion syndrome.
SETBP1 shows ubiquitous expression,257 which is in line with the multisystemic defects in
Schinzel-Giedion syndrome patients. Relatively little is known about the function of SETBP1
protein, except for its binding to SET domains. This domain is named after three Drosophilia
genes involved in epigenetic processes, Su(var), E(z) and trithorax,258 and is known to be
involved in methylation of lysine residues on histone tails. We note however that all muta-
tions are located outside of the SET interacting domain, nor do they affect the DNA bind-
ing domains. The protein sequence in which the mutations cluster, however, is highly con-
served throughout evolution (Figure 5.1). A glycosaminoglycan attachment site was predicted
at this position in the protein (amino acids p.815-p.818 (Ser, Gly, Ile, Gly)).259 At least for
one type of glycosaminoglycans, the keratan sulfates, an important role in bone development
was described.260 Of note, skeletal malformations are one of the major features of Schinzel-
Giedion syndrome. Interestingly, the mutation cluster overlaps with a region that shows ho-
mology to the oncogene SKI (amino acids 706-917) (Figure 5.1). Minakuchi et al.261 specu-
late that SETBP1 might be involved in the regulation of Ski/Ski homodimer and/or Ski/SnoN
heterodimer formation which cause cellular transformation. High SETBP1 expression is de-
scribed in cancer cell lines, and in a pediatric acute T cell lymphoblastic leukemia SETBP1
is reported as a chromosomal translocation partner of NUP98.262 Whether this relates to the
elevated risk for neuroepithelial neoplasia and sacroccygeal teratomas in Schinzel-Giedion
patients (Table 5.1) requires further investigation.
Conclusion
In conclusion, our study shows the potential of exome sequencing for disease gene identifi-
cation by unraveling the first dominant Mendelian disorder. It is highly likely that the muta-
tions cause disease through either a dominant negative or a gain-of-function effect. Exome
sequencing is particularly useful for identifying these types of mutations for which no other
genomewide approach is applicable. One limitation is the current inability to reliably iden-
tify structural genomic variation associated with disease, and we therefore recommend to
combine exome sequencing with microarray-based CNV detection. De novo mutations and
structural variations may be a frequent cause of sporadic conditions with reduced fecundity
such as congenital malformations, mental retardation, and psychiatric disorders.
65
Supplemental Methods
Clinical samples
All 13 Schinzel-Giedion syndrome patients fulfilled the diagnostic criteria suggested by Lehman
et al.252 (Table 5.1 and Supplementary Table S16) and are from various parts of the world
(Europe (n=7), New-Zealand (n=3), Australia (n=2) and the USA (n=1)). The DNA samples
studied from 13 subjects and 94 normal control DNAs were isolated from peripheral blood
leucocytes following standard techniques. This study was approved by the Medical Ethics
Committee of the Radboud University Nijmegen Medical Center. Written informed consent to
participate in the study was obtained for all patients as well as informed consent to publish
clinical photos for cases 1, 3 and 4.
Exome Sequencing
DNA was obtained from peripheral blood of all patients. This study was approved by the
Medical Ethics Committee of the Radboud University Nijmegen Medical Centre. For exome
enrichment 3µg genomic DNA was required. We used a AB SOLiD optimized SureSelect
human exome kit (Agilent, Santa Clara, CA, USA), which contained exonic sequences of
∼18.000 genes, covering a total of 37 Mb genomic sequences, following the manufacturer’s
instructions. The enriched exome libraries were subsequently used for e-PCRs following man-
ufacturer’s instructions (Life Technologies, Carlsbad, CA, USA), based on a library concentra-
tion of 0.5pM. For each sample one quad of a SOLiD sequencing slide (Life Technologies,
Carlsbad, CA, USA) was used.
Color space reads were mapped to the hg18 reference genome with the SOLiD bioscope
software which utilizes an iterative mapping approach. Single nucleotide variants were sub-
sequently called by the DiBayes algorithm163 using the conservative default call stringency.
Small insertions and deletions were detected using the SOLiD Small InDel Tool. Called SNP
variants and indels were combined and annotated using a custom analysis pipeline. For
prioritization we excluded known SNPs from dbSNP v1.30 and variants from our in-house
database which consists of data from in-house targeted resequencing projects (6,595 vari-
ants), the 1000 genomes project (http://www.1000genomes.org) as well as published data
from various studies178,213,214 (2,535,563 variants).
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Abstract
Sensenbrenner syndrome /Cranioectodermal Dysplasia (CED) is an autosomal recessive dis-
ease which is characterized by craniosynostosis, ectodermal and skeletal abnormalities. We
sequenced the exomes of two unrelated CED patients and identified compound heterozygous
mutations in WDR35 as the cause of the disease in each of the two patients independently,
showing that it is possible to find the causative gene by sequencing the exome of a single spo-
radic patient. With RT-PCR we demonstrate that a splice-site mutation in exon2 of WDR35
alters splicing of RNA on the affected allele, introducing a premature stop codon. WDR35 is
homologous to TULP4 (from the Tubby superfamily) and has previously been characterized
as an Intraflagellar Transport (IFT) component, confirming that Sensenbrenner syndrome is a
ciliary disorder.
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Introduction
Cranioectodermal dysplasia (CED [MIM 218330]) also known as Sensenbrenner syndrome
is an autosomal recessive disease which is characterized by sagital craniosynostosis, facial,
ectodermal and skeletal anomalies.263,264 A proportion of cases have nephronophthisis, hep-
atic fibrosis, retinitis pigmentosa and brain anomalies.265 This phenotype shows remarkable
overlap with the ciliopathies, a spectrum of disorders which is associated with dysfunction of
the cilium, a microtubule-based organel that protrudes from the membrane in many vertebrate
cell types.266 Furthermore, it has recently been shown that defects in the ciliary gene IFT122
can be a cause of CED.267
Materials and Methods
Here we report on two unrelated Sensenbrenner patients with remarkably similar pheno-
types (Figure 6.1 and Table 6.1). These cases were previously screened diagnostically us-
ing Affymetrix 250k arrays. As neither pathogenic CNVs nor large homozygous regions were
identified, we decided to use a different approach to identify the cause of disease in these two
patients. The current study was approved by the Medical Ethics Committee of the Radboud
University Nijmegen Medical Centre. Written informed consent to participate in the study was
obtained for both patients (and all other ciliopathy patients described in this paper) as well as
informed consent to publish clinical photos for patients 1 and 2.
We applied a genome wide approach and sequenced the exomes (targeting ∼18,000 genes)
of both patients. We obtained 3.6 Gb and 3.4 Gb of mappable sequence data per patient using
the SureSelect human exome kit (Agilent, Santa Clara, CA, USA) on one quarter of a SOLiD
sequencing slide (Life Technologies, Carlsbad, CA, USA). Color space reads were mapped
to the hg18 reference genome with the SOLiD bioscope software version 1.0 which utilizes
an iterative mapping approach. In total 89% and 86% of bases originated from the targeted
exome resulting in a mean coverage of 67- and 59-fold (Supplementary Table S17). Single
nucleotide variants were subsequently called by the DiBayes algorithm using a conservative
call stringency. The DiBayes SNP caller requires at least two variant reads to call a SNP.
We assumed a binomial distribution with probability 0.5 of sequencing the variant allele at
a heterozygous position. At least 10 reads are then required to obtain a 99% probability of
having at least two reads containing the variant allele. More than 89% of the targeted exons
was covered more than 10 times. Small insertions and deletions were detected using the
SOLiD Small InDel Tool. Called SNP variants and indels were then combined and annotated
using a custom analysis pipeline.
Results
On average 12,736 genetic variants were identified per patient in either the coding regions
or the canonical dinucleotide of the splice sites, including 5,657 non-synonymous changes
(Supplementary Table S18). A prioritization scheme was applied to identify the pathogenic mu-
tation in each patient separately, similar to a recent study.228 We excluded known dbSNP130
variants as well as variants from our in-house variant database, reducing the number of can-
didates by more than 98%. The in-house database consists of data from in-house exome
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Figure 6.1: Two patients with Sensenbrenner syndrome for which exome sequencing was
performed
A) Patient 1, small thorax, pectus excavatum, rhizomelic shortening limbs. B) Shortening proximal 2nd phalanx.
The proximal phalanx is indicated by "P"; the middle phalanx is indicated by "M". C) Syndactyly 2-3 right foot,
2-3-4 left foot. D) Hypertelorism, unilateral ptosis left eye, low set ears, everted lower lip. E) Patient 2, small
thorax, pectus excavatum, rhizomelic shortening limbs. F) Short, broad hands. G) Bilateral sandal gap between
1st and 2nd toe. H) Hypertelorism, low set, simple ears, thin hair.
resequencing projects of patients with rare syndromes (548,103 variants), the 1000 genomes
project as well as published data from various studies178,213,214 (2,535,563 variants). For a
recessive disease it is possible that heterozygous variants found in healthy individuals have
been reported as benign polymorphisms within dbSNP or our internal variant database. How-
ever given the rare incidence of CED it is almost impossible that heterozygous mutations occur
at a reasonable frequency in the healthy population and thus it is unlikely that they have been
included in dbSNP.
Under the assumption of an autosomal recessive disease model we found 3 candidate genes
with compound heterozygous variants in patient 1 (FLG, MRFP and WDR35). The inheri-
tance of the variants in the three candidate genes was determined by Sanger sequencing
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Table 6.1: Clinical details of 2 patients with Cranioectodermal dysplasia
Patient 1 2
Mutations DNA c.1877A>G, c.25-2A>G 1:c.2891delT, c.2623G>A
Mutations protein p.E626G, p.I9TfsX7 p.P964LfsX15, p.A875T
Age at diagnosis 7 9
Height < 2.5 SD < 2.5 SD
Dolichocephaly + +
Craniosynostosis Surgically corrected at age 1 Surgically corrected at age 1
Frontal bossing + +
Macrocephaly - -
Sparse, fine hair - +
Narrow palpebral fissure + +
Telecanthus + +
Hypermetropia + -
Nystagmus - -
Ptosis Unilateral -
Hypertelorism + +
Strabism + -
Low implanted ears + +
Simple ears + +
Everted lower lip + +
Micrognathia + -
Widely spaced teeth + +
Hypoplastic teeth + +
Fused teeth + +
Short neck + +
Narrow thorax + +
Pectus excavatum + +
Short limbs + +
Brachydactyly + +
Webbing fingers + +
Postaxial polydactyly + -
Restricted flexion fingers + -
Syndactyly 2-3(4th) toe + -
Bilateral sandal gap - +
Joint laxity + +
Inguinal hernia (bilat.) + +
Renal disease - -
Hepatic disease - -
Recurrent lung infections + -
Intelligence Normal Normal
Behaviour Happy, friendly Happy, friendly
showing that the two WDR35 (genbank: NM_001006657), and the two MFRP variants were
inherited from different parents (Supplementary Table S18). Based on evolutionary conserva-
tion score229 both variants in WDR35 ranked to the top position among all variants of the three
candidate genes (Supplementary Table S19). Moreover WDR35 was the only candidate with a
ciliary function according to the Ciliary Proteome database268 (cutoff e-value: 30; 2,127 en-
tries). In patient 2 we identified 4 candidate genes that harboured 2 or more variants. Sanger
validation excluded two of these as candidate genes because the variants were inherited from
a single parent. The remaining candidates, USH2A and WDR35 both had a putative ciliary
function. The two conserved variants in USH2A were both inherited paternally while a third
non-conserved variant was not inherited paternally, which makes USH2A an unlikely candi-
date for CED. Furthermore this patient had no signs of retinitis pigmentosa (MIM 608400) or
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Usher syndrome (MIM 276901). The WDR35 variants were inherited from both parents and
affected base pairs with high evolutionary conservation (Supplementary Table S19). In conclu-
sion we independently identified the WD repeat domain 35 gene as the most likely candidate
disease gene in both patients.
In patient 1 we identified a canonical splice site mutation two base pairs upstream of exon
2 (c.25-2A>G, p.I9TfsX7) and a missense mutation in exon 17 (c.1877A>G, p.Glu626Gly)
(Figure 6.2 and Supplementary Figure S9). With RT-PCR we demonstrated that splicing of
WDR35 RNA (derived from Epstein-Barr Virus (EBV) cell lines) is indeed altered in patient 1
compared to an unrelated control individual (Figure 6.2). Sequencing of the bands reveals that
the affected allele contains an additional 58 bp which introduces a premature stop codon. The
missense mutation in exon 17 is predicted to be "probably damaging" by PolyPhen.269 The
mutated amino acid is highly conserved up to insects and nematodes (Supplementary Figure
S10). Since the C. elegans protein WDR35 orthologue (IFTA-1) is most distantly related to
the human WDR35 protein (only 44.2% similar and 28.4% identical), the conservation of the
glutamine provides a strong indication for the importance of this amino acid for WDR35/IFTA-1
function.
In patient 2 a deletion of a C nucleotide in exon 25 predicts a frameshift and a premature
stop (1:c.2891delC, p.Pro964LeufsX15) (Supplementary Figure S9). On the second allele a
substitution in exon 23 (c.2623G>A, p.Ala875Thr) leads to the change of a highly conserved
alanine to a threonine (Supplementary Figure S9 and Supplementary Figure S10). The amino
acid substitution was classified as "potentially damaging" by PolyPhen. It is remarkable that
the variants in our patients are a combination of a missense- and a truncating mutation. In
ciliary diseases phenotypical severity is often determined by the combination of missense
and nonsense mutations.270 This phenomenon could be used in the prioritization of variants
from exome sequencing of other (ciliary) diseases, which in this case would have immediately
identified WDR35.
None of the four identified variants in WDR35 were detected in 210 control alleles, indicating
that the identified variants are uncommon in the Dutch population from which the patients orig-
inated, further supporting the thought that the WDR35 variants are pathogenic. Furthermore,
complete loss of WDR35 function leads to a severe Short-rib Polydactyly (SRP) syndrome,
another ciliopathy (PJ Lockhart, personal communication).
WDR35 contains 28 coding exons that encode at least 4 known protein isoforms (as deter-
mined in Ensembl). The WDR35 protein, which is part of the WD repeat protein family, was
first characterized in the green alga, Chlamydomonas reinhardtii.271 The Chlamydomonas
orthologue (IFT121) is part of the intraflagellar transport complex A, together with at least five
other proteins. One of them, IFT122/WDR10, also contains N-terminal WD repeats and has
recently been shown to be involved in CED as well.267 Like other IFT-A proteins WDR35 is
instrumental for a retrograde IFT (from the ciliary tip to the basal body) in mice.272 Studies
in Drosophila and C. elegans also demonstrate that the WDR35 orthologues (Oseg4 and
IFTA-1, respectively) localize to the cilium and act in IFT.273 It is thus most likely that cilium
dysfunction due to disrupted (retrograde) IFT is underlying the CED phenotype of patients
with mutations in WDR35.
To evaluate whether mutations in WDR35 are a common cause of CED, we performed mu-
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Figure 6.2: Splice site mutation in patient 1
A) Gene and protein structure of WDR35. WD-domains are indicated by triangles; the box indicates a low
complexity region B) Sequencing reads showing the heterozygous splice-site mutation at the splice-acceptor
site of exon 2 as well as a nearby exonic polymorphism (rs1060742). C) Maternal inheritance of the splice site
mutation in patient 1 shown by Sanger sequencing. D) Effect of the splice site mutation on the RNA shows two
different products of equal intensity in lane 1 (523 bp and 465 bp for the upper and lower band, respectively).
Lane 2 shows the product of an unrelated control (465 bp). E) Sequence of the two WDR35 RT-PCR products
from panel D, showing that the polymorphism (rs1060742) is predominantly present in the normal spliced product
as a C (panel D, lane 1, arrow a), while this is a T in the alternatively spliced product (panel D, lane 1, arrow b).
The sequence of the RT-PCR product of an unrelated individual with the same heterozygous SNP (rs1060742)
is shown as a control (panel D, lane 3, arrow c).
tation analysis in 6 additional CED patients. These patients were presented with additional
clinical phenotypes and did not show the striking phenotypic similarity as observed between
patients 1 and 2. In three of these patients mutations in IFT122 had been excluded, while
in two other patients linkage regions were identified that did not contain IFT122 (or IFT121).
We did not find any causative mutations in WDR35 in these patients. Thus only 25% of our
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cohort (2 out of 8 CED patients) carried mutations in WDR35, further confirming that CED is
a genetically heterogeneous disorder similar to other ciliopathies.267,270
Discussion
Our results match with the previously shown importance of IFT in bone development; mu-
tations in IFT80 and DYNC2H1 have been associated with Jeune syndrome (MIM 208500),
a disorder with significant clinical overlap with CED.274,275 Based on this and the fact that
many ciliary disease genes are associated with multiple ciliopathy syndromes270 we screened
WDR35 for mutations in 15 Jeune syndrome patients. No mutations were found in these pa-
tients, indicating that mutations in WDR35 are not a major cause of Jeune syndrome. So far,
Sensenbrenner syndrome is the only ciliopathy that includes a craniosynostosis phenotype.
Since conditional IFT knock-out mouse models indicate that Sonic and Indian Hedgehog sig-
naling is regulated by cilia during skeletal development, we hypothesize that disrupted ciliary
Hedgehog signaling due to disrupted IFT is involved in the skeletal features including cran-
iosynostosis in our CED patients. Wdr35 knockout mice do indeed display Hedgehog defects
during limb development.272
By using several bioinfomatic tools (i.e. the phylogenitcs tree database "Treefam", "Gene Tree"
from Ensembl and "BLAST" from NCBI) we found that TULP4 (a member of the Tubby super-
family) is homologous to WDR35. Although little is known about the function of TULP4, it is of
interest that the Tubby family member Tulp3 is known to modulate Shh signaling during early
embryonic development of the mouse,276 like WDR35272 and other IFT proteins. Moreover, as
the phenotype of Tulp3 knockout mice as well as other mutants from the Tubby family shares
phenotypic features with CED and other ciliopathies, we conclude that TULP4 is an excellent
candidate for such disorders.276–280 Together these findings also suggest that the IFT pro-
teins and some members of the Tubby family of proteins, in particular TULP4, are functionally
related.
In our study, the availability of two independent cases with a strikingly similar phenotype was
obviously very useful for identifying the causative gene. For both individual patients we iden-
tified only a small number of candidate disease genes. In each of the two cases this was
further reduced to a single candidate (WDR35) by segregation analysis and additional evi-
dence on evolutionary conservation and the ciliome database. The finding that WDR35 is
mutated in a family with Short Rib Polydactyly syndrome [MIM 263510] confirms that WDR35
is indeed involved in ’skeletal’ ciliopathies (PJ Lockhart, personal communication). Interest-
ingly, both patients are presented with sagittal craniosynostosis, a birth defect characterized
by premature closure of the skull sutures which occurs in 1.5 per 10,000 newborns. Familial
recurrences, and occasional concordant twins indicate the presence of genetic factors under-
lying sagittal synostosis, but these remain largely unknown. The involvement of WDR35 in
this phenotype might provide insight into the underlying biology of sagittal craniosynostosis.
Conclusion
It should be noted that theoretically we could have missed additional variants that are rele-
vant for the disease. Only high quality whole genome sequencing could have fully excluded
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disease-related genomic variants or modifiers. However we believe that the combined genetic
and functional data undoubtedly shows the involvement of WDR35 in CED. In summary, our
data indicate that for a rare recessive condition, it is possible to find the causative gene by se-
quencing the exome of a single sporadic patient. This is consistent with the results of a recent
study of a Perrault syndrome [MIM 233400] that also found the causative gene by sequencing
the exome of a single affected individual.281
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Abstract
Osteogenesis Imperfecta (OI) is a heterogeneous genetic disorder characterized by bone
fragility and susceptibility to fractures after minimal trauma. After mutations in all known OI
genes had been excluded by Sanger sequencing, we applied next-generation sequencing
to analyze the exome of a single individual with a severe form of the disease whose par-
ents are second cousins. A total of 26,922 variations from the human reference genome
sequence were subjected to several filtering steps. In addition, we extracted the genotypes
of all dbSNP130-annotated SNPs from the exome sequencing data and used these 299,494
genotypes as markers for the genome-wide identification of homozygous regions. A single ho-
mozygous truncating mutation, affecting SERPINF1 on chromosome 17p13.3, remained that
was embedded into a homozygous stretch of 2.99 Mb. The mutation was also homozygous
in the affected brother of the index patient. Subsequently, we identified homozygosity for two
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different truncating SERPINF1 mutations in two unrelated patients with OI and parental con-
sanguinity. All four individuals with SERPINF1 mutations have severe OI. Fractures of long
bones and severe vertebral compression fractures with resulting deformities were observed
as early as in their first year of life. Collagen analyses with cultured dermal fibroblasts dis-
played no evidence for impaired collagen folding, posttranslational modification, or secretion.
SERPINF1 encodes pigment epithelium-derived factor (PEDF), a secreted glycoprotein of the
serpin superfamily. PEDF is a multifunctional protein and one of the strongest inhibitors of an-
giogenesis currently known in humans. Our data provide genetic evidence for an involvement
of PEDF in human bone homeostasis.
Introduction
Osteogenesis imperfecta (OI; MIM 166200, 166210, 610854, 259420, 166220, 610967, 610968,
610682, 610915, and 259440 for type I to IX of the disease) is a genetic disorder character-
ized by bone fragility and susceptibility to fractures after minimal trauma. Disease severity
ranges from very mild forms without fractures to intrauterine fractures and perinatal lethal-
ity.282,283 Typical extraskeletal manifestations, which affect a variable number of OI patients,
are dentinogenesis imperfecta, hearing loss and blue sclera. Most individuals with OI have
autosomal-dominantly inherited mutations in one of the two genes that encode the α chains
of the major bone matrix protein collagen type 1, COL1A1 (MIM 120150) and COL1A2 (MIM
120160). Mutations in these genes result in quantitative and/or qualitative defects in type 1
collagen production by osteoblasts.284–287
In a minority of OI patients, the disorder is inherited in an autosomal-recessive manner. Re-
cently, mutations in six different genes have been associated with these OI forms. CRTAP
(MIM 605497), LEPRE1 (MIM 610339), and PPIB (MIM 123841) encode components of the
prolyl 3-hydroxylation complex.288–295 This protein complex is located in the rough endoplas-
matic reticulum and, among other functions, modifies the Pro986 residue of the type 1 colla-
gen α1 chains.293,296 SERPINH1 (MIM 600943) and FKBP10 (MIM 607063) encode collagen
chaperones.297–301 HSP47, the gene product of SERPINH1, possibly monitors the final in-
tegrity of the triple helix that is formed out of two α1 chains and one α2 chain.298 SP7/OSX
(MIM 606633) encodes a transcription factor that, based on the function of its murine homolog,
is assumed to regulate the differentiation of preosteoblasts to osteoblasts.302,303 In a substan-
tial number of COL1A1 and COL1A2 mutation-negative OI cases, the underlying molecular
defect is unknown.298
The current standard therapy for moderate and severe forms of OI (type II, III, and IV in
the Sillence classification304) is cyclic intravenous application of bisphophonates.282 These
compounds are synthetic analogs of pyrophosphate that deposit on the bone surface where
they inhibit osteoclasts.305,306 Bisphosphonate treatment, ideally starting in early childhood,
increases bone mineral density. There is evidence that it also reduces fracture rates, chronic
bone pain and immobility in OI patients.307
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Table 7.1: Clinical features of patients with recessive OI and mutations in SERPINF1
Findings Patient #1 Patient #2 Patient #3 Patient #4
OI type a III III III III
Age at first visit (years) 1 8/12 11 4/12 6/12 1 1/12
Age at last visit (years) 3 2/12 16 3/12 8 7/12 5 11/12
Age at start of bisphosphonate treatment 1 8/12 11 4/12 7/12 1 1/12
Birth length and birth weight normal normal normal normal
Confirmed prenatal fractures no no no no
Age at first fracture (months) 4 unknown 6 6
Color of sclera grayish grayish grayish grayish
Dentinogenesis imperfecta no no no no
Hypermobility of joints no no no no
Hearing impairment no no no no
Old fractures of extremities b yes yes yes yes
Vertebral fractures b multiple multiple multiple multiple
Bowing of upper extremities b moderate severe mild moderate
Bowing of lower extremities b severe severe moderate moderate
Shortening of upper extremities b moderate severe mild mild
Shortening of lower extremities b moderate severe moderate mild
Weight at first visit kg/BMI (SD) 9 /-0.5 40/+3.2 7.5/-1.4 11.9/+1.8
Weight at last visit kg/BMI (SD) 9.9/1.1 45/+3.5 17/-1.4 14/-1.5
Length at first visit cm/(SD) not done 98/-8.8 67/0.2 78.3/-0.7
Length at last visit cm/(SD) 76/-5.6 101/-10.2 110/-3.8 101.5/-2.8
Retarded gross motor functions yes yes yes yes
Mobility at first visit (BAMF c) 2 1 0 4
Mobility at last visit (BAMF cc) 4 2 6 6
Intelligence normal normal normal normal
Calcium-level b normal normal normal normal
Alkaline phosphatase at first visit [U/l] 353 283 295 348
Alkaline phosphatase at last visit [U/l] 328 154 269 344
Procollagen-1-C-peptide (marker for os-
teoblastic activity) [µg/l] b
720 430 200 375
Deoxypyridinoline / creatinine (marker for
osteoclastic activity) [nM/mM] at first visit
not done 86.5 118.9 not done
Deoxypyridinoline / creatinine (marker for
osteoclastic activity) [nM/mM] at last visit
64.9 60.1 63.1 65.3
First available Bone density, DXA Whole
body measurement (z-score)
- 6.1 (lumbar spine) -3.7 -2.7 -2.0
aaccording to the Sillence classification.304 b at first presentation. c brief assessment of motor function.308
Material and Methods
Here, we report the identification of a gene which is mutated in a severe form of OI. The
gene was identified in an affected male individual who has a similarly affected older brother.
The parents originate from the United Arab Emirates and are second cousins, suggesting
autosomal-recessive inheritance of the disease. Mutations in all genes known to cause
autosomal-dominant and -recessive OI (see above) had been excluded by direct Sanger se-
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quencing of genomic DNA. We therefore decided to follow a genome-wide sequencing ap-
proach to identify the cause of the disease in this patient. The study was approved by the
Medical Ethics Committee of the Radboud University Nijmegen Medical Centre. Written in-
formed consent to participate in the study and to publish clinical data and radiographs was
obtained for the index patient (and for all other OI patients described in this paper).
We sequenced the exome (∼18,600 genes) of the index patient using the SureSelect human
exome kit (Agilent, Santa Clara, CA, USA) and one quarter of a SOLiD
TM
4 system sequencing
slide (Life Technologies, Carlsbad, CA, USA). We obtained 3.7 Gb mappable sequence data.
Color space reads were mapped to the hg18 reference genome with the SOLiD bioscope
software version 1.2, which utilizes an iterative mapping approach. In total, 71% of bases
originated from the targeted exome, resulting in a mean coverage of 65-fold (Supplementary
Table S20). Single nucleotide variants were subsequently called by the DiBayes algorithm
using high call stringency. Ninety-two percent of the targeted exons were covered more than
10 times. Small insertions and deletions were detected using the SOLiD Small InDel Tool.
Called SNP variants and indels were then combined and annotated using a custom analysis
pipeline.
Results
Initial quality filtering (>5 variant reads and >15% variant reads) resulted in the identification of
13,487 genetic variants in the coding regions or the canonical dinucleotides of the splice sites,
including 6,298 non-synonymous changes (Supplementary Table S21). A prioritization scheme
was applied to identify the pathogenic mutation, similar to recent studies.67,228,309 For a re-
cessive disease, it is possible that pathogenic mutations are listed as benign polymorphisms
in dbSNP or in our internal variant database, as individuals without the respective phenotype
can be heterozygous carriers. However, given the rare incidence of autosomal-recessive OI,
we considered such a scenario as unlikely. We therefore excluded known dbSNP130 variants
as well as variants from our in-house variant database, reducing the number of candidates by
more than 98% to a total of 318 variants.
For further analysis, we applied an autosomal-recessive disease model and assumed that
the causal mutation was inherited from a common ancestor due to parental consanguinity.
Under this assumption, only 17 autosomal candidate genes with homozygous variants in the
index patient remained. To prioritize these candidate genes, we developed an algorithm for
unbiased identification of homozygous regions in the genome: We extracted the genotypes of
all autosomal SNPs annotated in dbSNP130 that had a read coverage of at least 15-fold from
the exome sequencing data of the index patient. This resulted in a total of 299,494 genotypes,
which increased the number of potential genetic markers for the identification of homozygous
regions in the genome more than 17-fold. Variants displaying an identical SNP allele in >95%
of all reads were considered to be homozygous, SNPs with 30% to 70% variation reads were
considered to be heterozygous, and SNPs with <30% or with 70% to 95% variation reads
were considered ambiguous. A genomic region was identified as a homozygous stretch if at
least 500 consecutive SNP markers were called as homozygous, with a maximum tolerance
of two heterozygous SNPs per 500 markers (to account for possible sequencing or mapping
errors). In the dataset of the index patient, this algorithm identified seven homozygous regions
78
Exome sequencing identifies truncating mutations in human SERPINF1 in
autosomal-recessive osteogenesis imperfecta
on the chromosomes 1, 6, 11, and 17 (Supplementary Table S22 and Supplementary Figure S11).
Only three of the 17 homozygous variants in the index patient’s exome were located in one of
these homozygous regions: two missense variants on chromosome 1 (p.Gln361Arg in LPHN2
[NM_012302] and p.Thr1799Met in INADL [MIM 603199]) and a stop mutation (c.696C>G;
p.Tyr232X) affecting SERPINF1 (MIM 172860) on chromosome 17p13.3 (Supplementary Table
S23). The stop mutation was embedded into a homozygous stretch spanning 2.99 Mb (Figure
7.1).
Figure 7.1: Identification of a homozygous mutation in SERPINF1 by exome sequencing
A) Overview of SERPINF1 coverage by exome sequencing. The upper panel contains an ideogram illustrating
the SERPINF1 location in the chromosomal band 17p13.3 (red bar). The middle panel displays the genomic
structure and localization of SERPINF1 in more detail. The lower panel shows the per-base coverage, with an
axis to the right ranging from 0 to 275-fold coverage. B) Detailed view of individual sequencing reads overlapping
the stop mutation in exon 6. All 18 reads at the genomic position g.1,625,154 (hg18) display the homozygous
stop mutation c.696C>G. C) Validation of the SERPINF1 mutation in exon 6 by Sanger sequencing of genomic
DNA. Electropherograms of a control individual, of the index patient and of his father are shown. The position of
the mutation is marked with an arrow. The affected codon is framed in black. The control individual carries the
wildtype sequence (wt) in both copies of the gene. The patient’s father is a heterozygous carrier of the mutation
(genotype wt/mut). The patient is homozygous for the c.696C>G mutation (mut/mut). D) The upper panel
contains an ideogram of the p-arm of chromosome 17 illustrating the localization of SERPINF1. In the graph
depicted in the lower panel, the homozygous regions on chromosome 17 at the genomic positions g.97,058-
3,091,589 and g.3,299,188-4,983,922 are recognizable. Each dot represents one of the SNP markers that were
included in the analysis. SNPs within a region that was called as homozygous are colored in a darker shade.
The position along the y-axis indicates the ratio of the number of reads with the non-reference allele to the total
number of reads; the value is 1.0 if only reference or non-reference reads are present at a given SNP position (y-
axis, ratio of variant reads / all reads per SNP position; x-axis, genomic position along the p-arm of chromosome
17)
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We regarded SERPINF1 as the best candidate for further evaluation. Validation by Sanger
sequencing confirmed that the c.696C>G (p.Tyr232X) mutation was indeed present in a ho-
mozygous state in the index patient (Figure 7.1). We also tested DNA samples of the patient’s
parents, of his affected brother (patient #2) and his two healthy sisters. Only the affected
brother carried the mutation in a homozygous state, whereas both parents and both sisters
were heterozygous carriers, compatible with autosomal-recessive inheritance of the disor-
der in the family (Supplementary Figure S12). The mutation was not detected on 460 control
chromosomes from individuals originating from the same region as the index patient. These
results confirmed that the identified mutation is not a rare polymorphism in the United Arab
Emirates population. No other SERPINF1 nonsense variant was observed in more than 120
in-house exomes, indicating the rare nature of loss-of-function mutations in this gene.
As a next step, we performed Sanger sequencing of all seven coding SERPINF1 exons on
genomic DNA samples obtained from two unrelated Turkish patients (patients #3 and #4), an
Iraqi patient and an Italian patient, all clinically diagnosed with OI. These four patients had
no detectable COL1A1 and COL1A2 mutations. The Italian patient had moderate OI (type
IV in the Sillence classification304), whereas the other patients suffered from a severe form
of OI, comparable to the course of the disease in the Arabian index family. Only the Turkish
patients were born to consanguineous parents. In these two patients, we identified truncat-
ing SERPINF1 mutations: Patient #3 was homozygous for the insertion c.324_325dupCT
(p.Tyr109SerfsX5) in exon 4, resulting in a frameshift with four substituted amino acids and
a premature stop codon (Figure 7.2 and Supplementary Figure S13). Patient #4 carried the
homozygous stop mutation c.1132C>T (p.Gln378X) in exon 8 (Figure 7.2 and Supplementary
Figure S13). The patients’ parents (as obligate carriers) and two healthy sisters of patient
#3 were heterozygous for the respective mutation (Supplementary Figure S12). The insertion
mutation c.324_325dupCT was excluded in 460 Turkish control chromosomes, and the stop
mutation c.1132C>T was not present on 272 Turkish control alleles, demonstrating that nei-
ther of these two sequence changes is a rare polymorphism. The Iraqi and the Italian patient
were negative for mutations in the coding region of SERPINF1.
SERPINF1 encodes pigment epithelium-derived factor (PEDF), a 50 kDa secreted glycopro-
tein of the serpin superfamily. The p.Tyr232X and p.Tyr109SerfsX5 mutations can be predicted
to cause null alleles due to Nonsense-mediated mRNA Decay. We found experimental evi-
dence for Nonsense-mediated mRNA Decay (NMD) of the mutated transcript in peripheral
blood by direct sequencing of a PCR-amplified cDNA fragment encompassing the frameshift
mutation p.Tyr109SerfsX5 (Supplementary Figure S14). In the father of patient #3, the cDNA
sequence of the mutated allele was only detectable as a faint background signal behind the
wildtype sequence, whereas Sanger sequencing on genomic DNA derived from this obligate
mutation carrier displayed equally strong signals for the mutated and the wildtype allele. This
observation suggests that the number of mutated transcripts serving as templates for the pre-
ceding RT-PCR reaction is strongly reduced compared to the number of transcripts with the
wildtype sequence. The c.1132C>T (p.Gln378X) mutation is located in the last coding exon
of SERPINF1, 123 bp upstream of the regular stop codon (Figure 7.2). The corresponding
transcript should therefore escape the NMD machinery.311 However, the C-terminus of PEDF
(amino acids 384 to 415) represents one of the four highly conserved regions of the protein.312
Extensive mutagenesis studies with cDNA expression vectors of human PEDF revealed that
any deletion of the C-terminus which encompasses more than the four C-terminal amino acids
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p.Tyr232Xp.Tyr109SerfsX5 p.Gln378X
Signal peptide Reactive center loop
Glycosylation site, Asn285
Phosphorylation sites, Ser24/114/227
Negatively charged residues 
involved in collagen binding
c.696C>G c.1132C>Tc.324_325dupCT
PEDF
SERPINF1 cDNA structure
Exon   2 3 4 5 6 7 8
Figure 7.2: SERPINF1 and PEDF scheme
Schematic representation of pigment epithelium-derived factor (PEDF, NP_002606) and of the coding exons of
the SERPINF1 cDNA (NM_002615.4). The locations of the exons are aligned relative to the regions of the PEDF
protein each exon encodes. The positions of the three truncating mutations identified in OI patients are indicated
by arrows. Several important protein domains described in the literature are depicted.310
(amino acids 415 - 418) abolishes secretion of the protein by transiently transfected mam-
malian cells.313 Moreover, the premature stop codon identified in patient #3 resides within
the Reactive Center Loop (RCL) of PEDF (Figure 7.2). An in vitro deletion of a segment of
the RCL (Pro373 - Ala380) as well as substitutions of Gly376 and Leu377 by alanine resulted
in abrogation of PEDF secretion, suggesting that the RCL is important for the interaction of
PEDF with the secretory apparatus.313 The p.Gln378X mutation therefore most likely rep-
resents a functional null allele. This interpretation is supported by the observation that the
phenotypic consequences of the p.Gln378X mutation are indistinguishable from those of the
p.Tyr232X and p.Tyr109SerfsX5 mutations (see below).
The four affected children with SERPINF1 mutations (referred to as patients #1, #2, #3, and
#4) exhibited similar clinical symptoms and disease severity, currently classified as OI type
III. There were no intrauterine fractures reported, and birth length and weight were normal.
Dentinogenesis imperfecta was not present. Formal hearing tests were not performed, but
there were no clinical signs of hearing impairment. The sclerae were grayish. No ophthalmo-
logical problems were seen. The serum levels showed moderately elevated levels for alkaline
phosphatase and procollagen-1-C-peptide, and moderately increased values for the osteo-
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clast marker deoxypyridinoline (Table 7.1). Compared to other OI-patients, these biochemical
findings are not uncommon and can also be found in patients with COL1A1 or COL1A2 muta-
tions. All four patients had fractures of long bones and severe vertebral compression fractures
with resulting deformities as early as in their first year of life. Some of the fractured bones re-
quired surgical corrections of deformities and insertions of telescopic rods. Figure 7.3 and
Figure 7.3 show a selection of radiographs of patient #3 and #4. The radiological findings
were typical for patients with OI type III. There were no distinctive radiological abnormalities
that would allow a further diagnostic subclassification. In Supplementary Figure S15, we present
whole body DXA-scans from patients #2, #3 and #4 taken during their last bone mineral den-
sity measurement. These DXA-scans give an impression of the degree of skeletal deformity.
Figure 7.3: Radiological features of patient #3
(A and B) Thorax and pelvis of patient #3 at the age of 6 months, showing no signs of rip or clavicular fractures,
only a slightly decreased vertebral height, a small pelvis and moderately delayed development of the hips. (C
and D) Radiographs of the right and left leg at age 1.6 years showing severe bowing of both femurs, multiple
old and new fractures, and a pseudarthrosis in the right femur. In the epiphysis, lines resulting from intravenous
bisphosphonate treatment are visible. The tibiae display no severe deformities.
In all patients, bone mineral density was severely reduced. All four patients developed short
stature during early childhood and were wheelchair-bound. Three patients had received early
medical treatment and physiotherapeutic training and were able to stand with assistance or
to walk a few steps with assistive devices. The fourth patient, who was 11 years old at first
presentation and severely adipose with a body-mass index of 44.1 kg/m2, was completely
immobile and depending on external support for all activities of daily life. The clinical findings
are summarized in Table 7.1. There were no hints for an involvement of other organ systems,
and abdominal ultrasound-scans gave normal results. All patients had received a cyclic intra-
venous bisphosphonate treatment with the compound neridronate prior to this study, accord-
ing to the Italian regime for children with OI.314 Upon treatment, there was vertebral reshaping
and an increase in vertebral height, an observation that has been reported previously by sev-
eral OI investigators.282 As an example of treatment outcome, the changes of vertebral size
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during treatment of patient #3 are presented in Supplementary Figure S16. This assumed ther-
apeutic effect was similar in all four patients. The parents of the patients, all heterozygous
carriers of the disease-causing mutations, were healthy and had no overt signs of reduced
bone mineral density and no history of previous fractures. DXA measurements have not been
performed in the parents.
Figure 7.4: Radiological features of patient #4
A) Hand radiogram of patient #4 at the age of 6 years showing no signs of fractures or skeletal dysplasia and
only a mild delay of bone age. B) The right arm at the age of 5.4 years showing severe deformities of the
humerus with multiple old fractures and callus formation in the diaphysis. C) Left hemi-thorax at the age of 4.3
years displaying no deformities or fractures of rips. D) Right leg at the age of 2.9 years after surgical rodding
with an intramedullar telescopic rod due to a fracture. E) Fractured right leg 3 months earlier. Also visible are
the epiphyseal lines resulting from cyclic intravenous bisphosphonate treatment. F) Left leg at the age of 2.2
years with a fracture after inadequate trauma. G) Left leg a few weeks later, after surgical treatment with an
intramedullar telescopic rod.
To analyse the effect of PEDF-truncating mutations on posttranslational modification of colla-
gens, we performed a standard biochemical analysis of collagens type I, III and V extracted
from cultured dermal fibroblasts of patient #3.315 SDS-PAGE showed normal migration of col-
lagens (Supplementary Figure S17), which suggests that altered posttranslational modification
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of collagens is unlikely to play a role in the disease pathogenesis. Abnormal type I collagen mi-
gration in SDS-PAGE analyses can be observed in autosomal-recessive OI caused by CRTAP,
LEPRE1 and PPIB mutations, as well as in most patients with autosomal-dominant OI due to
COL1A1 or COL1A2 mutations.283,290,291,294,295 In order to investigate whether the secretion
of triple helical collagen type I was impaired, pulse-chase experiments were performed. As
shown in Supplementary Figure S18, collagen secretion in fibroblasts of patient #3 was normal.
However, subtle impairments of type I collagen secretion may remain unrecognized with this
experimental design and can therefore not be excluded. Delayed collagen secretion has been
observed in fibroblasts from OI patients with LEPRE1, SERPINH1 and FKBP10 mutations,
and it is also a frequent effect of COL1A1 or COL1A2 glycine substitutions impairing triple
helix formation.291,297,298,316
Discussion
The human genome encodes 36 proteins of the serpin family, most of which are protease in-
hibitors.310 Based on the sequence similarities of the proteins and exon-intron organization of
the genes, serpins have been organized into 16 clades. PEDF falls into the F1 clade. HSP47,
which has been associated with autosomal-recessive OI in humans and in Dachshunds, is
categorized into clade H1 (and thus encoded by SERPINH1).298,299 The closest homologues
of PEDF are alpha-2 antiplasmin (encoded by SERPINF2, MIM 613168) and complement
component 1 inhibitor (encoded by SERPING1, MIM 606860).317 Unlike these two proteins,
PEDF and HSP47 are not thought to exhibit protease inhibitory activity.318,319 PEDF contains
two conserved regions with significant homology to other serpins.312 One of these regions
is the C-terminus (amino acids 384-415). Among 16 human serpins with strong sequence
similarities to the PEDF C-terminus, HSP47 displays the greatest homology (47% sequence
identity and 88% sequence homology).312
PEDF was initially isolated from conditioned medium of fetal human retinal pigment epithelium
cells and characterized as a factor which can induce the differentiation of retinoblastoma cells
into cells with several characteristics of normal neurons.320–322 With the discovery that the
protein is one of the strongest inhibitors of angiogenesis in humans known to date, utilizing this
property for therapeutic applications became a main focus of PEDF research.323,324 PEDF is
thought to counteract the effect of vascular endothelial growth factor (VEGF).325,326 VEGF-A is
the molecular target for the neutralizing humanized antibody bevacizumab (Avastatinr , FDA-
approved for the treatment of certain types of malignant tumors) and its fragment ranibizumab
(Lucentisr, a FDA-approved medication for wet macular degeneration).327 Consequently, the
first clinical FDA trials with PEDF are dedicated to the treatment of the wet form of AMD
as an ocular disease resulting from choroidal neovascularization. These clinical trials, with
intravitreal administration of virally delivered PEDF, are currently in Phase II.326,328,329 In a
mouse model of ischemia-induced retinal angiogenesis, systemically administered purified
PEDF was able to completely eliminate aberrant neovasularization.330
There is a growing list of other cellular functions of PEDF, among these immunomodulation,
protection against oxidative stress and expansion of the neural stem cell niche.310,331 The
underlying molecular mechanisms have only been partially elucidated. PEDF is expressed in
a wide range of fetal and adult tissues, including bone marrow, lung, brain, liver and eye.332
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An intracellular function, e.g. as a chaperone, has not been reported so far. As a secreted
protein, PEDF accumulates in the extracellular matrix and binds, among others, to collagen
type I.333,334
It is somewhat unexpected that loss of PEDF leads to severe OI in humans, as the murine
knock-out model has no overt bone phenotype, but exhibits vascular and epithelial abnormali-
ties. Serpinf1-/- mice lacking exons 3-6 of the gene are viable and fertile and display increased
microvessel density in the retina, the kidney, pancreas and prostate. On gross examination,
the pancreas appeared enlarged. At three months of age, the mice developed prostatic hyper-
plasia.335 However, impaired organ functions were not reported, as is also the case in our OI
patients with SERPINF1 mutations. Detailed analyses of bone homeostasis and bone mineral
density in Serpinf1-/- mice are required to clarify whether the OI phenotype is indeed restricted
to humans with loss of PEDF. Of note, experimental data demonstrating absence of mRNA
and protein expression have not been provided with the original publication.335 Therefore, it
remains possible that e.g. splicing between Serpinf1 exon 2 and exon 7 is able to produce a
form of the protein with a residual function that is essential to bone.
Expression analyses performed with bone tissue from wildtype mice as well as recent in vitro
experiments with murine cell systems strongly support a function of PEDF in bone formation
and remodelling. PEDF is expressed in osteoblasts, chondrocytes and, to a lesser extent,
in osteoclasts. The protein was detected in areas of active bone remodelling. In growing
mouse bone, strong positive immunostaining for PEDF protein was observed predominantly
in the bone matrix of the trabeculae of the primary spongiosa and the periosteum, adjacent to
osteoblasts with only faint staining.336,337 PEDF is also expressed in avascular layers of the
epiphyseal growth plate, as opposed to the expression pattern of VEGF as a protein found
in vascularized layers.336,338 Cell-culture experiments provided evidence that PEDF inhibits
osteoclast differentiation and hence bone resorption via osteoprotegerin (OPG) and RANKL
in a dose-dependent manner.339 This inhibitory effect was confirmed in vivo using a mouse
model system for inflammatory bone destruction. Receptor activator of NF-kB (RANK), its
ligand RANKL, and the decoy receptor OPG are central regulators of osteoclast development
and function.
In light of these literature data and of our collagen studies with patient fibroblasts, it is in-
triguing to speculate that the OI phenotype observed in patients with SERPINF1 mutations is
the result of a pathomechanism which is primarily independent of alterations in type I colla-
gen synthesis or intracellular processing. The published immunostaining pattern is consistent
with PEDF being rapidly secreted by osteoblasts and subsequently binding to the newly laid
type I collagen in the extracellular matrix.336 The balance between PEDF and VEGF expres-
sion in regions of active bone formation is thought to regulate neovascularisation at these
sites, a process which is necessary for the provision of osteoblast and osteoclast precursor
cells.325,337 Loss of PEDF could disturb this balance. As a result, there may be an excess of
osteoclast precursor cells in areas of active bone remodelling and at the epiphyseal plate. In
the absence of PEDF secretion by osteoblasts, osteoclast precursor cells could differentiate
into osteoclasts without restraints, leading to excessive bone resorption. Further experimental
studies are needed to dissect the pathomechanism of this OI form.
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Conclusion
In conclusion, we report the identification of pathogenic germline mutations in human SER-
PINF1. The fact that four patients with the uniform diagnosis of OI type III, descending from
consanguineous families and derived from two populations, are homozygous for three dif-
ferent truncating SERPINF1 mutations establishes loss of pigment epithelium-derived factor
as the molecular cause of the observed phenotype. The power of exome sequencing in
combination with homozygosity analysis as a strategy for unraveling the cause of autosomal-
recessive disorders in consanguineous families is highlighted by the fact that a single affected
individual sufficed to find the mutated gene. Since we identified mutations in two out of four
additional COL1A1- and COL1A2-negative families, there may be a substantial number of
other autosomal-recessively inherited OI cases caused by SERPINF1 mutations. The data
presented here provide in vivo evidence for an involvement of PEDF in human bone home-
ostasis. This well-characterized protein may be a promising candidate for the development
of a drug for the treatment of OI patients with inborn loss of PEDF and possibly also for the
treatment of other low bone-mass phenotypes. Deciphering the molecular pathway that leads
to reduced bone mineral density in patients with SERPINF1 mutations may unveil additional
targets for therapeutic interventions in this severe form of OI.
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Abstract
The per-generation mutation rate in humans is high. De novo mutations may compensate for
allele loss in frequent neurodevelopmental and psychiatric diseases due to severe reduced
fecundity, explaining a major paradox in evolutionary genetic theory. Here we used a family-
based exome sequencing approach to test this de novo mutation hypothesis in 10 patients with
unexplained mental retardation. Unique non-synonymous de novo mutations were identified
and validated in nine genes. Six of these, identified in different patients, are likely pathogenic
based on gene function, evolutionary conservation and mutation impact. Our findings provide
strong experimental support for a de novo paradigm for mental retardation. Together with de
novo copy number variation, de novo point mutations of large effect could explain the majority
of all mental retardation cases in the population.
Introduction
Recent studies have indicated that humans have an exceptionally high per-generation muta-
tion rate of 7.6×10−9 to 2.2×10−8.56,340 An average newborn is calculated to have acquired 50
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to 100 new mutations in his or her genome, resulting in approximately 0.86 novel amino acid
altering mutations.340 Spontaneous germline mutations can have serious phenotypic conse-
quences when affecting functionally relevant bases in the genome. In fact, their occurrence
may explain why diseases with a severely reduced fecundity remain frequent in the human
population, especially when the mutational target is large and comprised of many genes. This
would explain a major paradox in the evolutionary genetic theory of mental disorders.340,341 In
agreement with this hypothesis, de novo copy number variations (CNVs) are a known cause
of schizophrenia, autism and Mental Retardation.342,343 Much less is known about the fre-
quency and impact of de novo point mutations in these common diseases. Whole genome
or exome sequencing now allows us to study these mutations and their role in disease in a
systematic genome-wide manner. This approach has recently been used to identify causative
genes in several rare syndromes.56,139,228,344,345 In addition, targeted resequencing of the
coding exons of chromosome X revealed nine genes associated with X-linked forms of Mental
Retardation (MR),346 showing the strength of these analyses in common diseases. In this
study we used a family-based whole exome sequencing approach to test the de novo muta-
tion hypothesis in an unselected cohort of patients with MR.
Materials and Methods
We sequenced the exomes of 10 patient-parent trios. All patients, 8 males and 2 females,
had moderate to severe MR and a negative family history. Clinical evaluation did not lead
to a syndromic or etiologic diagnosis (Supplementary Methods). Prior cytogenetic analysis
showed normal chromosomes and array-based genomic profiling did not reveal de novo or
other CNVs associated with MR. In addition, fragile X syndrome was excluded by FMR1 re-
peat expansion analysis. On average, 3.1 Gb of mappable sequence data was obtained per
individual after exome enrichment (37 Mb of genomic sequence targeting 18,000 genes) and
sequencing on one quarter SOLiD sequencing slide (section 8 and Supplementary Table S24).
Color space reads were mapped to the reference genome. On average, 79.6% of bases origi-
nated from the targeted exome, with 90% of the targeted exons covered at least 10 times. The
median exon coverage was 42-fold, indicating that the majority of variants present in each ex-
ome could be robustly detected using a custom bioinformatic analysis pipeline (Supplementary
Figure S19).
Results
On average, 21,755 genetic variants were identified per individual with high confidence (Table
8.1, Supplementary Figure S20). An automated prioritization scheme was developed to sys-
tematically identify all candidate dominant de novo mutations in each patient (Figure 8.1). We
first excluded all non-genic, intronic, and synonymous variants other than those occurring at
canonical splice sites. This first step reduced the number of candidates to an average of 5,640
non-synonymous and canonical splice site variants per patient. This number was further re-
duced to 143 by excluding all known, likely benign, variants by comparison with data from
dbSNPv130 and our in-house variant database. Next, we used the exome data from accom-
panying parents to exclude all remaining inherited variants. This resulted in an average of five
(range two to seven) candidate de novo non-synonymous mutations per affected individual
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Figure 8.1: Experimental work flow for the detection and prioritization of sequence variants
For all 10 MR trios, prioritization of variants observed in the patients was based on selection for non-synonymous
changes of high quality only and exclusion of all variants previously observed in healthy individuals, together with
those variants that were inherited from an unaffected parent. Interpretation of de novo variants was based on
the gene function and the impact of the mutation.
Table 8.1: Overview of all variants detected per patient and impact of the prioritization steps
for selecting candidate non-synonymous de novo mutations
MR trio 1 2 3 4 5 6 7 8 9 10 average
High confidence variant calls 20,810 21,658 21,338 22,647 17,694 22,333 21,369 22,658 24,085 22,962 21,755
After exclusion of nongenic, intronic & syno-
nymous variants
5,556 5,665 5,691 5,991 4,607 5,567 5,716 5,628 5,985 5,994 5,640
After exclusion known variants 165 159 157 155 120 136 120 149 96 171 143
After exclusion inherited variants 4 7 3 7 7 2 2 6 6 7 5
(Table 8.1).
For all 51 candidate mutations (Supplementary Table S25) Sanger sequencing was performed
to (i) validate the mutations observed in the probands, and (ii) validate the absence of the
mutations in parental DNAs. Thirty-eight candidates could not be validated in the proband
(covered by a median of 5 variant reads in the exome sequencing experiment), whereas 13
were validated (covered by a median of 17 variant reads). Parental analysis validated de novo
occurrence for nine of these 13 mutations, detected in seven different patients (Table 8.2, Sup-
plementary Figure S21 and Supplementary Figure S22). These mutations were not identified in
a total of 1,664 control chromosomes, nor were other likely pathogenic mutations identified
in the affected genes, indicating that the population frequency of these de novo mutations in
these genes will be lower than 0.22% (Power=0.95, alpha=0.05). Eight of the de novo mu-
tations were present in a heterozygous state on the autosomes and one in a hemizygous
state on the X-chromosome. All de novo mutations occurred in different genes including two
recently identified MR genes (Table 8.2). In addition to a dominant disease model, we also
analyzed the data for recessive forms of MR. In the male patient of trio10, we identified a ma-
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Table 8.2: Overview of all de novo variants identified by exome sequencing in 10 cases with
unexplained mental retardation
Gene MR trio M/F# NM num-
ber
cDNA
level
Protein
level
PhyloP
score
Grantham
score
Probability
to be ob-
served in
dbSNP∗
Probability
to be ob-
served in
HGMD∗
Gene function
Dominant de novo mutations
DYNC1H1 1 M NM_001376 c.11465A>C p.His3822Pro 5.5 77 0.20 0.80 Retrograde axonal trans-
porter; interacts with
PAFAH1B1 (causing
Lissencephaly - a neu-
rodevelopmental disorder)
ZNF599 1 M NM_001007248c.532C>T p.Leu187Phe -1.5 22 1.00 2.65E−04 Unknown
RAB39B 2 M NM_171998 c.557G>A p.Trp186X 4.8 - - - Known X-linked mental re-
tardation gene
YY1 3 M NM_003403 c.1138G>T p.Asp380Tyr 6.9 160 2.27E−06 1.00 Ubiquitously expressed
transcription factor; Mouse
knock down results in
growth retardation, neu-
rulation defects and brain
abnormalities; interacts with
MeCP2, a known MR gene
BPIL3 3 M NM_174897 c.887G>A p.Arg269His 0.5 29 0.97 0.03 Innate immune respons
PGA5 4 F NM_014224 c.1058T>C p.Val353Ala 0.7 64 0.84 0.16 Precursor of pepsin
DEAF1 5 M NM_021008 c.683T>G p.Ile228Ser 4.9 142 0.01 0.99 Transcription factor; Regu-
lator of 5-HT1A receptor in
the brain; Mouse knockout
causes neural tube defects
CIC 6 M NM_015125 c.1474C>T p.Arg492Trp 2.6 101 0.46 0.54 Granule cell development in
central nervous system
SYNGAP1 8 F NM_006772 c.998_999del p.Val333AlafsX 3.3 - - - Known autosomal dominant
mental retardation gene
X-linked inherited mutations
JARID1C 10 M NM_001146702c.1919G>A p.Cys640Tyr 5.1 194 2.09E−06 1.00 Known X-linked mental re-
tardation gene
# Patient sex with M for male and F for female.
∗Visual representation of probabilities are provided in Supplementary Figure S23
Grantham scores for nonsense (RAB39B) and frameshift mutations (SYNGAP1) could not be calculated.
ternally inherited non-synonymous variant in JARID1C (Table 8.2), a well-described X-linked
MR gene.347 Subsequent analysis of this variant in DNA obtained from the grandparents indi-
cated that the mutation had occurred de novo in the mother of this patient. No conclusive ev-
idence for autosomal recessive inheritance, either homozygous or compound heterozygous,
was obtained in the other patients.
Next, we evaluated the function of each mutated gene in relation to the disorder (Table 8.2).
Three genes do not seem to play a role in biological pathways linked to MR. The BPIL3 gene
is involved in the innate immune response,348 whereas PGA5 is involved in protease activity
in the stomach.349 The function of ZNF599 is currently unknown. For the six other genes
affected by de novo mutations functional evidence suggests a role in MR. Two mutations oc-
curred in genes that, when disrupted, are known to cause mental retardation, RAB39B and
SYNGAP1 (Table 8.2).350,351 For the remaining four mutated genes, evidence for a causal link
to MR is provided by model organisms and protein-protein interaction studies. DYNC1H1 is
a cytoplasmic dynein that acts as a motor for intracellular retrograde axonal transport. Het-
erozygous Dync1h1+/- mutant mice exhibit sensory neuropathy,352 and studies in zebrafish
have shown the importance of dync1h1 in correct nuclear positioning. Mislocalization of nu-
clei in the vertebrate central nervous system is likely to result in profound patterning defects
and severely compromised function.353 Interestingly, DYNC1H1 interacts with PAFAH1B1, the
gene for type I lissencephaly, which involves gross disorganization of the neurons within the
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cerebral cortex.354 YY1 encodes the ubiquitously expressed transcription factor yin-yang 1
and directs histone deacetylases and histone acetyltransferases, implicating chromatin re-
modeling as its main function. Complete ablation of Yy1 in mice results in early embryonic
lethality, whereas Yy1 heterozygous mice display growth retardation, neurulation defects and
brain abnormalities.355 Recent studies show that YY1 interacts directly with MeCP2, causing
Rett syndrome.356 DEAF1 encodes a transcription factor that regulates the 5-HT1A receptor
in the human brain. Mutations in the Drosophila ortholog result in early embryonic arrest, sug-
gesting an essential role in early development.357 Additional evidence is provided by Deaf1-
deficient mice, which show neural tube defects including exencephaly.358 Finally, CIC is a
member of the HMG-box superfamily, associated with neuronal and glial development of the
nervous system. CIC is predominantly and transiently expressed in immature granule cells
of the cerebellum, hippocampus and neocortex, suggesting a critical role in central nervous
system development.359
We next examined the evolutionary conservation of affected nucleotides (PhyloP score) as
well as the potential of de novo mutation to affect the structure or function of the protein
(Grantham score; Table 8.2). All de novo missense mutations and the inherited X-linked mu-
tation were included in this analysis, no Grantham scores are available for the additional non-
sense and frameshift mutation. Of note, de novo mutations in genes with a functional link to
MR showed a higher PhyloP (avg. 4.7) and Grantham score (avg. 135), compared to muta-
tions in genes without such a functional indication (avg. PhyloP -0.5 and Grantham score 38).
We also compared these scores to those for all non-synonymous variants in dbSNP as well
as those in the Human Genome Mutation Database. The distribution of PhyloP scores and
Grantham scores differed markedly between dbSNP and the HGMD (Supplementary Meth-
ods and Supplementary Figure S23). The four mutations in genes functionally linked to MR
all showed higher probability values for being observed in HGMD (avg. 0.83) than for being
observed in dbSNP (avg. 0.17). The three mutations in genes without a functional link to MR
showed average probabilities of 0.94 for dbSNP and 0.06 for HGMD (Table 8.2). Additionally,
the inherited JARID1C mutation showed a probability of 1.00 for HGMD versus 2.09 × 10−06
for dbSNP.
Discussion
This analysis of the mutated nucleotides and their impact on gene function strongly supports
pathogenicity for six of nine de novo mutations. Importantly, these six mutations occurred in
genes with a functional link to MR, two of which are known MR genes. In contrast, three de
novo variants in genes without a functional link did not appear to significantly affect protein
function. Moreover, we identified a maternally inherited mutation in a known X-linked MR
gene that arose de novo in the patient’s mother. Although individual functional tests to prove
causality are not provided, collectively these data provide strong evidence for a major role of
de novo mutations in mental retardation. Additional proof for disease-causality will be provided
by the identification of recurrent mutations in these genes, but this may require the evaluation
of thousands of patients. Next to this, the identification of subtle CNVs encompassing (part
of) these genes, may provide additional proof, as was shown recently for mutations in X-linked
MR genes.360 As of yet, no such CNVs have been reported, neither have we found such CNVs
in our diagnostic cohort of ∼ 4,500 MR patients (results not shown).
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The amount of 9 de novo non-synonymous mutations observed in this cohort of 10 patients
fits well to the recently estimated background mutation rate of 0.86 amino acid altering muta-
tions per newborn in controls,57 but it would be important to compare this result to similar data
from healthy control trios when available. Interestingly, after applying the same systematic
filtering approach and Sanger sequencing, we could only validate a single de novo synony-
mous mutation which occurred in the GRIN1 gene (c.351C>T; MR trio10). This basepair is
not conserved through evolution (PhyloP score = -3.2) and does not seem to alter splicing,
suggesting that this mutation is an unlikely candidate for MR. Of note, this patient also carried
the JARID1C mutation. The observed ratio of non-synonymous (NS) to synonymous (S) de
novo mutations is far greater than would be expected for protein-coding genes under purifying
selection and indicates that many of these mutations will result in a reproductive disadvan-
tage. In contrast, the average NS/S ratio reported in dbSNP for the six genes with predicted
pathogenic mutations is significantly lower than that of the three genes with mutations reflect-
ing the background mutation rate (Fisher’s Exact test; p = 0.0016), which is to be expected for
disease genes in the normal population.
In summary, our results demonstrate that de novo mutations are a major cause of unexplained
mental retardation. These mutations can readily be identified using a family-based exome
sequencing approach and require only limited follow-up by Sanger sequencing. Our findings
have implications for preventive and diagnostic strategies in MR. Systematic genome-wide
resequencing in parent-child trios may uncover further examples of this de novo paradigm for
other human neurodevelopmental disorders.
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Supplementary Methods
Patient collection
Ten patients with unexplained moderate to severe mental retardation (normal karyotypes and
genomic profiles using 250K SNP arrays) were selected for exome sequencing (section 8).
Family history for mental retardation was negative for all patients. Non-genic causes for men-
tal retardation, including pre-, peri-, and postnatal infection and perinatal injury were excluded.
DNA was obtained from peripheral blood from the 10 patients as well as their unaffected par-
ents. DNA isolation was performed using QIAamp DNA mini kit (QIAgen, Valencia, CA, USA),
according to the instructions of the manufacturer. This study was approved by the Medical
Ethics Committee of the Radboud University Nijmegen Medical Centre, and all participants
signed informed consent.
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Library generation
Exome enrichment required 3µg genomic DNA and an AB SOLiD optimized SureSelect hu-
man exome kit (Agilent, Santa Clara, CA, USA) was used for enrichment, containing exonic
sequences of ∼18,000 genes, covering a total of ∼37 Mb genomic sequence, as specified
by the company. Manufacturer’s instructions (version 1.5) for enrichment were followed with
a minor modification, which was the reduction of the number of post-hybridization LM-PCR
cycles from twelve to nine cycles.
SOLiD sequencing
The enriched exome libraries were subsequently used for e-PCRs following manufacturer’s
instructions (Life Technologies, Carlsbad, CA, USA), based on a library concentration of 1 pM
(version March 2010). For each sample, one quad of a sequencing slide (Life Technologies,
Carlsbad, CA, USA) was used on a SOLiD
TM
3 Plus System.
Mapping of variants
Color space reads were mapped to the hg18 reference genome with the SOLiD bioscope
software v1.2 which utilizes an iterative mapping approach. Single nucleotide variants were
subsequently called by the diBayes algorithm163 using high stringency settings, requiring calls
on each strands. Small insertions and deletions were detected using the SOLiD Small InDel
Tool. We assumed a binomial distribution with probability 0.5 of sequencing the variant allele
at a heterozygous position. Under this assumption at least 10 reads are required to obtain
a 99% probability that at least two reads contain the variant allele. Variants and indels were
selected using strict quality settings which included the presence of at least 4 unique variant
reads (i.e. different start sites), as well as the variant being present in at least 15% of all reads.
All called variants and indels were combined and annotated using a custom analysis pipeline
(resulting in HCDiff files for each individual).
Custom bioinformatic analysis pipeline
All variants reported in the HCDiff files were filtered to ensure an optimal prioritization process.
For this we first excluded all non-genic, intronic (other than canonical splice sites) and non-
synonymous variants, reducing the number of variants to an average of 5,640 per patient.
Secondly, all known variants were excluded by comparison with data from dbSNPv130 as
well as from our in-house variant database. At the time of this study, this in-house database
contained variants from (i) 78 in-house performed ’exomes’, contributing 515,480 variants; and
(ii) the 1000-genomes project (http://www.1000genomes.org) and (iii) published data from
various other studies,178,213,214 contributing 3,059,835 variants, thereby bringing the number
of variants in the in-house database to 3,525,278 variants. Of note, if the variant observed
in patient occurred at a genomic position known in dbSNPv130, but the change was different
(e.g. A/C in dbSNP, but A/T in patient), the variant was not excluded from analysis. The filtering
step using this data further reduced the average number of variants to 143 per patient.
Next, for a dominant model of disease, we used the exome data from accompanying parents
to exclude all inherited variants. This step further reduced the number of potential de novo
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Table 8.3: Lilliefors (Kolmogorov-Smirnov) normality test
Value D p-value
PhyloP 0.0626 <2.2e-16
Grantham 0.0828 <2.2e-16
PhyloP*Grantham 0.1395 <2.2e-16
"D" represents the maximum absolute difference between the empirical and hypothetical cumulative distribution
function
variants to an average of 33 per patient. As not all variants identified in the exomes of the pa-
tients may have been sequenced at sufficient coverage in the parental samples, we checked
all remaining variants in the exome data from the accompanying parents. In brief, even if
only a single read showed the variant allele in one of the parental exome samples, the variant
was excluded for validation in the patient. Simultaneously, we checked all remaining potential
de novo indels for annotation differences in each patient-parent trio, and excluded those that
were found to be identical variants in both parent and child. After this final check, an aver-
age of 5 potential de novo variants per patient remained for further validation. To evaluate
the presence of recessive mutations, variant filtering was essentially performed as described
above, with the main difference that uniquely inherited parental variants were not excluded.
The remaining variants were evaluated for the presence compound heterozygous variants, as
well as variants that were present in >80% of all reads. Subsequently, parental exome data
were for segregation analysis of the variants identified.
dbSNP and HGMD
To establish the pathogenicity of our de novo variants, the genomic evolutionary conserva-
tion score (PhyloP) and the amino-acid change (Grantham) were compared to those scores
present in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/; build 130) and the
Human Genome Mutation Database; (http://www.hgmd.cf.ac.uk/ac/index.php; public
version March 2010). All non-synonymous changes reported in dbSNP and HGMD were
retrieved and overlap between databases was removed from both datasets. In addition, non-
synonymous variants in dbSNP with an Online Mendelian Inheritance in Man (OMIM) disease
entry, suggestive for a Mendelian phenotype, were omitted from the dbSNP dataset.
Next, Quadratic Discriminant Analysis (QDA)361 was performed on these two datasets to de-
termine the significance of the PhyloP and Grantham scores as discriminating factors. Statis-
tical tests were performed using the R statistics package. The assumption of normality in the
data required for the model was determined using Lilliefors normality testing.362
The combination of both scores together yielded highest power to discriminate the two datasets,
and as such, the combined value was used to calculate probabilities for our de novo variants
to be observed in either database.
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Validation experiments
Validation and de novo testing for candidate de novo mutations was performed using standard
Sanger sequencing approaches. Primers were designed to surround the candidate mutation,
and PCR reactions were performed using RedTaq r© ReadymixTM PCR reaction mix (Sigma-
Aldrich, St. Louis, MO, USA). Primer sequences and PCR conditions are available upon
request. For all de novo mutations identified, an additional control cohort of 75 ethnically
matched controls was tested for the presence of the same mutation by Sanger sequencing.
Together with the results from 679 control individuals from the 1000-genomes project as well
as the 78 ’exomes’ present in the in-house database, the control cohort for the de novo muta-
tions encompassed 1,664 control chromosomes.
Database accession numbers
The genomic reference sequence for DYNC1H1 can be found under the GenBank accession
numbers NM_001376; for ZNF599 under NM_0010072488; for RAB39 under NM_171998;
for YY1 under NM_003403; for BPIL3 under NM_174897; for PGA5 under NM_014224; for
DEAF1 under NM_021008; for CIC under NM_015125; for SYNGAP1 under NM_006772; for
JARID1C under NM_001146702; and for GRIN1 under NM_021569.2, respectively.
Clinical patient description
MR Trio 1
This boy was born a term after an uneventful pregnancy with a weight of 3850g (60th cen-
tile) to a healthy 35-year-old mother and 38-year-old father. He was the first child of non-
consanguineous parent and had a healthy sister. At 6 months hypotonia was noted and
physical therapy started. Development was delayed. He could sit at 18 months and walk at 3
years and spoke 10 words only at the age of 5. At the age of 4 years his developmental level
was tested which showed a 2 years delay. He has moderately severe mental retardation.
On physical examination at the age of 2 years he had a normal height of 85.2 cm (15th centile)
and head circumference of 47.5 cm (15th centile). He had mild (facial) dysmorphism consisting
of prominent forehead, plagiocephalic skull, a hypotonic face with down slanting palpebral
fissures and short broad hands and feet. Additional studies included a chromosome analysis
by 250 K SNP array, FMR1 repeat expansion (DNA level), metabolic studies, and MRI of the
brain. These revealed no abnormalities.
MR Trio 2
This boy was born at 38 weeks as the first child of a non-consanguineous couple (maternal
age 32 and paternal age 30 years) after an uncomplicated pregnancy with a weight of 3460g
(50th centile). He had a younger healthy sister and a nephew with a congenital heart defect.
Initially he had feeding problems due to unspecified swallowing difficulties. He walked at 18
months. At the age of 5 years he used a total of 5 words only. He attended special schooling
for children with severe learning difficulties. At the age of 5 years he had a height of 110 cm
(15th centile) and head circumference of 54 cm (90th centile). He had a left epicanthic fold
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and mild downslanting palpebral fissures without any additional dysmorphic features. Further
studies including chromosome analysis (250 K SNP array), FMR1 gene repeat expansion
(DNA level), metabolic studies and MRI of the brain revealed no abnormalities.
MR Trio 3
At 36 weeks pregnancy, growth retardation and unilateral dilatation of the renal pelvis were
noted. After a caesarian section because of breech position this boy was born with a low
birth weight of 2010g (- 2.5 SD). His non-consanguineous parents had 3 older healthy chil-
dren (two girls and a boy). Parental ages at time of birth of the proband were 33 (mother)
and 36 years (father). There were no neonatal problems, except for mild hypoglycemia and
hyperbilirubinemia, treated with UV therapy. As a neonate feeding remained slow and difficult
and the pyelectasy was confirmed with ultrasound. His development was delayed. He could
sit after 1 year and walk after 2 years 9 months. He spoke his first words at 2 years and his
level was 21 months at the age of 4 years 5 months, consistent with moderate mental retarda-
tion. At the age of 33 months his height was 84 cm (-3 SD) and head circumference 48.5 cm
(15th centile). He had telecanthus, down slanting palpebral fissures, high nasal bridge, and a
broad mouth. The dysmorphic features were not suggestive of any specific syndrome diag-
nosis according to an experienced clinical geneticist (B.B.A.d.V.). Additional studies including
chromosome analysis (250 K SNP array), FMR1 analysis (DNA level), metabolic studies and
ophthalmological investigations revealed no abnormalities.
MR Trio 4
This girl was born after 36 weeks following an uncomplicated pregnancy with a weight of
3660g (98th centile) as the first child of non-consanguineous parents (maternal age 32 and
paternal age 31 year). Her motor development was delayed due to hypotonia. With support
of physical therapy, she sat at 14 months and walked at 2 years. She spoke her first words
after 2 years and at the age of 3 years 8 months she used 30 words. At that age she had
a height of 100 cm (30th centile) and a head circumference of 47.5 cm (10th centile). She
had thin blond hair, periorbital fullness and a broad nose with full tip. No syndrome diagnosis
was made. Further studies including chromosome analysis (250 K SNP array), FMR1 repeat
expansion (DNA level), metabolic studies and MRI investigation of the brain which revealed
no abnormalities.
MR Trio 5
This boy was born at 41w 2d after an uncomplicated pregnancy with a low birth weight of
2600g (3rd centile) as the only child of a non-consanguineous couple (maternal age 32 and
paternal age 35 years). His development was clearly delayed. He walked at 17 months but at
the age of 6 years he still could not speak. His behavior was happy and he seldom cried. On
physical examination at the age of 2y 10m he had a low normal height of 91 cm (5th centile)
and his head circumference was 49.2 cm (25th centile). He had thin fair hair, upward slanting
palpebral fissures, epicanthic folds, almond shaped eyes, proximal implant of the thumbs and
a scrotal raphe. An initial clinical suspicion of Angelman syndrome led to methylation study of
the 15q11-q13 region and mutation analysis of UBE3A. These revealed no aberrations. Fur-
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ther studies including chromosome analysis (250 K SNP array), FMR1 repeat expansion (DNA
level) and metabolic studies and ophthalmological investigations revealed no abnormalities.
MR Trio 6
This boy was born at 38w 3d after an uncomplicated pregnancy by cesarean section with a
weight of 3000g (40th centile) as the second child of a non-consanguineous couple (maternal
age 29 and paternal age 27 years). His development was delayed. He sat at 15 months,
walked at 22 months and spoke his first words after 21 months and at the age of 3 years
used 20 words only. At the age of 21 months his height was 80.5 cm (5th centile) and head
circumference 47.3 cm (15th centile). He had no evident facial dysmorphisms. Further stu-
dies including chromosome analysis (250 K SNP array), FMR1 repeat expansion (DNA level),
metabolic studies and MRI investigation of the brain revealed no abnormalities.
MR Trio 7
This 19-year-old male was the second child of non-consanguineous parents and born at 40
weeks after an uncomplicated pregnancy with a weight of 3500g (50th centile). Parental ages
at time of birth were 28 and 29 years for mother and father, respectively. Early motor devel-
opment was slow but within normal range. Speech development was severely delayed, he
spoke his first words at the age of 4 years. He attended special school and his developmental
level was 3-3,5 years at the age of 19 years. He is severely retarded. He showed variable
aggressive behavior. On physical examination at the age of 19 years, a low-normal height of
172 cm (5th centile) and normal head circumference of 56 cm (15th centile) was noted. He
had minor facial dysmorphisms; upward slanting palpebral fissures, slightly everted ears, thin
upper lip with full everted lower lip without additional physical features. Further studies includ-
ing chromosome analysis (250 K SNP array), FMR1 expansion (chromosome level), EHMT1
gene and metabolic studies revealed no abnormalities.
MR Trio 8
This girl was born at 36w 5d after an uncomplicated pregnancy by cesarean section due to
breech position with a weight of 2800g (50th centile) as the only child of a non-consanguineous
couple (maternal age 32 and paternal age 29 years). Her motor development was delayed
due to hypotonia, she sat at 19 months. MRI of the brain revealed mild delay of myelinization
at 10 months. A muscle biopsy at the age of 20 months did not show any abnormalities. At the
age of 4.5 months she did not speak any words. At age 4 years epilepsy was diagnosed. On
physical examination at the age of 11 months she had a normal height of 70 cm (10th centile)
and head circumference of 46.3 cm (60th centile). She had a high forehead, upward slant-
ing palpebral fissures, mild hypertelorism, epicantical folds, low nasal bridge and full lips with
everted lower lips. A general, predominantly axial, hypotonia was present. Further studies,
including chromosome analysis (250 K SNP array), DNA analysis of FMR1, myotonic dystro-
phy, Prader Willi syndrome, as well as metabolic studies and ophthalmological investigation,
all revealed no abnormalities.
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MR Trio 9
This boy was born at 39w 1d after an uncomplicated pregnancy with a weight of 3520g (50th
centile) as the second child of a non-consanguineous couple (maternal age 31 and paternal
age 37 years). There were neonatal feeding difficulties. His development was delayed. He sat
at 12 months, walked at 18 months and spoke his first words at 2 years. At the age of 3 2/12
years he used 5-10 words only. He was moderately mentally retarded. On physical examina-
tion at that age he had a normal height of 103 cm (75th centile) and head circumference of
50.5 cm (50th centile). He had mild (facial) dysmorphism consisting of upward slanting palpe-
bral fissures, short palpebral fissures, flattened upper helices and broad nose with full tip.
Further studies including chromosome analysis (250 K SNP array), FMR1 repeat expansion
(DNA level) and metabolic studies revealed no abnormalities.
MR Trio 10
This boy was born after a normal gestation at 39w 6d with a weight of 3270g (25th centile)
as the second child of non-consanguineous parents (maternal age 29 and paternal age 31
years). At 6 months, delayed development was noted. , He sat at 10-11 months, walked at 13-
14 months and at the age of 4 years he only used 4 words and his developmental level at that
age was 15-18 months. On physical examination at the age of 2 4/12 years he had a height of
89.5 cm (25th centile) and head circumference of 49 cm (30th centile). He had a metopic ridge,
hypotelorism (ICD 2cm, < 3rd centile), mild ptosis, short palpebral fissures and a flat palate.
He had a broad, uncertain gait. Further studies, including G-banded chromosomes and FMR1
repeat expansion analysis (DNA level) were normal. Additional metabolic and chromosome
analysis (250K SNP array) revealed no abnormalities.
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Abstract
Molecular diagnostics for patients with RP has become increasingly important, especially with
respect to genetic counseling and gene therapy. The extreme genetic and clinical hetero-
geneity of RP however, with 52 causative genes known to date, has thus far limited diagnostic
evaluation. Here, we developed a comprehensive Next Generation Sequencing for the clin-
ical molecular diagnostics of RP. All known inherited retinal disease genes (n=111) were
captured and simultaneously analyzed using NGS on a Roche 454 GS FLX Titanium system
in 100 RP patients without a molecular diagnosis. A systematic data analysis pipeline was
developed and validated to prioritize and predict the pathogenicity of all genetic variants that
were identified in each patient. Each patient on average harbored ∼1,200 variants. After strin-
gent filtering, 0-9 potential pathogenic variants per patient remained. Subsequent segregation
analysis and in silico prediction of the pathogenicity resulted in a molecular diagnosis in 39
RP patients, comprising 27 recessive, 9 dominant and 3 X-linked cases. Intriguingly, de novo
mutations were present in at least 3 out of 28 isolated cases with causative mutations. This
study demonstrates the enormous potential and clinical utility of NGS in molecular diagno-
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sis of genetically heterogeneous diseases such as RP. Our results highlight the advantage
of simultaneously analyzing multiple genes and underscore the importance of considering all
modes of inheritance in isolated cases of RP. In addition, de novo dominant mutations appear
to play a significant role in these patients, having major implications for genetic counselling.
Introduction
Retinis Pigmentosa (RP) is a clinically and genetically highly heterogeneous disorder, and
the most frequent subtype of inherited retinal disease.363 Fifty-two genes are currently known
to be associated with non-syndromic RP, displaying all modes of inheritance.364 In addition,
another 60 genes are known to underlie other subtypes of syndromic and non-syndromic
retinal diseases (Retnet: http://www.sph.uth.tmc.edu/RetNet/). With a few exceptions,
there are no ophthalmologic characteristics specifically associated with the genetic subtypes
of RP, impeding a prioritization of genes to be analyzed using Sanger sequencing.
Molecular diagnostics is particularly challenging for isolated RP patients, which constitute the
majority of RP cases.365–367 Due to the unknown mode of inheritance, mutations in any of
the 52 known RP genes may be causative. The most widely applied diagnostic test for al-
lelic and genetic heterogeneous diseases, arrayed primer extension (APEX)-chip technology,
only detects known mutations.368 In addition, these chips are designed to separately test for
the presence of mutations in autosomal dominant or recessive RP genes, resulting in a di-
agnostic yield for autosomal recessive RP of only 10%.368 Altogether, the diagnostic yield
has remained disappointingly low for RP patients, despite the many important disease gene
discoveries in the last two decades.364
In this study, we employed an unbiased approach and analyzed all known inherited retinal dys-
trophy genes in parallel by targeted Next Generation Sequencing in a cohort of 100 patients
with autosomal recessive or isolated RP. All genetic variants identified entered a systematic
data analysis pipeline that included Sanger sequencing validation, segregation analysis and
a bioinformatic prediction of pathogenicity.
Material and Methods
Clinical diagnosis of RP
The diagnosis of RP was based on ophthalmologic examination including best corrected visual
acuity, slit-lamp biomicroscopy, ophthalmoscopy and fundus photography. Electroretinograms
(ERG), recorded according to the protocol of the International Society for Clinical Electrophys-
iology of Vision (ISCEV),369 and Goldmann visual field measurements were available from the
majority of patients.
Previous genotyping and patient ascertainment
A cohort of 234 RP patients had been collected over the last 15 years (Supplementary Fig-
ure S24). Several of these patients were screened by APEX analyses and Sanger sequen-
cing, achieving a molecular diagnosis in 20 patients.370–375 In 186 of the remaining probands,
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genome-wide homozygosity mapping was performed, identifying mutations in three novel au-
tosomal recessive RP genes, EYS, C2ORF71 and IMPG297,376,377 in 13 patients, and 24 ho-
mozygous mutations in previously known retinal dystrophy genes.378 From the remaining 177
probands, 100 were selected for the here described targeted NGS analysis. This selection
was based on the availability of DNAs from the patients and their family members. It included
78 cases with non-syndromic isolated RP and 22 cases with autosomal recessive RP, all with-
out a molecular diagnosis. Affected and non-affected relatives were either included prior to
this study, or requested to participate after the identification of potentially causative variants in
the proband. Some patients were clinically re-evaluated upon the identification of potentially
causative genetic variants.
After explaining the nature of this study, informed consents adhering to the tenets of the Dec-
laration of Helsinki were obtained from all patients and their relatives. DNA was extracted from
peripheral blood using standard procedures.379
In addition to the 100 selected patients, DNAs from twelve cases with various types of autoso-
mal recessive retinal diseases, carrying known compound heterozygous mutations in genes
represented on the NGS-array (Supplementary Table S27), were investigated to design and
optimize the current approach.
Array-based sequence capture, and targeted resequencing
To enrich multiple DNAs in a single procedure, a 12-plex NimbleGen sequence capture array
(Roche NimbleGen, Madison, WI, USA) consisting of 12 subarrays of 135k oligonucleotides
each was used (Figure 9.1). On these arrays probes targeting all coding exons, non-coding ex-
ons and UTRs of 111 known blindness genes were included, as well as probes for a fragment
of intron 26 of CEP290 that harbors a frequent mutation causing Leber congenital amauro-
sis. The array comprised a total of 723,662 bases targeting 111 genes consisting of 2,011
individual regions. Sequence capture was performed following the "Titanium Optimized Se-
quence Capture Array Delivery" protocol (version 1.0), as supplied by Roche and optimized
for sequence capture by NimbleGen arrays. Minor changes were made to adapt this proto-
col (for 385K arrays) to the 12-plex format. Sequence capture was performed following the
"Titanium Optimized Sequence Capture Array Delivery" protocol (version 1.0), as supplied by
Roche and optimized for sequence capture by NimbleGen arrays. Minor changes were made
to adapt this protocol (for 385K arrays) to the 12-plex format. In brief, 5 µg of genomic DNA
per sample were used in the preparation of DNA for sequence capture hybridization. Shearing
of DNA was done using the Covaris
TM
S2 system (Covaris Inc, Woburn, MA, USA) according
to instructions by the manufacturer for 500 bp fragments. Adapter ligation was done using
adapters including multiplex identifiers, as described in Technical Bulletins TCB No. 004-2009
and TCB No. 005-2009 (Roche NimbleGen, Madison, WI, USA). After pre ligation-mediated
(LM)-PCR, a final amount of 1.125 µg prepared sample was hybridized to each subarray,
together with 35.5 µg Cot1 DNA. The reagent volume used for hybridization was reduced cor-
responding to the smaller loading volume of the 12-plex format (6 µl). Samples were eluted
72 h after hybridization and subsequently amplified by post LM-PCR, resulting in a 12-plex
sequencing library. Small volume emulsion PCRs (emPCR) were performed for each library
using four different DNA concentrations as input to generate a titration curve, providing insight
into the optimal input of DNA for each run. Based on that titration curve a large volume em-
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Figure 9.1: Sequencing statistics
A) Schematic drawing of a 12-plex 2.1M NimbleGen sequence capture array. Samples were barcoded and
hybridized individually. After hybridization, all 12 samples were eluted simultaneously, allowing to proceed with
one pooled sample consisting of 12 different DNAs. B) Histogram of median target coverage. Only 15 targets
were covered less than 5 times. Most targets show a coverage of 20-30x. C) The minimum coverage of a
percentage of targets. Solid line indicates the average across 100 samples, whereas dotted and dash line
indicate first and second standard deviation respectively. D) Evenness of coverage for all samples. The average
evenness score over all samples is 97.3%. E) Example of a poorly covered target. This screenshot shows the
coverage of some exons of GRM6. The box highlights exon 1, which is poorly covered in comparison to the rest
of the gene. F) The 15 target that are poorly covered (median coverage of less than 5 times) have either a high
GC content (often an UTR or exon 1) or are containing repeat-rich regions.
PCR was performed and sequencing was done for each library on the Roche 454 GS FLX
sequencer with Titanium series reagents.
Assembly and variant calling
Reads were mapped against the human reference genome (hg18) using the Roche Newbler
software (version 2.3). Signal processing parameters were changed to use less stringent
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quality filtering. Additional mapping and coverage statistics were extracted from the mapping
output files using custom software. Variations were considered as high quality differences
(HCDiffs) when either 1) the variation was sequenced in at least three non-duplicate reads of
which at least one forward and one backward read or 2) the variation was seen in at least five
reads with quality scores over 20.
Variants were annotated using a custom annotation pipeline adding the following annotation
for each detected variant: annotation with known polymorphism data from dbSNP130, ge-
nomic feature annotation (e.g. exon, intron), amino acid translations, PhyloP conservation
score (based on conservation of 44 vertebrate species) and Grantham score.228,380 Addition-
ally variants were annotated with frequencies of the variants in: 1) all 100 blindness samples
2) internal database with 86 exomes, 3) internal database with known pathogenic blindness
mutations, and 4) internal database with mutations from the professional version of the Human
Genome Mutation Database (HGMD).
Quality control and coverage
Coverage was calculated by counting the amount of sequenced bases mapping to the target
regions. Bases mapping to regions within a 500 bp range of a target were considered "near
target". From this the average coverage across all the regions was calculated for each sample.
To evaluate the performance of targets we calculated the average coverage of each target
across all 100 samples. Evenness of coverage was calculated for all samples according to the
formula from Mokry et al., 2010 (Figure 9.1).381 Only 15 out of 2,011 exons were insufficiently
covered, due to high GC-content or the presence of repetitive sequences (Figure 9.1). Two
out of the three mutations that were missed in our validation study were located in an exon
with an extreme high GC-content (exon 1 of GRM6).
Prioritization of variants
Variants were selected for follow-up when all of the following criteria applied:
1. Variants are either non-synonymous variants or splice site variants (8 bp splice acceptor,
20 bp splice donor).
2. Variants are not known within dbSNP130 unless they are reported in HGMD or were pre-
viously defined as a pathogenic blindness mutation.
3. Variants do not occur with the 86 in-house exomes with a frequency greater than 5%.
4. Variants do not occur with a frequency of more than 15% within all 100 blindness samples.
5. Variants are covered by at least 10 reads with at least 20% variation reads or at least 5
reads with 80-100% variation reads.
6. Variants are consistent with the known pattern of inheritance of the respective gene (i.e.
homozygous/compound heterozygous or heterozygous).
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If prioritization resulted in single strong candidates (stop or canonical splice site variants) in
recessive genes, a manual search for a variant on the second allele was performed in the
unfiltered variant-set.
Data validation and segregation analysis
Data validation was done using conventional Sanger sequencing. Dependent on the selection
criteria described above, between 1 and 17 variants per sample were selected to be validated
(on average 3.6 variants per sample), leading to a total amount of 359 validated variants in the
cohort of 100 samples. If available, DNAs from additional family members were sequenced
for segregation analysis.
Determination of potential pathogenicity of variants
To systematically determine the pathogenicity of genetic variants, segregating variants were
sorted based on the type of variation. Nonsense, frameshift and canonical splice site variants
in the known blindness genes were considered to be pathogenic. Based on existing guide-
lines,382 a classification system for missense changes as well as for non-canonical splice site
variants was developed. Evidence was based on 1) in silico evidence and 2) combined evi-
dence of two mutations in a recessive gene. With regard to in silico evidence three different
features were considered important: (a) prediction of the functional effect of amino acid or
non-canonical splice site changes, (b) evolutionary conservation, and (c) population frequen-
cies (Supplementary Figure S25).
(a) Missense/Splice site prediction tools: In the case of missense prediction programs (SIFT,
PolyPhen, MutPred), the different scores for the three different tools were combined by a
majority vote resulting in a single classification as "pathogenic", "unknown" or "benign".
For splice site prediction programs (Splice Site Finder, MaxEntScan, NNSplice), wildtype
score (wt) and mutation score (mut) were compared using the following cutoffs. Splice Site
Finder: if wt > 50 and mut < 50, then "pathogenic", otherwise, if the difference between
wt and mut > 5 then "unknown" , otherwise "benign" ). MaxEntScan: If the difference
between wt and mut > 0.8 then "pathogenic", if no difference between wt an mutant then
"benign", else "unknown". NNSplice: If wt > 0.5 and mut < 0.5 then "pathogenic", if
the difference between wt and mut > 0.05, "unknown",otherwise "benign". The different
scores for the three different tools were combined by a majority vote resulting in a single
classification as "pathogenic", "unknown" or "benign".
(b) Evolutionary conservation: For classification based on evolutionary conservation, every
variant with a phyloP (44 vertebrate species) score of less than 1 was considered "be-
nign", everything with a phyloP value above 2.5 was considered to be "pathogenic", and
everything in between was classified as "unknown" (cutoffs were based upon a compari-
son of evolutionary conservation scores of dbSNP (build 130) and HGMD as described in
Vissers et al., 2010).380
(c) We established the frequencies of variants within 86 whole exome sequencing samples
of patients with unrelated disorders as well as in the 100 RP samples. Variants found at
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a frequency of more than 3% in the exome samples were classified as "benign", variants
with an exome frequency between 1% and 3% or variants with a frequency of 3% or more
in the 100 blindness samples were classified "unknown". The remaining variants were
classified as "pathogenic".
The three classifications (i.e. prediction tools, conservation and frequency) were combined
according to the following rules: If the prediction based on frequencies was "benign" then the
final classification of the variant was "probably benign" regardless of the other predictions. In
all other cases the three predictions were combined into a single prediction using a majority
vote. In case of three different votes the variant was predicted as "unknown". As a result,
all segregating (pairs of) variants were classified as either probably pathogenic, unknown, or
benign.
Biostatistical analyses
The diagnostic performance in this study was evaluated by calculating the mutation detec-
tion rate as a percentage of mutations detected for the cohort of 12 patients with 24 known
mutations, and by calculating the diagnostic yield as the percentage of patients for which a
molecular diagnosis was obtained (for details see Material and Methods).
Results
Targeted resequencing of 111 retinal dystrophy genes
In this study, the power of large-scale targeted re-sequencing to perform molecular genetic
analysis was extensively tested for RP, one of the most genetically heterogeneous diseases.
The coding regions of 111 retinal dystrophy genes were enriched by target capture and
screened for mutations by NGS in 112 subjects; 12 patients each carrying two known het-
erozygous mutations in one of the retinal dystrophy genes, and 100 RP patients without a
molecular diagnosis. The average amount of mappable sequence data per sample was 31
Mb, resulting in an evenly distributed average coverage of 26x per exon per sample (evenness
score: 97.3%, Figure 9.1). On average, 89% of all bases were covered at least 10x. Among
the 2,011 targeted exons, only 15 exons (0.7%) were covered poorly (less than five times on
average), either due to high GC-contents or the abundant presence of repetitive sequences
(Figure 9.1).
Development and application of a variant prioritization pipeline
Automated variant detection for all 112 samples resulted in an average of 1,274 variants per
sample. A systematic variant prioritization tool was developed to identify the pathogenic mu-
tation(s) amongst this substantial number of variants with high sensitivity and specificity. To
assess and optimize the performance of this methodology, 12 retinal disease samples each
carrying two known mutations were analyzed. In these 12 patients, a total of 14,144 genetic
variants were automatically detected, including 21 of the 24 known mutations (Figure 9.2),
resulting in a mutation detection rate of 87.5%. Two of the three mutations that were not de-
tected were located in an exon with an extreme high GC-content (exon 1 of GRM6), included
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Figure 9.2: Systematic variant prioritization tool to efficiently reduce the number of identified
variants
A) Reduction of identified variants in the 12 RD samples each carrying 2 variants in recessive RD genes. 14,144
genetic variants were automatically detected, including 21 of the 24 known mutations. A further systematic
prioritization reduced the number of variants to 97, including 18 of the 24 known pathogenic mutations (step 2).
Of these 97 variants, all variants were selected that were consistent with the known inheritance pattern of the
respective gene, resulting in 44 remaining variants, including 16 of the known variants (step 3). A manual search
for a variant on the second allele was performed for recessive genes where only one variant was found (step 4),
resulting in a total number of 48 variants, now including 20 of the 24 known mutations (step 5). B) In the group
of 100 RP samples with unknown cause of disease, in total, 128,557 variants (including 4 larger deletions) were
automatically annotated (step 1). After applying the same filtering steps as for the 12 known RD samples, 359
variants remained after prioritization (step 5).
in this study with the explicit purpose of determining whether the approach can deal with
extreme GC content. Systematic filtering of variants was accomplished as described in the
Material and Methods, and is summarized in Figure 9.2. Filtering reduced the total number of
putative pathogenic variants from 14,144 to 48 (99.7% reduction), while only one of the known
causative variants was eliminated during the course of the filtering. Hence, filtering enriched
the percentage of disease-causing mutations from 0.15% (21/14,144) to 41.6% (20/48). The
same systematic prioritization process was subsequently applied to all variants in the molec-
ularly undiagnosed RP cohort. In total, 128,557 variants (including 6 larger deletions) were
identified (Supplementary Figure S25). After applying the same filtering steps as for the 12
known retinal dystrophy samples, 359 variants remained (Supplementary Figure S25), reaching
the same reduction of putative causative variants of 99.7% (from 128,557 to 359).
Confirmation of variants and segregation analysis
Systematic Sanger sequencing of all 359 variants confirmed 283 variants (79%) in the total RP
cohort. The majority of non-confirmed variants (76%) were falsely called indels, many in the
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vicinity of homopolymer stretches, a known pitfall of the Roche 454 pyrosequencing techno-
logy. On the other hand, different larger homozygous and heterozygous deletions (>= 43bp)
were detected and validated by Sanger sequencing, underlining an advantageous feature of
the Roche long-read technology. Subsequently, all confirmed variants in a given sample were
sequenced in available samples from relatives.
Interpretation of genetic variants
To further determine whether a variant might be pathogenic or not, a systematic classification
scheme was developed (Material and Methods, and Supplementary Figure S25). In brief, clas-
sification of pathogenicity was performed using a combination of prediction programs, evolu-
tionary conservation and frequency data. This method was validated with 100% sensitivity on
an independent set of 20 functionally proven pathogenic missense mutations (Supplementary
Table S29), while it reached a specificity of 94% for a set of 36 putatively benign missense
mutations (Supplementary Table S30). This classification identified disease-causing variants in
39 out of the 100 investigated families (Table 9.1). In 21 of these, the pathogenicity was sup-
ported by a full segregation in available relatives, whereas in 18 cases segregation could not
be proven due to insufficient family data. Of all 39 families, inheritance was recessive in 27
cases, X-linked in three cases, and dominant in nine cases. In two isolated samples (samples
22315 and 27790) disease-causing mutations in the dominant genes RHO and PRPF31, re-
spectively, occurred de novo (Figure 9.3). In addition, in one case (family 28557) a de novo
mutation in the recessive gene USH2A was identified, with the second mutation being inher-
ited from the mother (Figure 9.3). Additional de novo mutations in dominant genes are likely in
four other cases (samples 8322, 17792, 22312, 31035) although the absence of at least one
parent hampers a definite conclusion.
Cumulative effect of multiple pathogenic alleles on the phenotype
In sample 9472, a homozygous canonical splice site mutation in PDE6B (c.1920 +2T>C;
splicing) and a known (dominant) missense mutation in PRPH2 (c.424C>T; p.R142W)383 were
identified. While the homozygous splice site mutation in PDE6B was segregating with the
disease in four affected siblings, the dominant missense mutation was not present in any of
the affected siblings. This may help to explain the earlier onset of macular abnormalities, that
are known to be associated with PRPM2 mutations, in patient 9472: at age 20 a bull’s eye
maculopathy with significant abnormalities of the retinal pigment epithelium was observed,
whereas his sibling 12273 at age 22 did not show any significant macular abnormality.
Diagnostic yield for an unscreened RP cohort
The mutation detection rate for the current NGS approach was 87.5% for the 12 patients with
24 known mutations (2124 = 87.5%). In 10 out of these 12 patients this would have resulted in
a molecular diagnosis, resulting in a solved rate (diagnostic yield) of 83% (1012 = 83%). We
estimate that for an unscreened RP population the diagnostic yield would be 50%, based on
the following calculation: The original cohort of 234 patients had undergone previous selected
genotyping, resulting in the identification of genetic defects in 57 patients (Supplementary Figure
S24). As a result of a solved rate of 83% for the NGS-based approach in 12 control patients,
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47 of these (83% × 57) would have been solved when analyzed by NGS, assuming autosomal
recessive inheritance. Of the remaining 177 patients, 100 were investigated by our approach,
of which 39 were diagnosed (39%). The residual 77 samples (177 - 100) have so far not been
analyzed by NGS. Assuming the same diagnostic yield of 39% with NGS in those, we would
diagnose additional 30 patients (39% × 77) with NGS. Together, our data indicate that this
approach could be used to establish a molecular diagnosis in 50% of a random RP cohort
( (47+39+30)234 ).
Overall, the results of this study underscore the extreme genetic heterogeneity in RP, by
identifying putatively causative mutations in no fewer than 22 different genes (Supplementary
Figure S26). Mutations in USH2A and PDE6B appear to be slightly overrepresented in the
mutational spectrum, as has been described previously.42 In five patients that were initially
diagnosed with RP (individuals 7554, 9437, 21141, 21334 and 31723), identification of the
genetic defect led to a re-appraisal of the phenotype, to either a different subtype of non-
syndromic retinal dystrophy, or to a (mild) syndromic form of RP (Supplementary Table S31).
For the 61 cases without a clear molecular diagnosis, either no segregating variants were
detected (9 cases), the identified variants appeared not to be pathogenic or did not segregate
completely (42 cases) or segregating variants were identified, but their pathogenicity remains
uncertain (10 samples).
Discussion
We have applied targeted NGS of all known retinal disease genes in 100 RP patients with
an unknown molecular cause of disease. Systematic variant prioritization reduced the over-
whelming amount of identified variants (∼1,200 per patient) by 99.7% to a number manage-
able to validate by Sanger sequencing (∼4 variants per patient). Combined with a systematic
assessment of pathogenicity of the validated variants, this NGS approach resulted in a molec-
ular diagnosis in no less than 39 patients.
Importantly, the 100 patients investigated here originally belonged to a cohort of 234 patients
that have previously undergone selected genotyping,378 resulting in the identification of ge-
netic defects in 57 of the patients before the start of this study (Supplementary Figure S24).
Taking into consideration a solved rate of 83%, we calculated a potential diagnostic yield of
approximately 50% in RP for this NGS-based diagnostic approach, thereby outperforming
previously used approaches such as traditional Sanger sequencing and APEX analysis.42,368
The usage of a completely unscreened, prospective cohort would probably have led to a more
accurate estimation of the success rate of this approach. While such prospective studies can
be performed in a research setting, it is however impossible within DNA diagnostics, where
every effort needs to be made to solve a sample in a timely fashion. Further improvements
in sequencing technology together with the identification of novel RP genes will undoubtedly
boost the success rate of NGS-based diagnostic approaches in RP in near future.
The 100 investigated samples comprised 78 isolated cases and 22 cases from multiplex fam-
ilies. Of the 22 multiplex families, a molecular diagnosis was achieved in eight: seven families
carried mutations in autosomal recessive RP genes, and one carried a mutation in the X-
linked gene RP2. Of the 78 isolated RP cases, a molecular diagnosis was established in 31:
20 families harbored mutations in autosomal recessive RP genes, whereas two male cases
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Figure 9.3: De novo mutations in isolated RP patients
A) De novo mutation in PRPF31. In patient 27790, a heterozygous nonsense mutation was detected in the
autosomal dominant RP-gene PRPF31, that was not present in both unaffected parents. To confirm that individ-
uals DNA11-01005 and DNA11-00996 are the biological parents, sixteen highly polymorphic markers distributed
across the genome were analyzed, showing a perfect Mendelian inheritance for all markers, thereby confirming
the de novo event (data not shown). B) De novo mutation in USH2A. In patient 28557, compound heterozygous
mutations were detected in the autosomal recessive RP-gene USH2A. One mutation (M1) was inherited from the
mother, but the second mutation (M2) was not present in both parents, and as such has occurred by a de novo
event. Again, parental testing confirmed that DNA11-02253 and DNA11-02247 were the biological parents of the
patient (data not shown). C) De novo mutation in RHO. In patient 22315, a heterozygous missense mutation was
detected that is predicted to be pathogenic (indicated by lighter shading). The mutation was not present in three
unaffected siblings and the unaffected mother. Since the unaffected father has deceased, seven microsatellite
markers surrounding and in close proximity of RHO were analyzed to determine haplotypes and the likelihood of
a de novo event. The proband 22315 and his three siblings all appeared to have inherited the same RHO allele
from the deceased father, strongly suggesting that the RHO mutation has occurred by a de novo event. The
genomic position of the microsatellite markers and RHO is indicated between parentheses.
carried mutations in X-linked genes. In three presumed isolated cases, mutations were found
in autosomal dominant RP genes, but re-evaluation of the families revealed RP in one of the
parents in all three families. Intriguingly, de novo mutations were proven to be present in three
of the isolated cases. Two of them were located in dominant genes, whereas in one patient
one of two autosomal recessive mutations in USH2A occurred de novo. Additional dominant
de novo mutations are likely in four other cases although the absence of at least one parent
hampers a definite conclusion. Though rare de novo mutations have recently been shown to
play a major role in human diseases with reduced reproductive fitness,67,228,351,384 the iden-
tification of a significant fraction of de novo dominant mutations in RP is a surprise. To our
opinion, de novo mutations thus far have been underappreciated as a cause of autosomal
dominant RP due to an ascertainment bias to collect sizeable families with clear autosomal
dominant inheritance pattern.385 Given a transmission risk of 50% and a recurrence risk of
<1% for autosomal dominant de novo mutations, compared to a transmission risk of <1% and
a recurrence risk of 25% for autosomal recessive inheritance, the relatively high amount of de
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Table 9.1: Diagnostic results of 39 RP patients with validated pathogenic variants
Patient Gene Inheritance Validated mutation M1 Validated mutation M2
7554 ABCA4 ar c.1554G>A; p.E518E; splicing c.4254-2A>G; splicing
8322 TOPORS ad c.1730C>A; p.S577Y -
8625 IMPG2 ar c.379G>A; p.R127X c.3423-8_c.3423-5del
9437 USH2A ar c.486-14G>A; splicing c.12729G>A; p.W4243X
9470 RP2 xl c.323G>A; p.C108Y -
9472 PDE6B ar, ad c.1920+2T>C; splicing c.1920+2T>C; splicing
PRPH2 ad c.424C>T; p.R142W -
9493 PDE6B ar, ad c.1043_1044insCG; p.A349GfsX11 c.1927_1969delinsGG; p.N643GfsX29
9518 RP1 ar, ad c.515T>G; p.L172R c.515T>G; p.L172R
9539 GPR98 ar c.12269C>A; p.T4090N c.8407G>A; p.A2803T
13480 RPE65 ar c.208T>G; p.F70V c.1102T>C; p.Y368H
15569 PRPH2 ad c.441del; p.P147PfsX4 -
17597 USH2A ar c.10525A>T; p.K3509X c.12343C>T; p.R4115C
c.13274C>T; p.T4425M
17792 RHO ar, ad c.403C>T; p.R135W -
18060 SPATA7 ar c.3G>A; p.M1I c.322C>T; p.R108X
18336 PDE6B ar, ad c.1401+4_1401+16delins14 c.1927_1969delinsGG; p.N643GfsX29
c.2326G>A; p.D776N
19081 TOPORS ad c.1730C>A; p.S577Y -
19693 PDE6B ar, ad c.299G>A; p.R100H c.1927_1969delinsGG; p.N643GfsX29
19733 USH2A ar p.R1653X c.10073G>A; p.C3358Y
c.7379G>A; p.R2460H
19735 RPE65 ar c.271C>T; p.R91W c.715T>G; p.Y239D
20984 PDE6B ar, ad c.1107+3A>G c.1107+3A>G
21141 CEP290 ar c.3559del; p.L1187CfsX2 c.4705-1G>T; splicing
21334 CACNA1F xl c.220T>C; p.C74R
21933 RP1 ar, ad c.368_369dup; p.P214AfsX20 c.4241_4242del; p.H1414QfsX5
22312 GUCY2D ar, ad c.1724C>T; p.P575L -
22315 RHO ar, ad c.538C>T; p.P180S -
22393 PDE6B ar, ad c.892C>T; p.Q298X c.892C>T; p.Q298X
22777 USH2A ar c.1256G>T; p.C419F c.12343C>T; p.R4115C
c.13274C>T; p.T4425M
27790 PRPF31 ad c.553G>T; p.E185X
28557 USH2A ar c.2276G>T; p.C759F c.5576T>G; p.F1859C
31035 NR2E3 ar, ad c.95G>A; p.W32X -
31124 USH2A ar c.486-14G>A; splicing c.2276G>T; p.C759F
31343 USH2A ar c.917_918insGCTG; p.S307LfsX17 c.11007C>A; p.Ser3669Arg
31723 ARL6 ar c.185+1G>A; splicing c.185+1G>A; splicing
31933 CRB1 ar, ad c.1602G>T; p.K534N c.2234C>T; p.T745M
31994 RHO ar, ad c.641T>A; p.I214N -
32594 NRL ar c.508C>A; p.R170S c.654del; p.C219VfsX4
32655 RP2 xl c.318_319delAG; p.D107LfsX16 -
33626 USH2A ar c.1227G>A; p.W409X c.12575G>A; p.R4192H
33672 RDH12 ar c.658+591_*603delinsCT; protein truncation X c.658+591_*603delinsCT; protein truncation X
37370 RLBP1 ar c.525_945del; protein truncation X c.525_945del; protein truncation X
Patient: patient identifier. Gene: RefSeq gene name of the gene in which mutations were identified. Inheritance:
possible inheritance of phenotype for known mutations in the corresponding gene. Validated mutation M1 and
Validated mutation M2: cDNA and protein annotation of the identified mutations. * = known mutation identified
in proband, not present in other affected siblings but contributing to a more severe phenotype in the proband.
Abbreviations: ar = autosomal recessive, ad = autosomal dominant, xl = X-linked.
novo mutations in our cohort has a major impact for genetic counseling of our patients and
their relatives.
An additional advantage of an NGS approach which targets all known retinal dystrophy genes
is the unprecedented possibility to study the cumulative effect of multiple pathogenic alleles
in different genes on the phenotype.253 This could be observed in family 9472, where the
proband carried three disease causing mutations in two different genes (one recessive and
one dominant gene), while his four affected siblings only carried the mutations in the recessive
gene. This led us to the conclusion that the additional mutation could explain the earlier onset
of macular abnormalities in the proband when compared to his siblings. The characterisation
of the genetic defect however is not only important for understanding the patients’ phenotypes,
but also confers benefits concerning eligibility for gene-therapy. Gene replacement therapy
has been proven to be beneficial in clinical trials for patients with RPE65 mutations.386–388
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Furthermore, preclinical gene therapy studies in animal models are ongoing for a substantial
set of retinal dystrophy genes,363 and are likely to enter clinical trials in near future.
Recently, others have also reported on the use of NGS for the identification of disease-causing
mutations in genetically heterogeneous disorders, including that of dominant389 and reces-
sive390 RP, although the number of genes that were analyzed, and/or the cohort sizes were
considerably smaller compared to our study.391–393 Together, these studies support our con-
clusion that NGS will become increasingly important for the identification of disease-causing
genes, and underscore the impact of this technology for the future of DNA diagnostics. An
alternative for parallel targeted resequencing of known disease genes is whole exome or -
genome sequencing,344,394,395 permitting a standardized laboratory workflow that can be used
for any type of genetic disorder. Data analysis can be restricted to designated genes, thereby
excluding the risk of incidental findings, and allowing gene filter sets to be adjusted following
the identification of novel genes, which would increase the diagnostic yield. The identifica-
tion of larger deletions however was enabled by the long reads of the Roche 454 sequencing
technology used in this study. These deletions would probably not have been detected by the
short-read NGS technologies that are used for whole exome or -genome sequencing.
Independent of the chosen NGS approach, straightforward clinical interpretation of the enor-
mous number of genetic variants obtained will remain the major obstacle to routine diagnostic
implementation, requiring very stringent and systematic data analysis as developed in this
study. The most substantial filtering step follows from excluding known variants (commonly
from dbSNP, the 1,000 Genomes Project, and/or in-house databases). A challenge in this as-
pect may be erroneous submissions as well as the presence of carriers of recessive disease
in these databases.309 This problem will likely be solved by the further expansion of con-
trol datasets that allow exclusion of variants present at frequencies higher than the expected
carrier frequency.
Conclusion
In conclusion, we have developed a comprehensive diagnostic tool for RP by simultaneously
sequencing all known retinal disease genes, and systematically analyzing and interpreting
all genetic variants detected. Our interpretation workflow provides a general approach for the
interpretation of the vast amount of data generated by NGS-based molecular diagnostics. The
enormous potential and clinical utility of NGS is highlighted by a high diagnostic yield thorough
identification of mutations of all modes of inheritance as well as de novo mutations. The
high degree of (inherited and de novo) autosomal dominant and X-linked mutations confers
a significant risk for transmitting the disease to the patients’ offspring, thereby illustrating not
only the molecular diagnostic power of NGS but also the huge impact of this method for the
affected families.
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Disease gene identification strategies for
exome sequencing
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Abstract
Next generation sequencing can be used to search for Mendelian disease genes in an un-
biased manner by sequencing the entire protein-coding sequence, known as the exome, or
even the entire human genome. Identifying the pathogenic mutation amongst thousands to
millions of genomic variants is a major challenge, and novel variant prioritization strategies
are required. The choice of these strategies depends on the availability of well-phenotyped
patients and family members, the mode of inheritance, the severity of the disease and its pop-
ulation frequency. In this review we discuss the current strategies for Mendelian disease gene
identification by exome resequencing. We conclude that exome strategies are successful and
identify new Mendelian disease genes in approximately 60% of the projects. Improvements in
bioinformatics as well as in sequencing technology will likely increase the success rate even
further. Exome sequencing is likely to become the most commonly used tool for Mendelian
disease gene identification for the coming years.
Introduction
The number of rare monogenic diseases is estimated to be more than 5,000 and for half
of these the underlying genes are unknown.43 In addition, an increasing proportion of com-
mon diseases, such as intellectual disability, schizophrenia and autism, previously thought to
be due to complex multifactorial inheritance, are now thought to represent a heterogeneous
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spectrum of rare monogenic disorders,380,396,397 the large majority of which is still unknown.
The identification of genes responsible for these diseases enables molecular diagnosis of pa-
tients, as well as testing gene carriers and prenatal testing. Gene identification represents
the first step to a better understanding of the physiological role of the underlying protein and
disease pathways which in turn serves as a starting point for developing therapeutic inter-
ventions.35 Recent advances in next-generation sequencing technologies have dramatically
changed the process of disease gene identification, in particular by using exome sequencing
in which the protein-coding part of the genome of a patient can be studied in a single ex-
periment (see Majewski et al.398) for an overview of exome sequencing technology and its
applications). As tens of thousands of genomic variants can be identified in each exome, it
is important to carefully consider strategies for efficiently and robustly prioritizing pathogenic
variants. In order to do so much can be learned from traditional disease gene identification
approaches but also novel strategies need to be established.
Traditional disease gene identification
Past identification of Mendelian disease genes was carried out by Sanger sequencing of can-
didate genes. Candidate genes can be selected because they resemble genes associated
with similar diseases, because the predicted protein function seems relevant to the physiol-
ogy of the disease, or because a positional mapping approach pointed to these genes in a
genomic region.77 This last approach has been most successful as it does not rely on prior
biological or medical knowledge and can be applied in an unbiased fashion. The most im-
portant genetic mapping approaches rely on karyotyping,81 linkage analysis,80 homozygosity
mapping,82 and copy number variation (CNV) analysis83 and SNP-based association analy-
sis.399 One problem associated with using genetic mapping approaches is that it is difficult
if not impossible to predict whether a disease is caused by a single nucleotide mutation or
by structural genomic variation. Without family information it is also often difficult to predict
whether a disease is dominantly or recessively inherited. Therefore, different mapping ap-
proaches often need to be applied in a sequential order before a disease locus is identified.
In addition, these mapping approaches commonly do not reduce the number of candidate
genes sufficiently for follow-up by Sanger sequencing when the disease locus remains very
large. This is especially the case if these mapping approaches are applied to only a single
patient or family with a limited number of informative relatives. Combining data from multiple
unrelated but phenotypically similar patients or families is useful to reduce this to a manage-
able number but carries a risk that patients with similar phenotypes are affected by mutations
in different genes. Alternatively, a candidate gene approach can be used to select the best
candidate genes from a large genomic region for Sanger sequencing. Many bioinformatic
tools have been developed to identify candidate disease genes.400–402 Candidate gene selec-
tion is however critically dependent on prior knowledge and only few disease genes have been
identified by specifically using these bioinformatic tools.403 A particular category of diseases
that has remained largely unresolved is that of the rare genetic disorders that occur spo-
radically and for which neither a family-based approach nor an association-based approach
can be used. These diseases require unbiased gene identification approaches that can be
successfully applied in small cohorts or single patients.
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Next generation sequencing technology
Next Generation Sequencing (NGS) technology is changing medical genomics by making
high-throughput sequencing of DNA and RNA available and affordable.404 Mendelian dis-
ease gene identification in particular benefits from this development. Rapid sequencing of
the entire genome of a patient removes the necessity to prioritize candidate genes for se-
quencing, and can therefore reduce the disease gene identification process from a two step
approach (positional mapping followed by Sanger sequencing) to a one step approach (whole
genome sequencing). The technical simplicity of this approach allows large scale application
in Mendelian disease research and diagnostics. With NGS the disease gene identification
challenge shifts from the identification to the interpretation phase; millions of genomic vari-
ants are identified, but for a Mendelian disease only one or two may explain the Mendelian
disease. Prioritization of variants is therefore crucial to the disease gene identification pro-
cess. For (severe) Mendelian disorders prioritization assumes that the mutation has a large
effect and is therefore (1) unique in patients or at least very rare in the general population,
(2) located within the protein-coding regions of the genome, and (3) directly affecting the func-
tion of the protein encoded by the mutated gene.139
Most whole genome studies published so far have focused on the 2% of the genome that is
coding, as roughly 85% of the known genetic causes for Mendelian disorders affect the protein
coding regions (although this may have to do with an ascertainment bias).77 This reduces the
amount of variants from 3-4 million to less than 25 thousand for follow-up.56,344,345,405 Because
whole genome sequencing is still limited in throughput and too costly to be applied as the main
tool for disease gene discovery, different capturing approaches have been developed to enrich
the exome prior to NGS.136 The advantage of this enrichment is that many more exomes than
genomes can be sequenced per NGS system per run, and despite the additional enrichment,
costs are lower by a factor of 5-10. A single run on the latest generation of such NGS systems
can generate enough sequence data to simultaneously study up to 100 exomes in parallel.
Disease gene identification strategies for exome
sequencing
The number of variants that are identified in exome sequencing studies varies greatly. This
depends on the exome enrichment set that was used, the sequencing platform and the algo-
rithms used for mapping and variant calling (see Figure 10.1). Typically between 20,000 and
50,000 variants are identified per sequenced exome. In order to reduce the number of false
positive calls, variants are first filtered based on quality criteria, such as the total number of
independent reads showing the variant (e.g. at least 5 independent reads), and the percent-
age of reads showing the variant (e.g. at least 20% for heterozygous variants, at least 80% for
homozygous variants). Subsequently, variants outside the coding regions can be filtered out,
as well as synonymous coding variants, based on the assumption that these will have minimal
effect on the protein as described above. This typically reduces the number of potential dis-
ease causing variants to roughly 5,000. The most substantial reduction follows from excluding
known variants (commonly from dbSNP, the 1,000 genomes,1 or in-house databases). This
step typically reduces the amount of potential candidate mutations by 90 to 95%. After this,
typically between 150 and 500 private non-synonymous or splice-site variants are prioritized
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Figure 10.1: Number of variants identified in published exome studies
A) Number of non-synonymous variants identified in published exome studies. From left to
right:39,228,309,390,407,409–418 B) Number of novel non-synonymous variants identified in published exome studies.
From left to right:39,228,309,390,407,410–412,414–419
as potential pathogenic variants (Figure 10.1 and Figure 10.2).224,228,253,309,380,406–408
It is important to emphasize that prioritization may discard the pathogenic variant. A variant
that is present at low frequency in a heterozygous state in the normal population may be
removed even though it causes disease if present in a homozygous state. For a very rare
recessive disorder the expected carrier frequency in the population will be extremely low,
which allows for the use of large control sets to exclude previously identified variants. To
assume that there are no carriers for recessive disorders in the population and thereby in the
control data is dangerous, especially when the disease occurs more frequently. Hence it is
important that reliable population frequencies are obtained for variants in control datasets as
this will allow the exclusion of variants that are present at frequencies higher than the expected
carrier frequency. Walsh et al.420 warned about the use of uncurated variant databases.
One of the pathogenic mutations they identified was recorded in dbSNP as a known variant
based on a single study. The authors did not observe the variant in 768 individuals, which
lead them to speculate that the entry was likely an artifact due to alignment errors in short
mononucleotide runs.
It is clear that this initial prioritization is no more than a first selection, and will rarely identify
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All variants detected in an exome
Exonic and splice-site variants
Private variants 
Figure 10.2: Prioritization of NGS variants
Common prioritization of variants. The size of the enclosing circles is indicative of the relative number of variants
that remains after each prioritization step.
the pathogenic variant by itself. Additional strategies are needed to find the causative muta-
tion among this list of 150-500 private variants. For this, both traditional positional mapping
strategies as well as other common approaches have been adapted for exome sequencing
(Figure 10.3 and Table 10.1). We briefly discuss each of these strategies:
A. Linkage strategy
For a family with a monogenic inherited disorder, multiple affected family members can
be sequenced to identify shared variation. In addition, non-affected family members can
be sequenced to exclude private benign variation. By selecting the most distantly related
affected family members, the amount of shared benign variation can be kept to a minimum.
For example, two affected siblings are expected to share about 50% of their DNA. By
combining sequence data this will lead to a similar reduction in private variants that needs
to be considered. The first application of this approach was by Ng et al. who used data
from two affected siblings to determine shared variation, reducing the amount of recessive
candidates to a mere 9 genes.139 Krawitz et al. applied a more sophisticated version of this
approach using only exome sequencing data. The authors determined the haplotype for
all variants shared by three affected siblings, and selected those variants that are identical
by descent. In this way they reduced the number of candidate genes from 14 to only 2
genes.409
B. Homozygosity strategy
In case of a rare recessively inherited disorder and suspected consanguinity, the initial
assumptions are that the disease is caused by a homozygous variant inherited from both
parents and that this variant resides within a large stretch of homozygosity. Homozygous
variants can therefore be prioritized by their presence in large homozygous regions of the
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Figure 10.3: Sequencing strategies
The strategies (A-F) are detailed in the main text. Pedigrees indicate the inheritance model loosely underlying
the strategy; filled symbols represent affected individuals, empty symbols represent presumably healthy individ-
uals and carriers are depicted by a symbol with a dot. Dashed rectangle encloses individuals that are exome
sequenced. Circles below each pedigree symbolize sets of genetic variants identified in the exomes. Solid
circles represent variants from affected individuals, while dashed circles represent variants from unaffected.
patient’s genome. These regions can be identified by SNP microarrays and used dur-
ing the prioritization process,420 but Becker et al.407 recently showed that exome data
itself may contain sufficient numbers of informative SNPs to allow reliable homozygos-
ity mapping. In this study 17 of the 318 private non-synonymous variants observed in
the index patient were autosomal homozygous variants, but only three were located in
large homozygous region and the causative mutation was located in the largest of these
three. The main difference of this strategy compared to the linkage strategy is that vari-
ants although homozygous are only selected when contained within a large homozygous
stretch. As such this approach reduces the amount of variants for follow-up sufficiently to
allow disease gene identification in individual cases, and does not require additional fam-
ily members, at least not for initial variant identification. This approach however can only
detect homozygous loci in regions with a sufficient target density containing informative
SNPs.
C. Double-hit strategy
When only a single patient is available without additional family members and the disorder
is suspected to be recessively inherited (but without any indication for consanguinity), it
is possible to sequence only this single patient’s exome and select for genes carrying
118
Disease gene identification strategies for exome sequencing
homozygous as well as compound heterozygous variants, as there are relatively few of
these private non-synonymous variants in the average outbred individual. Gilissen et al.
used this strategy to reduce the number of candidate disease genes in two individuals with
Sensenbrenner syndrome from 139 and 158 to only 3 and 4, respectively.309 Pierce et al.
used the same approach for a patient with Perrault syndrome, prioritizing a single gene
among 207 private non-synonymous variants.281 Both studies show that this is a powerful
approach that can identify the genetic cause of a disorder from just sequencing a single
individual.
D. Overlap strategy
In the absence of genetic heterogeneity, one can search for mutations in a single gene in
multiple unrelated patients with a similar phenotype. This is particularly important for dis-
ease gene identification in dominant disorders as there are many more genes with private
heterozygous non-synonymous variants than there are genes with private homozygous or
compound heterozygote non-synonymous variants. The number of genes with mutations
in multiple affected patients will decrease rapidly by combining data from increasing num-
bers of patients, resulting in less candidate genes for follow-up. The first study to find the
mutated gene for a dominant disorder by using this overlap approach in exome sequen-
cing data used 4 unrelated individuals.228 Recently, we showed that combining data from
3 individuals is enough to identify the gene for Bohring-Opitz syndrome.408 Although in
the individual patients we found between 130 and 222 novel non-synonymous variants,
the overlap for any two patients yielded 26 candidate genes while the overlap from three
patients pointed only to a single gene.
The overlap strategy will work best for true monogenic disease and will have to be adapted
for diseases that show genetic heterogeneity. In addition, the incompleteness (i.e. failure
to enrich specific targets) of current exome sequencing data may cause a problem be-
cause pathogenic mutations may be missed in one or more patients, complicating the
filtering strategy. A good example of both levels of complexity is displayed in the recent
publication by Ng et al. in which the authors sequenced the exomes of 10 patients with the
clinical diagnosis of Kabuki syndrome.406 After filtering against existing SNP databases,
no compelling candidate gene was identified that contained previously unknown variants
in all affected individuals. Next, the authors conducted a less stringent analysis by look-
ing for variation in candidate genes shared among subsets of affected individuals. This
analysis pinpointed to MLL2 as the major cause of this syndrome. Based on the exome
data mutations in this gene were observed in 7 out of 10 patients. Sanger sequencing of
the entire coding region of this gene in the mutation negative cases, however, revealed
MLL2 mutation in 2 out of the 3 cases, both being frameshift indels that were missed by
exome sequencing. Similarly, one should be mindful of CNVs, inversions or translocations
overlapping with the nucleotide variants identified in patients with the same phenotype, as
these can cause the same disease but are easily missed by exome sequencing as illus-
trated by Norton et al.421 The clinical and genetic heterogeneity of Kabuki syndrome was
further highlighted in the replication cohort used in the study of Ng et al. in which only 60%
(26 out of 43 patients) of cases were found to have MLL2 mutations. The difference in the
percentage of MLL2 mutation positive cases between the discovery and replication cohort
illustrates that the authors were able to clinically select canonical Kabuki cases for exome
sequencing, highlighting the importance of accurate and consistent clinical phenotyping
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for successful disease gene identification using this overlap strategy.
E. De novo strategy
The overlap strategy described above only works for rare diseases that are largely mono-
genic. For common disorders that are genetically highly heterogeneous the mutational
target, i.e. the amount of genome occupied by genes that when mutated result in disease,
is too large to have a reasonable chance of finding two patients with mutations in the same
gene. This large mutational target however also increases the chance that a de novo mu-
tation during meiosis occurs in one of these genes and causes disease. Especially when
a disorder occurs mostly sporadic and is associated with reduced fecundity, as is the case
for example for Intellectual Disability (ID), the underlying cause can be hypothesized to
lie with these de novo mutations. De novo mutations in these patients can be identified
by using a family-based exome sequencing approach. By sequencing the exome of the
patient as well as his or her parents, de novo candidates can be selected by filtering out
all inherited variants. This will yield a limited number of potential pathogenic variants since
the average exome contains only 0-3 de novo mutations.1,56,380,422 Vissers et al. showed
that de novo point mutations could be linked to disease in 7 out of 10 patients with ID, indi-
cating that these mutations may explain the large majority of the genetic burden. Note that,
as for the other strategies, variants prioritized in this way are more likely to be causative
for disease, but de novo occurrence in itself is not sufficient evidence and follow-up stu-
dies are required to identify recurrence or functional proof of pathogenicity. In addition, the
focus on variants that are present only in an affected child and not in the parents does not
only enrich for de novo mutations but also for sequencing and mapping artifacts and re-
quires equal coverage in all three samples investigated. It may therefore be wise to enrich
and sequence all samples of a trio in the same experiment. Finally, the de novo strategy
requires three experiments per patient, and will therefore only be applied when none of
the other strategies is likely to be successful and parental samples are available.
F. Candidate strategy
In case of a single dominantly affected individual, without further availability of family mem-
bers or other affected individuals, the options are limited. Prioritization may be based on
the predicted impact of the variant on protein function and structure, i.e. one prioritizes
for stop mutations, frame-shifting mutations and mutations in the canonical splice-sites.
In case of missense variants the two main criteria currently applied are predicted impact
on protein structure (e.g. Grantham score) and evolutionary conservation of the variant
nucleotide (e.g. phyloP or GERP scores). Pathogenic mutations tend to have a markedly
higher conservation than benign variants.380,423 Based on a comparison of scores for
benign and pathogenic variants from dbSNP and HGMD respectively, we estimated that
most pathogenic missense variants have a PhyloP score above 2.5.380 Indeed, so far al-
most all published missense and nonsense mutations that have been identified by exome
sequencing are more conserved than expected (see Figure 10.4).
Similar to the traditional candidate gene approach, information on gene function in relation
to the phenotype and what is known or inferred about its pathophysiology may be used in
further prioritization. Methods for selecting candidate variants on this scale are relatively
new. When there are no obvious candidate variants available (i.e. truncating mutations),
most studies have turned to computational predictors of the impact of missense variants
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on the protein structure or function.424 There are some practical issues with regard to the
utility of these prediction programs for next generation sequencing data. Ideally the pro-
grams can handle predictions for all detected variants within a reasonable amount of time
and allow automated (batch) execution. Furthermore, they should be run on local com-
puters such that sensitive patient data need not be transferred onto the internet. But most
importantly the sensitivity and specificity needs to be very high given the large amount of
predictions that is performed for a single exome. As an example, one of the two mutations
identified as the cause for Miller syndrome by Ng et al.139 was initially missed because it
was predicted to be benign. Hence, some studies have used combinations of predictions
by different methods to evaluate missense variants.393 On the other hand, predictions on a
complete set of detected exonic variants will usually yield far too many potential damaging
mutations for follow up.395 Recently Erlich et al. demonstrated how gene prediction tools
typically applied in combination with traditional mapping approaches, can also successfully
be applied to prioritize candidate genes from exome resequencing experiments.425 They
used three different bioinformatics tools (SUSPECTS,426 ToppGene,427 and Endeavour401)
to prioritize KIF1A as the most likely candidate gene for hereditary spastic paraparesis.
Prioritization of the variants itself using MutationTaster,428 Polyphen,429 and SIFT,430 inde-
pendently pointed to the variant in KIF1A as being the most likely pathogenic variant. This
nicely illustrates the potential of combining gene level information with genomic variant
information.
In practice, not all studies use a single strategy, and most rely on a combination of approaches.
For example Wang et al.412 used a combination of a homozygosity and linkage based ap-
proach while Musunuru et al.414 used the combination of a linkage and double hit based strat-
egy (Table 10.1). As a final step in this process validation by traditional Sanger sequencing as
the golden standard for mutation detection is still required. Definite proof of the pathogenicity
then needs to be obtained by validation in independent patient cohorts and/or by performing
functional experiments.
Success rate
In order to evaluate the success rate of exome sequencing for Mendelian diseases, we inves-
tigated the exome coverage of known disease causing mutations. We considered all 37,424
non-synonymous coding variants annotated as disease causing in the Human Genome Mu-
tation Database (HGMD) that do not overlap with known dbSNP132 positions.451 For each
of these mutations we evaluated the sequence coverage of corresponding targets from 51
exomes, with a median coverage of 49-fold, that were sequenced in-house using the Agilent
50 Mb exome kit with SOLiD4 sequencing.
First we observed that all 37,424 disease causing variant positions were targeted by the en-
richment kit. Of these 2,128 (5.7%) positions were not covered with sequencing reads at all
(median < 1.0), whereas 80.8% of the positions were covered with a median coverage of at
least 10-fold. We conclude, that for up to 80% of all mutations reliable variants calling would
have been possible, i.e. a detection with exome sequencing would have been likely.
Additionally, we performed a more biased analysis by evaluating all projects involving rare
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Figure 10.4: Base pair conservation of published pathogenic missense variants identified by
exome sequencing
A) Histogram plots of PhyloP evolutionary conservation score for non-synonymous variants from dbSNP and
HGMD showing a clear difference. B) Conservation of published missense mutations ranked from low to high.
Each bar represents the conservation of a missense mutation. Mutations are labeled with gene name, amino
acid change and affected base within the codon (in parentheses). Horizontal dotted line indicates conservation
of 2.5 where the distributions of the two distributions from panel A intersect.
Mendelian disorders from the first year of exome sequencing at our institute. We revisited data
from 10 likely dominant syndromes as well as 14 suspected recessive disorders. For 6 out of
the 10 dominant diseases we identified heterozygous mutations in a novel gene. In addition
we identified homozygous or compound heterozygous mutations in a novel gene in 8 out of 14
recessive disorders. All these mutations were Sanger validated and independently replicated
in at least one unrelated patient with the same disorder, and/or functionally implicated in the
disease. This results in a success rate of 58% (14 out of 24), a number that may increase
slightly as some of the projects are still ongoing.
Among the 10 projects where we did not find any novel genes, in 3 we identified mutations
in previously known disease genes (∼13%). One of the other unsuccessful projects involved
Kabuki syndrome where we sequenced 4 patients and 2 unaffected parents and applied both
the overlap as well as the de novo approach without identifying the (at that time unknown)
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causative gene. After the publication of MLL2 as the causative gene,406 we identified the
reason for our lack of success. MLL2 was not represented on the exome enrichment kit that
we used at that time, and therefore no sequence data for this gene was obtained. While this
explains why we were not able to identify any disease causing mutation, it also shows that we
were not misled by false positive variants and identified wrong candidate genes.
There are several other possible reasons why we are unable to identify the genetic cause by
exome sequencing in some projects. Variants have not been identified due to a) lack of se-
quence coverage of the variant b) bioinformatic variant calling issues c) miss-interpretation of
variants. Moreover it may be that d) the cause of the disease is located outside the coding se-
quences or e) being a large indel or structural genomic variant missed by exome sequencing.
In addition, for some projects too many candidate variants remained after filtering and no inde-
pendent recurrence or functional proof has been obtained so far. Finally, clinical heterogeneity
or incorrect diagnosis may have falsely impacted our filtering strategy.
Conclusion
The introduction of NGS is transforming Mendelian disease gene identification. No longer
is there a need for a complex and time-consuming laboratory workflow consisting of many
different positional cloning approaches. Instead, a single streamlined laboratory workflow will
rapidly identify most of the genomic variation present in an individual exome. By applying
tailored strategies for disease variant prioritization many new Mendelian disease genes have
been identified in the last two years. We estimate that straightforward application of these
approaches achieves a success rate of 60 to 80% for Mendelian disorders. Improvements in
the technology and bioinformatics are likely to increase this success rate. It is therefore likely
that exome sequencing will become the most commonly used tool for Mendelian disease gene
identification in the next few years.
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Unlocking Mendelian disease using exome
sequencing
Christian Gilissen, Alexander Hoischen, Han G. Brunner, Joris A. Veltman
Abstract
Exome sequencing is revolutionizing Mendelian disease gene identification. This results in
improved clinical diagnosis, more accurate genotype-phenotype correlations and insight into
the role of rare genomic variation in disease.
Introduction
The identification of a Mendelian disease gene enables molecular diagnosis and carrier test-
ing in the patient and his or her family. This is of great importance for patient management and
family counseling, and serves as a starting point for therapeutic interventions.35 Furthermore,
Mendelian disease gene identification contributes to our understanding of gene functions and
biological pathways underlying health and disease in general,452 and lessons learned from
rare diseases are often also relevant to common disease.453 Research aimed at the identifi-
cation of genes that cause Mendelian disease has received a boost over the past couple of
years by the introduction of new technologies that enable the sequencing of DNA at a much
higher throughput and at much lower costs than previously possible.120
Although traditional gene mapping approaches (e.g. karyotyping,81 linkage analysis,80 ho-
mozygosity mapping,82 and Copy Number Variation (CNV) analysis83) have lead to great in-
sights into Mendelian disease over the past few decades (Figure 11.1) they are unable to
detect all forms of genomic variation (Table 11.1). The approach applied is dependent on
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Figure 11.1: Timeline illustrating technological breakthroughs and hallmark publications for
Mendelian disease gene identification
A) The historical hallmarks leading up to the introduction of exome sequencing. The vast majority of all Mendelian
disease genes known to date have been identified based on conventional methods, including linkage analysis,454
homozygosity mapping,82 karyotyping and CNV detection.65,455 Many studies following the initial descriptions
have been based on technical achievements such as the first human linkage map456 or the first draft of the
human genome.75,457 The next generation sequencing era was accelerated by the first commercial release of
an NGS instrument,125 based on the same technology the first individual human genome was sequenced by
NGS.458 B) Exome sequencing hallmarks and publications since its introduction, illustrating that to date more
than 30 Mendelian disease genes have been identified by exome sequencing. Exome sequencing is now the
tool of choice for Mendelian disease gene identification, starting with the proof of concept178 and identification
of the first recessive253 and dominant disease genes.228 It has been shown that linkage and homozygosity
information can be retrieved directly from exome sequencing data, allowing the application for traditional mapping
approaches.407,409 References, from left to right, top to bottom: Botstein et al.454 Gusella et al.459 Royer-Pokora
et al.460 Lander et al.82 Kerem et al.80 Riordan et al.87 Olson et al.456 Solinas-Toldo et al.455 Pinkel et al.65
Venter et al.457 Lander et al.75 Vissers et al.83 Margulies et al.125 Wheeler et al.458 Ng et al.178 Ng et al.253
Lupski et al.344 Hoischen et al.228 Sobreira et al.345 Krawitz et al.409 Vissers et al.67 Becker et al.407
whether the disease is, for example, caused by single nucleotide mutations or by CNVs, which
is difficult to predict in advance. In addition, mapping approaches would often not reduce the
number of candidate genes sufficiently for straightforward follow-up by Sanger sequencing.77
126
Unlocking Mendelian disease using exome sequencing
As a typical example, genome-wide SNP analysis in a large Dutch pedigree with autosomal-
dominant Familial Exudative Vitreoretinopathy (FEVR) (MIM 613310), a retinal disorder, iden-
tified a linkage peak of ∼ 40 Mb on chromosome 7, containing more than 300 genes.461 Even
after adding linkage data from a second FEVR family still the region was too large for straight-
forward disease gene identification, and Sanger sequencing of a few candidate genes did not
identify causative mutations. Next Generation Sequencing (NGS) has the potential to iden-
tify all kinds of genetic variation at a base-pair resolution throughout the human genome in a
single experiment. Moreover this can be performed much faster and more cost efficient than
with traditional techniques. Whereas the sequencing of a genome by traditional techniques
needed many years at a cost of millions of dollars, using next generation sequencing tech-
nology one can now sequence a genome for less than 7,000 dollars within a week.457 This
enables the detailed genomic analysis of large numbers of patients.404 In the case of the two
families with FEVR we used next generation sequencing to investigate the entire coding se-
quence of the 40 Mb region in a single affected individual from the first family and identified
mutations in tetraspanin 12 (TSPAN12) to be the cause in FEVR in both families as well as
3 additional families. In most Mendelian disorders, however, there is no disease locus known
and an unbiased approach is required.
There are two unbiased sequencing approaches for detecting genetic variation within an indi-
vidual: whole genome sequencing and whole exome sequencing. Whole genome sequencing
is the ultimate approach for detecting all genomic variation in a patient’s genome in a single
experiment and has already been applied to Mendelian diseases (see Table 11.1). However,
current NGS instruments are limited in terms of throughput and cost efficiency. While sequen-
cing a complete genome may take only one week on a single machine, one can sequence
more than 20 exomes instead. Therefore this approach is limited to gene discovery projects
in large genome sequencing centers and service companies. Alternatively, more cost efficient
sequencing strategies have been developed to study the 1% of our genome that is protein-
coding, i.e. the exome, by using different capturing approaches to enrich prior to NGS. Ex-
ome sequencing has rapidly become one of the main tools for studying the genetic causes of
Mendelian disease,137 because academic groups with access to only one or two NGS systems
can use this approach to study the exomes of hundreds of patients with Mendelian diseases
per year and the bioinformatic challenges are modest when compared with whole genome
sequencing. Since November 2009, exome sequencing has lead to the identification of over
30 new genes in Mendelian diseases (see Table 11.2).139,253 Publication bias makes it difficult
to assess the actual success rate of these approaches, but from our own studies we esti-
mate that whole exome sequencing identifies the major disease gene in at least 50% of the
projects focused on rare but clinically well-defined Mendelian diseases (unpublished data).
The rapid expansion of Mendelian disease genes by exome sequencing is providing novel in-
sights because technological limitations have probably biased our current knowledge. In this
review, we discuss how our view of Mendelian disease is changing as a result of whole exome
sequencing experiments and a limited number of whole genome sequencing approaches.
Lessons learned from exome sequencing
In the last 2 years we have seen many proof of concept studies, using exome or genome stu-
dies to identify new Mendelian disease genes for recessive and dominant disorders. These
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Table 11.1: Traditional and novel approaches for Mendelian disease gene identification and
their advantages / disadvantages
Approach Applies to Advantages Disadvantages
Candidate gene Any disease • Easy to perform for one or two genes
• Requires no mapping, can directly identify
the causative variant/mutation
• Relies heavily on current biological knowl-
edge
• Success rate very low
Genomic mapping by karyotyping Any disease • Easy to perform
• No familial cases required
• Can detect (large) balanced events
• Low resolution, only detects large chromoso-
mal aberrations
• Mutation detection requires 2nd step
Genomic mapping by linkage ana-
lysis
Inherited disease • Easy to perform • Requires large families, often identifies large
loci
• Mutation detection requires 2nd step
Genomic mapping by homozygos-
ity mapping
Recessive monogenic
disease • Small families can be used • Most useful for consanguineous families, of-
ten identifies large loci
• Mutation detection requires 2nd step
Genomic mapping by CNV analy-
sis
Monogenic / monolo-
cus disease • High resolution CNV screening• No familial cases required, can potentially
identify small loci
• Only investigates CNVs
• Cannot detect balanced events, no base pair
resolution
• Mutation detection requires 2nd step
Whole exome sequencing (WES) Any disease • Basepair resolution exomewide
• Detects most types of genomic variation
• Can directly identify the causative vari-
ant/mutation
• Unable to detect non-coding variants
• Limited resolution for CNVs and other struc-
tural variation
• Coverage variability due to enrichment pro-
cess
• Relatively expensive
Whole genome sequencing
(WGS)
Any disease • Basepair resolution genomewide
• Detects all types of genomic variation
• Can directly identify the causative vari-
ant/mutation
• Data analysis complex
• Even more expensive than exome sequen-
cing
publications paint a mixed picture of phenotypes, genes and mutations underlying Mendelian
disease (see Figure 11.1 and Table 11.2, also for references). There is definitely a bias to-
wards recessive disorders as their genetic causes are more easy to identify than those that
cause dominant disorders. This is because genes carrying rare homozygous or compound
heterozygous variants are uncommon in the normal population, and these can easily be prior-
itized for follow-up. In addition, past sample collection has for a large part focused on familial
cases with recessive inheritance.
Improving clinical diagnosis
From a review of the Mendelian diseases studied (see Table 11.2) it is immediately apparent
that not every whole exome sequencing experiment will result in the identification of a new
disease gene. There are several examples in which the underlying genetic cause was not
evident from the phenotype, yet whole exome sequencing revealed mutations in a known
disease gene. For example Choi et al. identified mutations in the gene solute carrier family
26, member 3 (SLC26A3) encoding an epithelial Cl−/HCO−3 exchanger in a case with the
initial differential diagnosis of Bartter syndrome, a renal salt-wasting disease.394 After these
mutations were identified the clinical diagnosis was re-evaluated and changed to congenital
chloride diarrhea (CLD, MID 214700), a disease which was already known to result from
mutations in this gene.462 Similarly, Worthey et al. reported a case in which a diagnosis of
intractable inflammatory bowel disease (MIM 266600)was initially missed, but was revealed
after the identification of a missense mutation in XIAP the X-linked inhibitor of apoptosis gene
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Table 11.2: Mendelian disease gene identifications by exome or genome sequencing
Disorder Inheritance Gene identified Scope Reference
Congenital chloride diarrhea Recessive SLC26A3 Exome Choi et al.394
Miller syndrome Recessive DHODH Exome Ng et al.224
Charcot-Marie-Tooth neuropathy Recessive SH3TC2 Genome Lupski et al.344
Metachondromatosis Dominant PTPN11 Genome Sobreira et al.345
Schinzel-Giedion syndrom Dominant SETBP1 Exome Hoischen et al.228
Nonsyndromic hearing loss Recessive GPSM2 Exome Walsh et al.420
Perrault syndrome Recessive HSD17B4 Exome Pierce et al.281
Hyperphosphatasia mental retardation
syndrome
Recessive PIGV Exome Krawitz et al.409
Sensenbrenner syndrome Recessive WDR35 Exome Gilissen et al.309
Cerebral cortical malformations Recessive WDR62 Exome Bilguvar et al.437
Kaposi sarcoma Recessive STIM1 Exome Byun et al.448
Spinocerebellar ataxia Dominant TGM6 Exome Wang et al.412
Combined hypolipidemia Recessive ANGPTL3 Exome Musunuru et al.414
Complex I deficiency Recessive ACAD9 Exome Haack et al.410
Autoimmune Lymphoproliferative syn-
drome
Recessive FADD Exome Bolze et al.418
Amyotrophic Lateral Sclerosis Dominant VCP Exome Johnson et al.431
Nonsyndromic mental retardation Dominant Various Exome Vissers et al.67
Kabuki syndrome Dominant MLL2 Exome Ng et al.406
Inflammatory bowel disease Dominant XIAP Exome Worthey et al.395
Nonsyndromic mental retardation Recessive TECR Exome Caliskan et al.436
Retinis Pigmentosa Recessive DHDDS Exome Zuchner et al.432
Osteogenesis Imperfecta Recessive SERPINF1 Exome Becker et al.407
Dilated Cardiomyopathy Dominant BAG3 Exome Norton et al.421
Hajdu-Cheney syndrome Dominant NOTCH2 Exome Simpson et al.390
Hajdu-Cheney syndrome Dominant NOTCH2 Exome Isidor et al.39
Skeletal dysplasia Recessive POP1 Exome Glazov et al.419
Amelogenesis Recessive FAM20A Exome O’Sullivan et al.417
Chondrodyplasia and abnormal joint devel-
opment
Recessive IMPAD1 Exome Vissers et al.411
Progeroid syndrome Recessive BANF1 Exome Puente et al.415
Infantile mitocondrial cardiomypathie Recessive AARS2 Exome Götz et al.441
sensory neuropathy with dementia and
hearing loss
Dominant DNMT1 Exome Klein et al.413
Autism Dominant Various Exome O’Roak et al.422
(XIAP) by exome sequencing.395 Both of these examples show that unbiased whole exome
sequencing can have an enormous impact on patient management by assisting clinicians in
making the proper diagnosis, a phenomenon known as reverse phenotyping.463
Mutations in genes that are known to cause disease will also be identified frequently when
whole exome or genome sequencing is applied to genetically heterogeneous diseases that
can be caused by mutations in many different genes. The technological limitations of Sanger
sequencing often did not allow routine analysis of all known disease genes in patients with
genetically heterogeneous disorders prior to whole exome approaches. The most prominent
example of this was the identification of mutations in sh3 domain and tetratricopeptide re-
peat domain 2 (SH3TC2, a gene known to cause neuropathy) as the cause of Charcot-Marie
Tooth neuropathy (MIM 601596) in a family by whole genome sequencing.344 An unbiased
base-pair resolution approach can also reveal mutations in multiple genes that jointly explain
a combination of two Mendelian phenotypes. For example, a study identified mutations in
dihydroorotate dehydrogenase (DHODH) and dynein, axonemal, heavy chain 5 (DNAH5) in
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two siblings as the explanation of the combined phenotype of Miller syndrome (postaxial acro-
facial dysostosis; MIM 263750), and primary ciliary dyskinesia, respectively.253 Traditional
mapping approaches would likely have missed the mutations in DNAH5 as these were unique
to this sibling and not present in other patients with Miller syndrome, which severely compli-
cates mapping. Unbiased whole exome sequencing on the other hand identifies all variants
and allows for detailed analysis of individual cases and families. This is very advantageous
because often the clinical spectrum of a disease may be wider than previously appreciated,
and multiple mutations might jointly explain a more complex phenotype.
Phenotypic heterogeneity
Allelic heterogeneity, where a disease can be caused by mutations in different genes, has long
been recognized to occur in Mendelian diseases. For example in the case of Fanconi anemia
(MIM 227650), a myelodysplastic disorder with chromosome breakage, affecting all bone mar-
row elements and associated with cardiac, renal, and limb malformations, where mutations in
many genes give rise to the exact same phenotype.464 Conversely it is also clear that different
mutations in the same gene can result in completely different phenotypes such as is the case
for Tumor Protein P63 which in which different mutations can lead to a several monogenic mal-
formation syndromes.465 This extreme forms of phenotypic variability suggest completely dif-
ferent biological pathways to be involved. Unbiased whole exome and/or genome sequencing
has identified further ides examples of unrelated phenotypes caused by different mutations
in the same gene. Sobreira et al. sequenced the complete genome of a single patient (MIM
156250) with metachondromatosis, a skeletal dysplasia. They identified pathogenic loss of
function mutations in protein-tyrosine phosphatase, nonreceptor-type 11 (PTPN11) for which
gain-of-function mutations are known to cause Noonan syndrome (MIM 163950), character-
ized by short stature and facial features, and pulmonary stenosis.345 Another example comes
from Norton et al. who identified both truncating and missense mutations in bcl2-associated
athanogene 3 (BAG3) in patients with dilated cardiomyopathy (MIM 115200), characterized
by cardiac dilatation and reduced systolic function.421 A missense variant in this gene was
previously known to cause myofibrillar myopathy (MIM 612954), a strikingly different pheno-
type characterized by skeletal muscle weakness associated with cardiac conduction blocks,
arrhythmias, and restrictive heart failure. The authors also observed phenotypic variability in
a zebrafish model, where translation initiation-blocking of the whole gene gave a single phe-
notype of heart failure. In contrast, a second morpholino that specifically splices out exon 2
resulted in axis curvature and may be analogous to skeletal myopathy. This observation lead
the authors to suggest fundamental differences in mechanisms of disease. Similarly, Pierce
et al. observed mutations in HSD174B which encodes 17beta-hydroxysteroid dehydrogenase
type 4 in two adult patients with Perrault syndrome, characterized by ovarian dysgenesis and
deafness.281 Different classes of HSD17B4 mutations have previously been associated with
three different types of D-bifunctional protein (DBP) deficiency (MIM 261515), which is gen-
erally fatal within the first two years of life. The authors suggested that the specific mutations
they identified lead to a much milder phenotype that allows patients to survive to puberty and
causes ovarian dysgenesis in females in addition to the known neurological defects associ-
ated with DBP. Using traditional approaches, these genes might not have been considered
likely candidates for the disease. In addition, for some novel disease genes the type of mu-
tation may be specific to the disease in which these were observed. In two patients with
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Sensenbrenner syndrome, an autosomal recessive disorder characterized by ectodermal fea-
tures, craniosynostosis and hypodontia, whole exome sequencing revealed a missense and
a nonsense mutation in WD repeat-containing protein 35 (WDR35).309 It may well be that two
missense mutations result in a milder phenotype, whereas other mutations could result in a
more severe phenotype as confirmed by a subsequent study of patients with a lethal short rib
polydactyly syndrome.466
The role of de novo mutations in rare and common disorders
Many dominantly inherited Mendelian disorders occur sporadically because the severity and
early-onset of the disorder preclude transmission to subsequent generations. Consequently,
there are no families available for genetic studies. Genetic variants associated with these
diseases are under strong negative selection and will be rapidly eliminated from the genetic
pool.467 For these reasons, many genes that cause ’sporadic’ disease remain to be identified.
However, some novel insights have come from studying these sporadic forms of Mendelian
disease by whole exome sequencing.
Exome sequencing was first applied to rare syndromic forms of dominant sporadic Mendelian
disease such as Schinzel-Giedion syndrome (MIM 269150) and Kabuki syndrome (MIM
147920).228,406 Both disorders are characterized by intellectual disability as well as typical
facial features, and were anticipated to be largely caused by mutations in a single gene, which
facilitated interpretation of exome sequencing data. Multiple unrelated patients with the same
syndrome were sequenced and variant prioritization was focused on genes showing severe
mutations in multiple if not all patients. For Schinzel-Giedion syndrome this resulted in the
identification of heterozygous mutations in SETBP1 in 12 out of 13 patients tested.228 All
SETBP1 mutations occurred de novo in the patient and were not detected in DNA from the
unaffected parents. The disease mutations clustered in a genomic stretch of just 11 nu-
cleotides, affecting three of four consecutive amino acids. It is known that individuals with
partial chromosome 18 deletions affecting SETBP1 do not resemble Schinzel-Giedion syn-
drome. Collectively, this indicates that these mutations are likely to confer a gain-of function.
Exome sequencing is particularly useful for identifying these types of mutations for which no
other genome-wide approach is applicable. We suspect that gain-of-function mutations are
largely underrepresented in the current databases, and that many more will be detected by
exome sequencing.
After the detection of de novo mutation in rare Mendelian disorders subsequent studies fo-
cused on their role in common neurodevelopmental disorders such as Intellectual Disability
(ID)380 and autism (MIM 209850).422 The high population frequency of these disorders has
been hypothesized to reflect de novo mutations that compensate for allele loss due to severely
reduced fecundity. If this were the case, the frequency of these disorders would reflect the size
of the mutational target; disease caused by de novo mutations in a single gene will be very
rare, whereas disorders caused by de novo mutations in many genes can occur at a high
prevalence (Figure 11.2). In other words, the complexity of many common diseases might be
primarily due to genetic heterogeneity, with novel defects in different genes causing the same
disease.396 This would explain both the genetic and the clinical heterogeneity observed for
mental illnesses and would explain why these disorders have a low recurrence risk.468 In order
to investigate this hypothesis, Vissers et al. sequenced the exome of ten patients with ID and
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their healthy parents. After filtering out all inherited genomic variation, 9 de novo mutations
were identified in 10 patients, between 0-2 per patient. Two de novo mutations were observed
in genes previously linked to ID, and an analysis of the gene function and the mutation type
indicated that an additional four de novo mutations in novel genes are likely to be pathogenic.
Similar results were recently reported by O’Roak et al. who studied 20 patients with sporadic
autism using the same approach.422 Related work has also been reported for patients with
schizophrenia (MIM 181500), although not yet using unbiased whole genome or exome ap-
proaches In this case the authors performed Sanger sequencing for 401 synapse-expressed
genes in 143 patients with schizophrenia and identified 8 de novo mutations, two of which in
sh3 and multiple ankyrin repeat domains 3 (SHANK3), a known schizophrenia gene.469,470 If
confirmed in larger follow-up studies, this would indicate that a significant proportion of these
common disorders is due to rare de novo mutations. This provides strong support for the
hypothesis that rare variants might substantially contribute to common diseases and also rep-
resent a change of focus in Mendelian genetic disease research, where the emphasis has
for a long time been on studying familial forms of the disease. Severe early-onset disorders
such as intellectual disability, autism and childhood schizophrenia are clearly a first group of
disorders to test this de novo mutation hypothesis on, as inherited mutations are less likely to
play a major role in these disorders due to the reduced fitness.471 The contribution of de novo
mutations to adult-onset diseases with less impact on fertility is expected to be lower. How-
ever, we note that this is mainly dependent on the size of the mutational target and remains
to be determined. A problem in this respect, however, is the availability of surviving parents of
offspring who have a late-onset disease in order to proof de novo occurrence.472 Related to
this, Conrad et al. recently published the first genome sequencing study in 2 healthy parent-
offspring trios and validated 49 de novo germline mutations in one offspring and 35 in the
other.473 This study also highlighted the fact that cell lines are not the preferred material for
this analysis as 952 and 643 non-germline de novo mutations were observed in both offspring
that are likely to have been caused by cell line creation and culturing. Given the apparent role
of rare de novo mutations in disease it is evident that we need to learn much more about the
general occurrence of these mutations in our population and perform detailed comparisons of
de novo mutations in patients versus controls.
Finding the Mendelian contribution to common traits
While some studies support the arguments that a significant proportion of common disor-
ders (ID, autism, schizophrenia), represent an accumulation of rare disorders true multigenic
/ complex diseases can also benefit from exome sequencing. Until GWAS-size genome se-
quencing studies are broadly applicable and affordable (i.e. until one can run and analyze
1000 exomes routinely), insights can be obtained by studying small cohorts from the extreme
ends of the phenotypic spectrum of common traits, because the Mendelian forms of these
traits are expected to be overrepresented in this group. The first example of this approach
was provided by whole exome sequencing in patients with extremely low LDL cholesterol lev-
els, which identified mutations in ANGPTL3.414 The identified gene is secreted and expressed
primarily in the liver and encodes for the angiopoietin-like 3 protein. ANGPTL3 plays a role in
lipoprotein lipase and endothelial lipase inhibition, thereby increasing plasma triglyceride and
HDL cholesterol levels. The very low LDL levels in humans could therefore be explained by
two mutated alleles for this gene.
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Figure 11.2: Schematic representation of the relation between the size of the mutational target
and the frequency of disease for disorders caused by de novo mutations
Vertical dotted lines separate different sizes of mutational target. Rounded rectangles represent genes.
From genes and pathways
Although only a few exome studies have been conducted to date (Table 11.2) these have al-
ready provided new insights into human gene networks. For example, it was known through
classical disease gene identification that histone modifiers play an important role in human de-
velopmental diseases. Haploinsufficiency of histone methyltransferases such as NSD1(encoding
nuclear receptor binding SET domain protein 1), NSD2 (encoding nuclear SET domain-containing
protein 2) / WHSC1 (Wolf-Hirschhorn syndrome candidate 1) and EHMT1 (euchromatic histone-
lysine N-methyltransferase 1) cause several congenital diseases.474 Exome sequencing stu-
dies have confirmed the importance of this class of genes. Among the few exome studies that
identified dominant genes for a Mendelian disorders, three disease genes function in histone
modification: (1) Mutations in the histone methyltransferase gene MLL2 (H3K4me) have been
shown to cause Kabuki syndrome.406 ; (2) Point mutations in SETBP1 - encoding the SET
binding protein 1, a histone-lysine N-methyltransferase - have been identified as the cause
of Schinzel-Giedion syndrome.228 ; (3) Most recently, ASXL1 encoding the protein additional
sex combs like 1, was implicated in Bohring-Opitz syndrome (MIM 605039), characterized by
severe malformations and intellectual disability.408 ASXL1 is an interactor of lysine-specific
demethylase 1 (LSD1) and therefore can be considered another histone modification gene.475
Histone modifiers might play a dual role in disease. While germline mutations in these genes
can lead to developmental disorders, somatic mutations have been reported in leukemias
and other malignancies. Translocations of NSD1 to NUP98 (nucleoporin 98kDa) as well as
of NSD2/WHSC1 to IgH occur in some hematologic malignancies.475 In addition, SETBP1
translocations with NUP98 have been described in pediatric acute T-cell lymphoblastic leu-
kemia,262 and somatic mutations in ASXL1 occur in several forms of leukemia.476,477 Further
credence for this dual role for genes involved in histone modification have been given by re-
cent studies. It was already anticipated that DNMT3A, DNMT3B, and DNMT3L proteins were
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primarily responsible for the establishment of genomic DNA methylation patterns and should
therefore play an important role in human developmental, reproductive, and mental health.478
Exome sequencing, identified DNMT3A (encoding DNA methyltransferase 3A) mutations in
monocytic leukemia, confirming the suspected link with cancer development.479 Exome se-
quencing also led to the identification of mutations in DNMT1 (encoding DNA methyltrans-
ferase 1), that cause both central and peripheral neurodegeneration in a form of hereditary
sensory and autonomic neuropathy with dementia and hearing loss.413 These exome sequen-
cing findings add to a growing list of genes for which somatic mutations have been identified
in malignancies and germline mutations in developmental disorders.
The importance of evolutionary conservation
The interpretation of missense variants in Mendelian diseases is challenging. A common
method to address pathogenicity is to assume that purifying selection ’constrains’ evolutionary
divergence at phenotypically important nucleotides and amino acids.423 Following an earlier
suggestion,480 exome studies have now confirmed that indeed pathogenic missense variants
tend to affect highly conserved nucleotides (using GERP, PhyloP or PhastCons scores), or
amino acids (by multiple sequence alignment). All scores in some way measure the difference
between the amount of nucleotide substitutions that have occurred at a site during evolution
and the amount of substitutions that are expected based on neutral evolution. As an example,
the nucleotides affected by de novo mutations in SETBP1 causing Schinzel-Giedion syndrome
are among the most highly conserved bases in the genome, according to PhyloP vertebrate
conservation scores.228 This observation is unlikely to be explained by an ascertainment bias,
as evolutionary conservation is generally used only to strengthen the existing evidence of
pathogenicity, rather than to prioritize variants for follow-up.
Towards therapy for Mendelian disease
Exome studies have revealed mutations causing Mendelian disease in more than 30 genes,
for many of which had no previously known function. This new knowledge can help to iden-
tify essential biological pathways disrupted in these often severe disorders. For example,
Haack et al. obtained a promising clinical response to a multivitamin scheme including daily
riboflavin treatment in a patient with a complex 1 deficiency (MIM 252010) after whole exome
sequencing revealed mutations in ACAD9, a member of the mitochondrial acyl-CoA dehy-
drogenase protein family.410 Another example involves SERPINF1 in which mutations were
detected by whole exome sequencing in patients with Osteogenesis Imperfecta (OI) (Becker
et al.).407 There is much to learn from the first gene therapy trials with PEDF (encoded by
SERPINF1). PEDF is thought to counteract the effect of VEGF and trials are dedicated to
the treatment of the wet form of age-related macular degeneration.329 In a mouse model of
ischemia-induced retinal angiogenesis, administered PEDF was able to completely eliminate
aberrant neovascularization,330 this knowledge could now allow to also think about potential
therapeutic intervention for the new PEDF condition OI. Finally Züchner et al. used whole
exome sequencing to identify dehydrodolichyl diphosphate synthase (DDHDS) mutations in
patients with Retinis Pigmentosa (RP), linking this disease to N-linked glycosylation pathways
and opening possibilities for new avenues for therapeutic interventions.432 Though the number
of these promising examples is still small, one might foresee that several clinical conditions
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will be better understood after the identification of the underlying disease gene, and in some
cases this will allow actionable therapy.
Conclusion
Exome sequencing, and in a few cases, genome sequencing, has significantly progressed the
field of Mendelian disease in the last two years. The unbiased nature of these approaches
is providing significant insight in the genetic causes of Mendelian disease in general, and in
sporadic disease in particular by revealing rare de novo mutations as a common cause of dis-
ease. This approach is crucial for drawing accurate genotype-phenotype correlations and will
undoubtedly improve diagnosis for the millions of individuals with Mendelian disease, improve
family counseling and reveal targets for therapy. The next challenge in disease research will
be to systematically study the role of variation in the non-coding part of our genome in health
and disease. Mendelian diseases will be instrumental for this as they offer the advantage of
high penetrant mutations, the possibility to perform family studies and look for segregation of
variation with disease and the possibility to find recurrent mutations in unrelated patients with
similar phenotypes.
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General discussion
Introduction
In 2001 Francis Collins, one of the leading scientists of the international human genome
project, inspired by the near completion of the human genome and the arrival of the new
millennium, made several predictions about the role of genetics in research, medicine and
society, by the year 2010.481 Among others he predicted that by 2010, (1) therapies would be
available for most developmental Mendelian disorders, implying that their genetic basis would
have been identified. For many common illnesses disease gene associations would have
been established and individualized preventive medicine for such disorders would be based
on genetic risk. (2) Moreover, genetics would be mainstream in the practice of medicine and
(3) both clinicians and patients would be genetically literate. Although Collins himself claims
these predictions have come true,482 it is fair to say that they have not done so in the way that
was originally envisioned.
Francis Collins believed that the completion of the human genome would impact genetics
such that it enabled all of his predictions to come true. Next Generation Sequencing (NGS)
technology may, however, be the technology that is needed for this, and therefore warrants
a re-evaluation of some of the predictions made by Francis Collins. Here I look ahead into
the future and try to infer where the current developments are taking us with respect to these
predictions, specifically for: (1) finding the genetic cause of human disorders, being it rare
Mendelian disorders or common complex disorders, (2) the application of NGS for the clinical
diagnosis of patients, and (3) the impact of main stream personal genome sequencing for the
society in general.
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Finding the genetic basis for disorders
It is clear that for many Mendelian disorders the genetic basis is still unknown, but in the
previous chapters we have shown that by leveraging NGS technology and applying different
strategies we can identify new Mendelian disease genes (chapters 3-8 and 10) much faster
than ever before. From these chapters a trend becomes apparent, moving away from targeted
resequencing approaches towards more unbiased whole exome strategies. This trend devel-
oped by grace of the significant improvements of sequencing technologies; sequencing has
become much faster, cheaper, and more reliable at an increasing pace. The final goal is clear:
affordable Whole Genome Sequencing (WGS). Reducing the per genome cost to $1,000 has
been a stated goal of the US National Human Genome Research Institute since 2004483 and
is also the goal of a $10 million competition sponsored by the X Prize Foundation.132,484
Whole genome sequencing
The advantages of WGS compared to targeted resequencing, including exome sequencing,
are evident.
1) Ease of use
The procedure of sequence enrichment is quite laborious and introduces room for addi-
tional errors in the experiment. WGS is experimentally more straightforward and simple,
being less prone to introducing artifacts or amplification biases in the experiment. Further-
more, as the price of sequencing itself is dropping, the costs of enrichment are becoming
more and more a substantial part of the total experimental costs.
2) Completeness
Although exome sequencing arguably covers the most relevant part of the genome, it does
not cover the entire genome. Most importantly, it does not cover intronic sequences, pro-
moter and enhancer elements, or other regulatory sequences that can contribute to dis-
ease. Deep intronic mutations currently comprise <1% of the known splicing mutations,
but this proportion is likely to be a serious underestimate of the actual number because
deep intronic sequences are rarely screened and alternative splicing is prevalent in human
genes.7
Furthermore, whole genome sequencing is attractive because it can be done in a single
experiment that makes future experiments with respect to the DNA superfluous.485 As a
patient’s DNA remains the same in most cells, across his or her life, there is no need for
additional experiments to interrogate the DNA as a result of new insights. This is, however,
not taking into account somatic mutations, or epigenetic modifications that play a role in
disease.
3) All kinds of variation
The detection of larger genomic variation, other than SNVs and indels, is much easier
using whole genome data. Potentially, WGS allows the detection of all kinds of genomic
variation in a single experiment, such as genomic inversions, aneuploidies, copy number
changes and translocations.
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One commercial company has already anticipated this goal and, contrary to other companies,
does not sell its sequencing technology but rather uses a service model for whole human
genome sequencing only.486 However, as with all current technologies, throughput, accuracy
and pricing still need to be improved to make WGS a main-stream tool that can readily be
applied for all purposes.147 The genome is magnitudes in size larger than the exome, which
will result in a proportional increase of false positive variants. In order for genome sequencing
to become more useful the amount of false positives has to be kept to a minimum. This re-
quires higher sequencing accuracy and less biased assembly approaches, by either using a
pan-genome approach (i.e., a collection of genomes), or if possible a complete de novo as-
sembly.487 Another way of achieving higher accuracy is by applying a family-based approach
in which all real variants will be identified in multiple family members (except for a few de novo
variants).56
Third generation technologies.
Current sequencing technologies do not deliver complete high quality whole genome se-
quences, i.e., genomes that are completely finished including difficult repeat regions such
as telomeres, but also having a high sequencing accuracy resulting in reliable variant de-
tection. More advanced technologies may be required to accomplish this. These so-called
third-generation DNA-sequencing technologies are distinguished by direct inspection of sin-
gle molecules.488,489 These Single Molecule Sequencing (SMS) technologies can roughly be
binned into three different categories: (i) technologies in which single molecules of DNA poly-
merase are observed as they synthesize a single molecule of DNA; (ii) nanopore-sequencing
technologies in which single molecules of DNA are threaded through a nanopore or positioned
in the vicinity of a nanopore, whereby individual bases are detected as they pass through the
nanopore; and (iii) direct imaging of individual DNA molecules using advanced microscopy
techniques. The combined promise of these technologies is an abolishment to the need of
DNA amplification that can introduce artefacts, long sequence read lengths (>10 kb) able to
bridge difficult genomic regions, and much more rapid sequencing. However, the throughput
of these 3rd generation sequencing technologies as compared to the current (second) genera-
tion is still limited. At present these instruments are not used to sequence whole genomes by
itself but rather to finish whole genomes that have been sequenced with the current generation
of instruments. Further development is needed to allow the cheap, fast, accurate and compre-
hensive resequencing of genomes as needed for any application.488 Next to improvements in
sequencing instruments itself, similar improvements are needed in terms of bioinformatics to
store, analyze and interpret large amounts of whole genome data.
Interpretation of genomic variation
Francis Collins expected that by now most of the genetic causes for Mendelian disorders,
as well as common disorders, would have been identified. In order for Collins’ predication
to come true within the next 10 years some challenges still need to be overcome. From the
previous chapters it is clear that the key to resolving genetic disorders is no longer primarily the
identification of variation but rather the interpretation thereof. In the previous chapters we have
mostly discussed the interpretation of single nucleotide variations within the human protein
coding regions for Mendelian disorders. We also discussed the role of de novo mutations as
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a non-Mendelian cause of both rare and common disorders.
Interpretation faces three further challenges: (1) the interpretation of larger indels and struc-
tural variants, (2) the interpretation of non-coding variation, (3) the interpretation of variation
in heritable non-Mendelian disorders.
Indels and structural variation
Although it is clear that NGS allows the detection of structural variation, it still remains unclear
how easy and accurately this can be done. This depends not only on the laboratory protocols
that may be required, but also on the bioinformatics. The use of mate-pair and paired end
libraries of different insert sizes is facilitating the detection of structural variants by allowing
the detection of much smaller structural variants at a genome wide scale. Moreover, it is
now possible to detect inversion polymorphisms, a category of structural variants that was
previously impossible to identify genome-wide.70 Much work, however, still needs to be done
on the bioinformatic-wise identification of structural variants using these kinds of data.
Regardless of the remaining challenges of identifying structural variation, the interpretation
also remains an unresolved issue.490,491 Although there is quite some experience from inter-
preting larger genomic structural variations, current paradigms are being challenged. Many
genomic disorders show highly variable penetrances, blurring the boundary of how to define
benign versus pathogenic variants.491 For smaller structural variants (< 1 kb) there is even
less experience on how to interpret them. Interpretation will mostly need to be based on com-
mon themes such as population frequencies, de novo occurrence of variants, and possible
impact on protein function.
Non-coding variation
The burden of finding causative variants and providing evidence for the causality of variation
outside the coding regions is much larger than for variants within the protein coding regions.
There are two main factors contributing to this: First of all, the number of variants that needs
to be considered increases substantially as the exome comprises only a small part of the
entire genome, while the degree of genetic variation is much higher outside of the protein
coding regions. Future research will need to cope with large amounts of genomic variation
that are difficult to interpret. Secondly, as briefly discussed in Chapter 10, there are only few
features known that may aid the interpretation of genome-wide non-coding variants. The most
promising approach is also the most straightforward one, deducing the impact of a variant by
its recurrence in other individuals.422 This, however, will require large scale data sharing as
very large control and patient cohorts are necessary. Two ways to extend this approach is
by looking for the same variant in orthologous regions in different species, or by looking at all
variation in a functional genomic entity. For finding the cause of sporadic disorders using whole
genome sequencing, the most attractive approach would be to focus on de novo mutations.380
We expect only 50-100 de novo variants per genome, which seems a manageable number.1
It may well be that genomic information on its own does not provide enough information to un-
ravel the consequences of non-coding genomic variants. Genomic data can be supplemented
with the complete transcriptome, that would provide information about gene regulation and
alternative gene splicing events, and even the epigenome, providing information on chromatin
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modifications. Such information may ease the interpretation of genetic variation by providing
endo-phenotypes that point more directly to possibly pathogenic variation, or it may be used
to confirm the pathogenic nature of previously implicated mutations. A general disadvantage
of both the transcriptome and epigenome is that it is not, as is generally assumed for the ge-
nome, the same among different tissues. As such, transcriptome and epigenome information
can only provide a partial picture, as it is in general impossible to obtain this information for
every tissue type.
Non-Mendelian disorders and complex genetics
The non-Mendelian inheritance and broad range of phenotypes observed in many common
disorders is usually attributed to a complex interplay between common genetic variants and
the environment. The underlying assumption is that many genes play a role in the disease
process and a cumulative effect of certain common genetic polymorphisms results in a dis-
ease.51 Genome wide association analyses have, however, sofar captured only a minority of
the genetic heritability in most of these diseases due to common polymorphisms.118 As an
alternative hypothesis, some of this missing heritability may be explained by rare mutations
with large effects.53,396 It may be that similar phenotypes result from any one of thousands
of different mutations in any one of multiple different genes, all encoding proteins in related
pathways.54 The non-Mendelian inheritance of these diseases may be caused by incomplete
penetrance due to modifier alleles, and/or, as we have shown more recently due to de novo
mutations (see Chapter 11). The extent to which rare mutations may explain this missing
heritability is still under debate but can now be tested with the help of NGS technology.
The contribution of rare variants in specific diseases has already been shown by others, using
traditional genetic techniques.492 We and others are now starting to leverage NGS to do this
on a larger scale and replicate these results to assess the full extent of the contribution of
rare variants to disease.380,493 The screening for rare variants in GWAS cohorts may identify
patients where disease is caused by single rare variants of large effect. Removing these
patients from existing cohorts may result in better cohorts that can be used to obtain new and
more significant association results. Additionally, GWAS studies may extend their collection
of common genetic variation by including common insertions, deletions and inversions that
are now being identified more easily with the help of NGS technology. Given the current pace
of technological developments and the growing understanding on how to interpret large scale
genomic information, it is safe to postulate that the genetic background of almost all Mendelian
disorders will be clarified within the next ten years. The ease with which genome-wide genetic
variation can be measured in the upcoming years will show whether the extreme parts of the
phenotypic spectrum of common disorders are for a large part due to single events of large
effect. The biological pathways uncovered by these findings will again provide insight into
more complex genetic causes for common disorders.
The rapid identification of the genetics underlying Mendelian disorders will open up possibil-
ities for therapy and treatment, which will be the focus of genetics in the years to come. The
broad uptake of therapies may require even more time, due to the intensive testing that needs
to be done before a therapy is put to the market. In some cases however, existing medicine
may be applied resulting in a rapid cure for patients with specific disorders. For this to happen,
genome diagnostics has to become available to all patients with disease, being it common or
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Next generation diagnostics
Most applications of next generation sequencing are currently aimed at research questions.
NGS technology also holds great promise for susceptibility testing for preventive purposes,
pharmacogenetic testing for drug responsiveness and genetic testing for diagnosing and
staging disease.494 In all of these areas NGS is currently being tested in proof-of-concept
studies.393,394,495
In the previous chapters we have seen that diagnosing the genetic cause of a disease is still
not as straightforward as was suggested by Francis Collins,481 and that substantial improve-
ments can be made by applying NGS technology (chapters 2 and 9). Current diagnostics
involves testing of single loci for mutations based on clinical phenotyping of the patient. De-
pending on this phenotyping, either a single locus or multiple loci need to be tested.496 NGS is
less labor intensive and time-consuming than the standard Sanger protocol for genetically het-
erogenous disorders.497,498 The mainstream use of genetics in medicine as Collins postulated
requires genetic testing that is able to rapidly identify any kind of pathogenic mutation in an
unbiased genome-wide way, for large numbers of patients within a short period of time. The
results should have a high accuracy and specificity. Although NGS has not been extensively
tested in a diagnostic setting, it is clear that there are still some challenges. NGS is continu-
ously being adopted and undergoing many improvements which is why it currently compares
less favorably with established diagnostics in terms of accuracy, time until report, reproducibil-
ity and costs. Although all of these are considered critical for a diagnostic application, the
potential benefit of improved diagnostic yields outweighs all of these. Furthermore, given the
continuous improvements, these disadvantages are likely to be overcome very soon.
Targeted resequencing for diagnostic purposes
For the time being, issues of diagnostic accuracy and time to reporting remain a challenge
and different approaches to the implementation of NGS are being applied (see Table 12.1). A
targeted assay can be optimized for a single disorder that is caused by mutations in multiple
genes. Such a specific design can be fully optimized to improve accuracy for reliable detection
of variants, but requires a large effort to be set up. This approach has the advantage that it
minimizes the chance of findings that are unrelated to the initial test referral. However, now
that many new disease genes are being identified, a fixed design would need to be updated
frequently to accommodate new findings. In addition samples need to be multiplexed and
sequenced in a single run in order to be cost efficient. When the disease is relatively rare this
may cause long delays before a diagnosis can be established.
Exome resequencing for diagnostic purposes
Another approach is to sequence the entire exome of a patient.394 Although this is currently
more expensive than sequencing a disease-specific gene set, it is still many times cheaper
than whole genome sequencing. The advantage of exome sequencing is that there is a single
procedure for all patients and that for new findings the design does not need to be changed.
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This is beneficial for rare diseases where one does not require a minimum number of patients
with a specific disease before it becomes cost efficient to sequence. Furthermore, clinical
diagnoses are not always correct, and phenotypes vary considerably. Exome sequencing al-
lows for a more unbiased approach of genetic diagnosis, that will reveal many instances in
which the phenotype does not adhere to the standard clinical phenotypes associated with the
disease.395,499 A disadvantage compared to a more disease-specific design is that exome
sequencing does not allow for much optimization and, therefore, it is very difficult to diagnose
patients reliably for the complete set of known genes for a disease. For instance, many have
remarked that regions with high GC content are generally not well covered, which makes it
difficult to identify variants in these regions. A negative test result, i.e., excluding the pres-
ence of mutations in a specific gene will, therefore, be more difficult based solely on exome
sequencing results than based on results from current diagnostic procedures.
Whole genome resequencing for diagnostic purposes
Whole genome sequencing will likely be implemented for diagnostics, once throughput, accu-
racy and running time make it feasible. Though sequencing itself may become affordable in
the clinic, there is still the challenge of combining cheap human genome resequencing with
efficient and reliable interpretation.500 Alternatives are to (1) focus interpretation initially only
on known mutations, as a complete genome analysis would be too laborious;501,502 (2) fo-
cus analysis only on known genes. This would circumvent chance findings, while obtaining
a high diagnostic yield. However, this approach does not take into account wrong diagnosis,
and is completely ignorant towards potential novel disease loci and mechanisms. A targeted
approach may be used as an initial step. When no diagnostic result is obtained this may be
followed by a more unbiased approach.
Each of these approaches has some specific advantages (Table 12.1). The targeted approach
is clearly most suited for specific diseases that are clinically well defined, for which the major
disease genes are known and that show very low genetic heterogeneity. Exome sequencing
is more appropriate for diseases exhibiting larger phenotypic and genetic heterogeneity, as
it allows a more unbiased approach. This is the method of choice until genome sequencing
becomes affordable as a diagnostic tool, because of limited sequencing throughput and re-
maining bioinformatic challenges.
Clinical interpretation
Clinical interpretation of variants from unbiased exome and whole genome sequencing is more
difficult than with a more targeted approach, as the amount of potential pathogenic variants is
much higher. An initial focus on known disease genes during interpretation of exome or ge-
nome sequencing data can limit the number of candidates (Table 12.2). For sporadic patients
with a genetically heterogeneous disorder, a de novo approach can be applied which has the
same effect of reducing the number of variants that needs to be assessed (see Chapter 10).
All approaches require the collection of DNA from family members to establish a reliable diag-
nosis. Especially when interpreting non-coding variation, family members need to be analyzed
to obtain reasonable certainty that the variant is pathogenic.
Another way of interpreting variants in unknown genes is by conducting functional studies.
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Table 12.1: Advantages and disadvantages of different approaches towards next generation
diagnostics
Approach Advantages Disadvantages
Single gene Sanger
sequencing • Very accurate• Low cost per exon
• High throughput
• Low diagnostic yield for ge-
netically heterogenous disor-
ders
Targeted NGS of dis-
ease loci • Can be optimized• Low chance of incidental find-
ings
• Ease of data handling
• Ease of interpretation
• Design and redesign required
with new loci
• Different experiments for dif-
ferent diseases
Exome sequencing • Unbiased
• The same experiment for all
diseases
• Every experiment contributes
to the interpretation of other
experiments
• Can be re-interpreted
• Better for detection of low-
grade mosaisism
• Suffers from sequencing
biases
• Does not target non-coding
disease loci
• Possibility of incidental find-
ings
WGS • Completely unbiased
• No sequencing bias
• Better for detection of struc-
tural variants
• Difficult data handling
• Difficult interpretation
• Possibility of incidental find-
ings
Most of these studies, however, require major laboratory efforts, while the results may not
establish a gene’s involvement in a disorder with 100% certainty. Testing the effect of unknown
variants in known pathogenic genes may establish causality more straightforward, but time
and effort are still an issue. This makes current functional tests less suitable for immediate
application within a diagnostics setting.
Incidental findings
The strict separation between diagnostics and research becomes increasingly blurred as un-
biased testing approaches are finding their way into diagnostics. On one hand, unbiased
diagnostic testing results in bulk quantities of genetic data that have a large potential use for
research applications or the diagnosis of other patients. On the other hand, similar experi-
ments with research participants may result in unanticipated chance findings that are medi-
cally relevant for the participant. There is now an increased risk of such incidental findings
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Table 12.2: Proposal for interpretation of rare variants within a diagnostic setting
Variant locus Interpretation Report to patient
Known pathogenic Known disease locus Pathogenic Positive test result
Unknown, protein inhibiting Known disease locus Pathogenic Positive test result
Unknown, protein affecting known disease locus Unknown Based on other
information
Unknown, not affecting protein Known disease locus Unknown, more
research needed
Negative test result
Unknown, protein inhibiting Unknown locus Unknown Based on other
information
Unknown, protein affecting Unknown locus Unknown, more
research needed
Negative test result
Unknown, not affecting protein Unknown locus Likely benign Negative test result
Other information constitutes: population frequency of the variant, evolutionary conservation of the variant and
amino acid, predictions of pathogenicity, gene function etc.
due to the more unbiased ways of research and diagnosis that are offered by NGS.503 How
to deal with incidental findings has become a major concern now that genome diagnosis is
becoming a reality. Although there are also other concerns with unbiased genetic testing, I
would like to touch upon this specific discussion as its outcome will have large consequences
for future diagnostics and research.
Incidental findings constitute findings with implications for a patient’s current or future health
that are not related to the initial referral for the diagnostic test or research that is being per-
formed. For example, when a patient is being tested for the genetic cause of blindness, there
may be an incidental finding of pathogenic mutations in the BRCA1 gene. Such mutations can
increase the risk for early-onset breast cancer to more than 80%. Discussions focus on what
kind of incidental findings should be disclosed to individuals within different research or diag-
nostics settings, depending on the consent given by the individual. Arguments center around
issues such as (1) a patient’s right to decide whether to know or not know about incidental
findings504 (2) a patient’s ability to a-priori comprehend and oversee the possible outcomes of
a test503,505,506 (3) the potential impact and actionability of an incidental finding503,505 (4) the
additional workload and costs associated with incidental findings because of the additional
follow-up that is required to confirm and interpret the finding.507
Again, these issues are not new in genetics diagnostics and are similar in other fields.508
In general the decision to follow up or report an incidental genetic finding cannot be made
beforehand as the complexity and spectrum of possible findings and implications thereof are
too large. A patient might indicate that he/she does not wish to be informed about very specific
(types of) findings but cannot do so for incidental findings in general. I believe there should be
(quality) procedures about the minimum requirements for follow up, but the eventual decision
should be made by specialists based on the specific finding and circumstances of the finding,
taking into consideration possible specific wishes of the patient. Clearly it is impossible to
know a patient’s decision without informing him of the actual finding.
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Francis Collins envisioned the current as a time wherein genetic diagnosis would be a stan-
dard test.481 I think it is safe to say that currently genetic diagnosis is still in many cases a last
resort when all other diagnostic methods have failed and that, although genetic diagnosis is
indeed widely available as Collins postulated, this is not so for every condition. NGS techno-
logy will enable genetic testing for much more conditions, while the diagnostic yield for many
existing tests will increase substantially. However, the unbiased way in which patients will be
tested will give rise to new interpretation challenges that will stimulate research, but will take
many more years to resolve. Moreover, known ethical dilemma’s of unbiased genetic testing
will become more acute and will require practical solutions in which common sense should
prevail over misplaced protectionism of individuals at the expense of others.
Societal impact
The fact that most clinicians and patients are currently not as genetically literate as Collins
hoped for, is explained for a large part by the limited exposure to genetic information due to
the relatively high costs associated with genetic information. Many technical challenges still
lie ahead, but it is clear that the $1000 dollar human genome is approaching rapidly, and will
be succeeded by even cheaper genomes. Once whole genome sequencing is within finan-
cial reach, it is likely to be used on a mass or even a population basis for medical and other
purposes.494 The potential benefits will be numerous in the fields of research, diagnostics,
and personalized medicine; a complete genome sequence will become a common good. This
raises some important ethical questions concerning the interpretation and use of genetic in-
formation. Although none of these issues are conceptually new, they are more actual now that
complete genome sequencing might well become affordable for everyone.494 I touch upon two
of the most prominent issues related to the growing availability of genetic information: 1) Pri-
vacy, as this topic is very acute with the growing amount publicly available genetic data from
NGS. 2) personal genomes, as this will for the majority of the (healthy) society be their most
likely encounter with genetics.
Privacy versus data sharing
The properties of DNA are such that it is by nature very private. It contributes an almost
unique identifier for every individual, and contains detailed information about identity, health
risks, and kinship. Most of this information is still largely undecipherable, but this will soon
change. This warrants the safekeeping of genetic information against misuse by others.
When considering exome sequencing to answer a medical question, individuals often have
a limited choice about whether they wish to be genetically tested, without running a poten-
tial risk to their health. Patients should have the right to keep their genetic data private and
protected against unauthorized access. Strong legal protection will be necessary if health
care providers and consumers are to embrace whole genome sequencing or genomic char-
acterization of individuals as an integral part of medicine.494,509 However, the availability of
well-phenotyped control cohorts is a necessity for the reliable interpretation of genomic varia-
tion in a patient. Different patient’s interests may collide, as some patients may not be willing
to share their genetic data to the benefit of others. To anonymise this kind of genetic data is
not straightforward, as the identity of the patient can potentially be inferred from the genetic
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data itself. A practical solution to this is to bundle patients into groups and share only the
frequencies of variants within the group. Although it has been shown that it is possible to infer
the presence of any individual in such a frequency cohort based on a person’s genotype.510
Patient grouping needs to be done based on disease indication in order to make sure that
patients with blindness are not used as a control cohort for another blindness patient. The
sharing of this (frequency based) genetic information in an access-controlled environment will
safeguard a patient’s privacy sufficiently, but not at the expense of other patients.509
In case of WGS of individuals without a direct medical purpose, opinions about privacy con-
cerns vary. Some argue for strict privacy. Because whole-genome sequencing will show
that every individual has an above average risk for some disorders, every individual could
face some negative social consequences from those risks, whether in insurance, employment
stigma or otherwise.505 Others, however, argue against safekeeping, as they maintain that
this is an empty promise, considering that the digital nature of most of this information makes
it prone to sharing, loss, or theft.511,512 Additionally, anyone’s DNA is easily obtainable from
as much as a single hair, and much of one’s genetic information can be inferred from the DNA
of their relatives. A conceptionally interesting but controversial position states that it is better
that the information is made completely public and that participants are aware of this on be-
forehand, while fully understanding the implications. In this way, there is no risk for privacy as
there effectively is no privacy.
Clearly, some may refuse any kind of genetic testing while others happily share their genome
on Facebook.513 Regardless of this, it is clear that the large scale availability of genetic infor-
mation should be accompanied by efforts to raise awareness of the issues that are involved,
and to educate people on the use and interpretation of genetic information.
Personal genomes
Direct-to-Consumer (DTC) refers to genetic testing performed by commercial companies, of
which the results are directly communicated to the consumer without an intermediate. The
varying different pieces of genetic information that are potentially covered by this definition
makes it difficult to argue about the benefits and risks of such tests.514 Several commercial
companies are already offering genetic testing, mostly of known genetic markers. However,
many are starting to offer whole genome testing, and will thus offer consumers their complete
genetic profile.515 In the light of this, one of the major ethical concerns with respect to DTC
is the lack of an intermediate physician or counselor who explains the risk beforehand and
interprets the findings into what is relevant for the consumer and, in addition, provides some
guidance in decision making. The interpretation of most results that are obtained from any
genetic test evolve around risk probabilities, concepts that are inherently difficult to use for
most people.506 Although a recent study did reveal any clear behavioral effects of DTC testing,
the authors ascribed this to the fact that early adopters represent a genetically more literate
part of society.515 More relevant, however, is the fact that only common polymorphisms were
tested, having little impact.
Any decision towards acting on a genetic result will necessarily depend on the post-test prob-
ability threshold for action, the consequences of action and the usefulness and effectiveness
of action.405 For example mutations in BRCA1 and BRCA2 can increase a women’s risk for
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breast cancer many times yielding a large post-test probability. The consequences of action
based on such a result would be regular screening to allow for early detection and interven-
tion,516 or maybe even more severe preventive measures. On the other side of the spectrum
are genetic risk factors who’s potential effect is still unclear, giving rise to either only marginally
increased chances or, due to the very small prior chance of the disease to a negligible post-
test risk.405 This does not only apply to increased risk probabilities, but also decreased risks.
The most difficult cases are genetic factors that substantially increase the risk of an untreat-
able disease. For example certain risk factors in the APOE gene result in at least a 4 times
increase of Alzheimer disease.517 This is a late onset disease that is currently untreatable.
For this reason some public genomes have blocked the status of this gene.
In all of these cases, counseling seems relevant in order to make sure that individuals are
aware of the potential outcome of genetic testing and that they do not misinterpret genetic
results, either taking harmful actions aimed at prevention, or changing their lifestyle under
the assumption that they are at less risk for certain conditions.514 As such, prior testing of
a participants awareness and understanding of genetic principles should perhaps become
mandatory in case of genetic testing without the supervision of a professional. It is clear that
most genetic information is still difficult to interpret at this time, even by such a professional.405
Bioinformatics
Bioinformatics is a relatively new profession that only gained real interest with the introduction
of high throughput technologies such as microarrays, in genetics research. Bioinformatics for
NGS is still in its infancy but many commercial companies are recognizing the need for all-in-
one software solutions that can easily be used by biologists. Within a few years software will be
available that solves many of the current bottlenecks. Although this may seem a disappointing
future for bioinformatics, it is clear that 1) a lot of bioinformatics is needed in the coming
years to achieve this. 2) any analysis or handling of NGS data will, due to its size, require
bioinformatics skills. 3) additionally, bioinformatics will be a necessity for those working with
future cutting-edge high-throughput technologies.
The fact that bioinformatics has become this important also requires that biologists working
with these data become more knowledgable in this field than they used to be. Already some
educational programs are reflecting these changes by offering bioinformatics courses, such
that students will be able to manage large datasets. In the future the classical biologist may
disappear and be replaced by researchers who are equally skilled in laboratory work as well
as bioinformatics.
Conclusion
The future that Francis Collins foresaw 10 years ago is not here yet but NGS technologies will
enable many of the hopes that Collins had within the next 10 years. In medical research, the
focus is shifting from the identification of genomic variation to the interpretation thereof, and
in 10 years will move on to intervention and treatment of diseases. In healthcare, genetics
will become a standard tool for diagnosis and, in some cases, treatment of patients. Society
in general will become more exposed to genetics than ever before, requiring that the general
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General discussion
knowledge on genetics increases similarly as with the recent large scale adoption of ICT
technology.
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Chapter 2: Massively parallel sequencing of ataxia genes after array-based enrichment
Figure S1: Schematic workflow of the experiments
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Supplementary Figures
Figure S2: Coverage histograms for all 7 disease genes for all samples
This figure shows a UCSC genome browser view with genomic position, custom tracks representing sequence
coverage obtained for each individual sample, target region, tiled region, i.e. region covered on the enrichment
array, and the RepeatMasker track. This figure is shown for all seven disease genes: (A) APTX, (B) ATM, (C)
FXN, (D) SACS, (E) SETX, (F) SYNE1, (G) TDP1. This figure clearly shows a high reproducibility of target
enrichment for the 7 samples.
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Chapter 3: Next generation sequencing of a 40 Mb linkage interval reveals TSPAN12
mutations in patients with familial exudative vitreoretinopathy
Figure S3: Coverage histogram for the complete 40.5-Mb FEVR locus
Coverage histogram for the whole region targeted for next-generation sequencing, displayed in 6 panels. This
figure shows a UCSC genome browser view with genomic position, custom tracks representing the sequence
coverage that was obtained, the target region (e.g. regions covered on the enrichment array), and the UCSC
gene track. The array design included all known exons, untranslated regions, microRNAs and highly conserved
regions complemented with the complete genomic sequence of the candidate genes WNT2 and WNT16. The
positions of the genes WNT2, WNT16 and TSPAN12 are indicated with a black arrowhead. In total, 3,048 exons
from 338 RefSeq genes and 313 UCSC genes as well as 14 microRNAs and 23 non coding RNAs were targeted.
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Figure S4: Pedigree structure and mutation segregation in all families with TSPAN12 muta-
tions
A) Complete pedigrees for families A to E, and the segregation of the mutations identified in these families. M1/+
indicates heterozygous carriers of the p.Ala273Pro mutation, M2/+ heterozygous carriers of the p.Gly188Arg
mutation, whereas +/+ indicates individuals with two wild-type alleles. All affected individuals in the families
carry the respective causative mutations. In family A, the clinical status of individual III:1 was uncertain, as well
as for individual III:15 and IV:2 in family B (indicated in grey). These three individuals all carried the mutation,
as did the healthy individual III:8 in family B, suggesting non-penetrance. Probands in each family are indicated
with an arrow. B) Sequence chromatograms for the two mutations in TSPAN12. The upper two chromatograms
show the heterozygous mutations, whereas the lower two indicate the sequences detected in controls. The
corresponding amino acids are indicated above the sequence traces. M1 and M2 correspond to the mutations
as described in panel A.
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Chapter 4: Targeted next generation sequencing of a 12.5 Mb homozygous region
reveals ANO10 mutations in patients with autosomal recessive cerebellar ataxia
Figure S5: Magnetic resonance imaging of one of the affected patients displaying marked
diffuse cerebellar atrophy both on saggital (upper picture) and axial (lower picture) images.
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Chapter 5: De novo mutations of SETBP1 cause Schinzel-Giedion syndrome
Figure S6: Comparison of fold coverage of the targeted exomes for all 4 samples
Comparison of fold coverage (x-axis) and percentage of covered targets (y-axis) for all 4 samples.
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Figure S7: Comparison of fold coverage of the SETBP1 gene for all 4 samples
A) Coverage histogram of read depth per basepair of exon 4 of SETBP1, displayed in hg18 version of the UCSC
genome browser. B) SOLiD sequencing reads displayed for patient 1. Reads overlapping the mutation in exon
4 of SETBP1 (bp position g.40785915, hg18, NCBI36) show the heterozygous T>C change.
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Supplementary Figures
Figure S8: Confirmation of de novo SETBP1 mutations by Sanger sequencing
Confirmation and de novo proof by Sanger sequencing, shown for Patient 1-4 (A = affected), in comparison with
their respective parents (M = mother, F = father).
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Chapter 6: Exome sequencing identifies WDR35 variants involved in Sensenbrenner
syndrome
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Figure S9: Pathogenic variants detected in WDR35
A) Schematic overview of the WDR35 gene. WD-domains are indicated by triangles; the box indicates a low
complexity region. B) Schematic overview of the WDR35 protein. C) Sequence reads covering the site of the
pathogenic mutations. D) Validation of the pathogenic mutation and inheritance analysis by Sanger sequencing.
For patient two there was no maternal DNA available. Mutation positions are indicated by arrows.
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     H.sapiens_WDR35     (1) MFFYLSKKISIPNNVKLQCVSWNKEQGFIACGGEDGLLKVLKLETQTDDA 
    M.musculus_Wdr35     (1) MFFYLSKKIAVPNNVKLKCISWNKDQGFIACGGEDGLLKVLRLETQTDDS 
  R.norvegicus-Wdr35     (1) MFFYLSKKIAVPNNVKLKCISWNKDQGFIACGGEDGLLKVLRLETQTDDS 
D.melanogaster_Oseg4     (1) MFVYLSKKIAIPNNVKLNCIAWNKEEGYIAVAGTDGLLKVLKLDQATPNG 
    C.elegans_IFTA-1     (1) MSVFRKFNLGLPEHGQLHFAEWNYNSNYIACGGALGKLKVVKIGTDATDL 
                             51                                             100 
     H.sapiens_WDR35    (51) KLRG-LAAPSNLSMNQTLEGHSGSVQVVTWNEQYQKLTTSDENGLIIVWM 
    M.musculus_Wdr35    (51) KLRG-LAAPSNLSMNQNLEGHSGAVQVVTWNEQYQKLTTSDQNGLIIVWM 
  R.norvegicus-Wdr35    (51) KLRG-LAAPSNLSMNQNLEGHSGAVQVVTWNEQYQKLTTSDQNGLIIVWM 
D.melanogaster_Oseg4    (51) QSKGGLAAVSNLSMNQTLDGHKESVRVVTWNDAQQKLTSSDTDGVIMVWM 
    C.elegans_IFTA-1    (51) NKSP---NAATLVVNQALEGHNATVMNATWNENNQKLTTSDTSGLIIVWG 
                             101                                            150 
     H.sapiens_WDR35   (100) LYKGSWIEEMINNRNKSVVRSMSWNADGQKICIVYEDGAVIVGSVDGNRI 
    M.musculus_Wdr35   (100) LYKGSWYEEMINNRNKSVVRSMSWNADGQKICIVYEDGAVIVGSVDGNRI 
  R.norvegicus-Wdr35   (100) LYKGSWYEEMINNRNKSVVRSMSWNADGQKICIVYEDGAVIVGSVDGNRI 
D.melanogaster_Oseg4   (101) LYKGSWYEEMTNDRKKSTVASMSWTSDGSRICIVYEDGAIIVGSVDGNRI 
    C.elegans_IFTA-1    (98) MFNEQWCEEMINNRNKSVVVSICWNLEGTKIAIAYADGNVIVGTLEGNRI 
                             151                                            200 
     H.sapiens_WDR35   (150) WGKDLKGIQLSHVTWSADSKVLLFGMANGEIHIYDN-------------- 
    M.musculus_Wdr35   (150) WGKDLKGIQLCHVTWSADSKILLFGMANGEIHIYDN-------------- 
  R.norvegicus-Wdr35   (150) WGKDLKGIQLCHVTWSADSKILLFGMANGEIHIYDN-------------- 
D.melanogaster_Oseg4   (151) FGKELKGTHLTGVQWSPDNRLILFALANGECHLYDN-------------- 
    C.elegans_IFTA-1   (148) WNKELEIQLAACELDIPMHCLEAEDLEQALAKKEHQKEEIVCLKYWSPTL 
                             201                                            250 
     H.sapiens_WDR35   (186) ---------QGNFMIKMKLSCLVNVTGAIS----------IAGIHWYHGT 
    M.musculus_Wdr35   (186) ---------QGNFIMKMKLNCLVNVTGAIS----------IAGIHWYHGT 
  R.norvegicus-Wdr35   (186) ---------QGNFIMKMKLNCLVNVTGAIS----------IAGIHWYHGT 
D.melanogaster_Oseg4   (187) ---------QGNFAMKLHIQCVNISGGSSSRGHR------IASICWFSGR 
    C.elegans_IFTA-1   (198) KSKTILDEMERDFERKLEKDREVTGTAIFTNFPTKPPPKELPEHEKNTEP 
                             251                                            300 
     H.sapiens_WDR35   (217) EGYVEPDCPCLAVCFDNGRCQIMRHENDQNPVLIDTG-MYVVGIQWNHMG 
    M.musculus_Wdr35   (217) EGYVEPDCPCLAICFDNGRCQIMRHENDQNPVLIDTG-MYVVGIQWNHIG 
  R.norvegicus-Wdr35   (217) EGYVEPDCPCLAICFDNGRCQIMRHENDQNPVLIDTG-MYVVGIQWNHIG 
D.melanogaster_Oseg4   (222) VVQSR-KRPVLAICYENGRVQIMRNENDDAPAIFDTG-MRNVDAKWNHDG 
    C.elegans_IFTA-1   (248) YQPVPPDRPRFVVAYARGMMQLMRSLNDPEPVVVSIPNFKITGAKWSPNG 
                             301                                            350 
     H.sapiens_WDR35   (266) SVLAVAGF---QKAAMQDKDVNIVQFYTPFGEHLGTLKVPGKEISALSWE 
    M.musculus_Wdr35   (266) SVLAVAGS---QKVVTQDKDINIVQFYTPFGEHLGTLKVPGKQMCSLSWE 
  R.norvegicus-Wdr35   (266) SVLAVAGS---QKVVTQDKDVNIVQFYTPFGEHLGTLKVPGKQMCSLSWE 
D.melanogaster_Oseg4   (270) TVLAICGTTLDAVSPTSQRDTNQVCFYSPLGKIYRTLKVPGTDITSLSWE 
    C.elegans_IFTA-1   (298) AFLAVCGN----DSDKDEPTFSKIHFLSAYGHIVGYFQTNDSCITGICWE 
                             351                                            400 
     H.sapiens_WDR35   (313) GGGLKIALAVDSFIYFANIRPNYKWGYCSNTVVYAYTR---PDRPEYCVV 
    M.musculus_Wdr35   (313) GGGLKIALAVDSFIYFANIRPDYKWGYCSNTVVYAYTR---PDRPEYCVV 
  R.norvegicus-Wdr35   (313) GGGLKIALAVDSFIYFANIRPDYKWGYCSNTVVYAYTR---PDRPEYCVV 
D.melanogaster_Oseg4   (320) GKSLRIAMAVDSFIYFANIRPDYIWCYFEKTVVFLNSGSATRESPMSVIT 
    C.elegans_IFTA-1   (344) STGLRMAIAAAGTLLIGQIRPEFKWGSIEETIVYVYQK---EELYQYGIM 
                             401                                            450 
     H.sapiens_WDR35   (360) FWDTKNNEKYVKYVKGLISITTCGDFCILATKADENHPQEENEMETFGA- 
    M.musculus_Wdr35   (360) FWDTKNSEKYVKYVKSLISITTCGDFCILATKADENHPQEENEMETFGA- 
  R.norvegicus-Wdr35   (360) FWDTKNNEKYVKYVKSLISITTCGDFCILATKADENHP------------ 
D.melanogaster_Oseg4   (370) FWNTVSNQSFLKEVEPTLCLASSSEHCVLGVECVSSNIKEIALSTLENRS 
    C.elegans_IFTA-1   (391) FYDYKTDEKTVKTVTHFENMAFYREHCVLINRQDDGVIP----------- 
                             451                                            500 
     H.sapiens_WDR35   (409) ------TFVLVLCNSIGTPLDPKYIDIVPLFVAMTKTHVIAASKEAFYTW 
    M.musculus_Wdr35   (409) ------TFVLVLCNSIGTPLDPKYIDLVPLFVAMTKTHVIAASKEAFYTW 
  R.norvegicus-Wdr35   (398) ------QFVLVLCNSIGTPLDPKYIDLVPLFVAMTKTHVIAASKEALYTW 
D.melanogaster_Oseg4   (420) NPADDRVYQLLLCNSIGTTVDSKYTDIRPCFVGINSSYVAIASQEEILIW 
    C.elegans_IFTA-1   (430) ------HYFCQLCNSIGTSLDYNVTTVRPKFACVNGICAVIASEDRYFIW 
                             501                                            550 
     H.sapiens_WDR35   (453) QYRVAKKLTALEINQITRSRKEGRERIYHVDDTPS--------GSMDGVL 
    M.musculus_Wdr35   (453) QYRVAKKLTALEINQITRSRKEGRERIYHVDDVPS--------GSVDGVF 
  R.norvegicus-Wdr35   (442) QYRVAKKLTALEINQITRSRKEGRERIYHVDDVPS--------GSVDGVF 
D.melanogaster_Oseg4   (470) HYHTPKSASTLHNVKARKEKR------FHIDDTPTGVEMAKDLMLSSSSG 
    C.elegans_IFTA-1   (474) HFVLPKFNSVQAGIHVPGKSG-----DYVLEEQQR------------TIE 
                             551                                            600 
     H.sapiens_WDR35   (495) DYSKTIQGTRDPICAITASDKILIVGRESGTIQRYSLPNVGLIQKYSLNC 
    M.musculus_Wdr35   (495) DYSKAIQGTRDPICAITASDKTLIVGRESGVIQRYSFPNVALIQKYSLDC 
  R.norvegicus-Wdr35   (484) DYSKAIQGTRDPICAITASDKTLIVGRESGVIQRYSFPNVALIQKYSLDC 
D.melanogaster_Oseg4   (514) DGHSTQRGISDPICALALSEKLLLVARESGAINEYSIANVALRNRHLMNA 
Figure S10: WDR35 missense mutations occur in conserved residues
Multiple sequence alignment of the WDR35 in different species. Completely conserved residues are indicated
by black boxes, and residues conserved in the majority of sequences are indicated by dark gray boxes. Sim-
ilar and weakly similar amino acids are indicated by light grey boxes and grey letters, respectively. The po-
sitions corresponding to the missense mutations found by exome sequencing (p.E626G and p.A875T) are
indicated by red blocks (and an asterisk). WDR35 sequences were subtracted from Genbank; H. sapiens
NP_001006658.1; M. musculus NP_766058.3; R. norvegicus NP_001092810.1; D. melanogaster NP_647653.1;
C. elegans NP_508940.3.
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Chapter 7: Exome sequencing identifies truncating mutations in human SERPINF1 in
autosomal-recessive osteogenesis imperfecta
Figure S11: Overview of all identified homozygous regions
The graph shows the identified homozygous regions on chromosomes 1, 6, 11 and 17 (y-axis, ratio of variant
reads/all reads per SNP position; x-axis, genomic position on the respective chromosome). Each dot represents
one of the SNP markers that were included in the analysis. SNPs within a region that was called as homozy-
gous are colored in purple. The position along the y-axis indicates whether all reads or just a fraction of reads
contained a certain variant. To identify homozygous regions in an unbiased genome-wide fashion, all autosomal
SNP genotypes were considered, not only variants identified in the course of the initial quality filtering step of the
exome data analysis (i.e., differences from the reference genome). We extracted the genotypes of all autosomal
SNPs annotated in dbSNP130 that had a read coverage of at least 15-fold. This resulted in a total of 299,494
genotypes (38,927 SNPs on chromosome 1, 21,275 on chromosome 6, 16,279 on chromosome 11 and 18,031
on chromosome 17). Variants displaying in >95% of all reads an identical SNP allele were considered to be ho-
mozygous, SNPs with 30% to 70% variation reads were considered to be heterozygous, and SNPs with <30%
or with more than 70% and less than 95% variation reads were considered ambiguous. A genomic region was
identified as a homozygous stretch if at least 500 consecutive SNP markers were called as homozygous, with a
maximum tolerance of two heterozygous SNPs per 500 markers (to account for possible sequencing or mapping
errors). The genomic positions of all homozygous regions are highlighted by purple bars. The two homozy-
gous regions on chromosome 17 are just separated by a few heterozygous variants, possibly false-positives,
i.e. mapping artifacts in a cluster of olfactory receptor genes (stretch of 111 SNPs with 14 heterozygous calls,
chr17:3,091,589-3,299,082), and therefore likely represents one homozygous stretch of more than 4.5Mb.
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Figure S12: Pedigrees of three OI families with SERPINF1 mutations
Affected family members carry a number sign (#1 to #4). The genotypes of the patients, of their healthy siblings
and of their parents are displayed, with mut indicating a mutated allele and wt indicating the wildtype allele.
A) Pedigree of the index family from the United Arab Emirates. The patients’ parents are second cousins. B)
Pedigree of patient #3. The family originates from Turkey. The patient’s parents are half first cousins, i.e., their
fathers are half siblings. C) Pedigree of patient #4. The family originates from Turkey. The patient’s parents are
first cousins.
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Figure S13: Electropherograms of SERPINF1 mutations obtained by Sanger sequencing
The coding exons of SERPINF1 (NM_002615.4) were PCR-amplified from genomic DNA and analyzed by direct
sequencing on an ABI3100 capillary sequencer. Primer sequences can be obtained upon request. A) Electro-
pherograms of individuals which carried the wild-type allele (wt) or the mutated allele c.324_325dupCT (mut) on
one or both copies of SERPINF1 exon 4. The position of the mutation is marked with an arrow. The two inserted
nucleotides and the premature stop codon resulting from the frame-shift are framed in black. Note the "dou-
ble" sequence downstream of the insertion in the heterozygous mutation carrier. This mutation was identified
in patient #3. B) Electropherograms of individuals which carried the wild-type allele (wt) or the mutated allele
c.1132C>T (mut) on one or both copies of SERPINF1 exon 8. The position of the mutation is marked with an
arrow. The affected codon is framed in black. This mutation was identified in patient #4.
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Figure S14: SERPINF1 cDNA analysis
RNA was isolated from whole blood of patient #3, his father and a control individual using standard methods.
First strand cDNA synthesis was performed with the ReverseAidTM-Kit (Thermo Fisher Scientific, Waltham,
Massachusetts, USA). In the upper panel, the exon/intron structure of SERPINF1 is depicted and the locations
of the forward and reverse primer used for the subsequent cDNA amplification are given. Primer sequences can
be obtained upon request. The resulting cDNA fragment encompasses the frameshift mutation c.324_325dupCT
in exon 4 of SERPINF1. This cDNA fragment could be amplified from RNA of the control individual, of patient
#3 and of the patient’s father. Sanger sequencing revealed, as expected, that the control individual carried the
wildtype sequence (wt / wt) and that patient #3 was homozygous for the CT duplication (mut / mut). In the father
of patient #3, the cDNA sequence of the mutated allele was only detectable as a faint background signal behind
the wildtype sequence. The red arrow marks the beginning of the overlay or "double" sequence that can be
observed in heterozygous carriers of insertion mutations. Sanger sequencing on genomic DNA derived from
the patient’s father displayed equally strong signals for the mutated and the wildtype allele (lower panel). This
observation suggests that the number of mutated transcripts serving as templates for the RT-PCR reaction is
strongly reduced compared to the number of transcripts with the wildtype sequence, most certainly as a result
of nonsense-mediated mRNA decay.
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Figure S15: Whole body DXA scans of three patients with SERPINF1 mutations
The scans were performed with the DXA-machine GE Lunar Prodigy (GE Healthcare, Pollards Wood, United
Kingdom). The pictures show patient #2 at the age of 15.9 years, patient #3 at 5.9 years, and patient #4 at
7.8 years. All patients display deformities of their humeri, which is a rather rare finding in patients with OI.
Note that all received intramedullar rodding of their femura due to fractures and deformities. Patient #2 (left
picture) is severely adipose, a fact that decreases the quality of the DXA picture. He had multiple fractures of
his forearms, resulting in severe deformities, and bowing of his tibiae. Additionally, he is affected by a severe
scoliosis. Bisphosphonate and physical treatment started considerably later (at age 11) than in the other patients.
Patient #3 (middle) received additional rodding of his left tibia. He has only a mild scoliosis, but he displays severe
bowing of his forearms, especially on the left side. Patient #4 (right picture) underwent additional surgery of his
left humerus with remaining osteosynthetic material. He also has a mild scoliosis.
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Figure S16: Development of vertebral deformities in patient #4
Upper Panel: (A) Lateral spine x-ray picture of patient #4 at treatment start with i.v. bisphosphonates at the age of
7 months. (B-H) Yearly x-ray follow-up over a treatment period of 7 years. The lumbar vertebrae increased in size
during this time and showed a reshaping close to the normal cuboid form. These radiographs are representative
for the development in the other three OI patients with SERPINF1 mutations, all of which received i.v. neridronate
treatment. Patient #4 was selected for presentation as there is the longest follow-up available. Middle Panel:
Schematic illustration of vertebral deformities of patient #4 during the treatment period with i.v. bisphosphonates.
Vertebrae L1 - L5 on the lateral spine radiograms shown above were analyzed with an established 8-point
measurement method and later converted into the schematic view. Lower panel: Anterior-posterior index of
lumbar vertebra of patient #4 over a period of 7 years. The index is calculated by dividing the measured anterior
height (in mm) by the posterior height (in mm). This method is established to quantify the reshaping of vertebral
compression fractures in children with OI.518,519 A normalization of the anterior-posterior index close to the ratio
of 1.0 can be observed over the treatment period.
167
Figure S17: Collagen analysis
Pepsin-treated procollagens from medium and cell layers produced by fibroblasts from patient #3 and a control
(C) were electrophoresed on a 5% SDS-polyacrylamide gel, processed for fluorography, and exposed to X-ray
films. The α1(I), α2(I), α1(V), α2(V), α3(V), and [ 1(III)]3 chains, and β components are indicated. The patient’s
collagens migrate similarly to those from the control.
Figure S18: Collagen synthesis and secretion analysis
Pulse-chase experiments were performed as follows: Fibroblasts of a healthy control individual (= "-" in the
figure), of patient #3 from this study, and of a type II OI patient (= "+" in the figure, serves as a positive control
for delayed collagen secretion due to a p.Gly988Cys mutation in the α1(I) chain315) were grown to confluence
in DMEM and 10% FCS, and then plated (2.5x105 cells) in 35-mm dishes. Cells were stimulated overnight with
ascorbic acid supplementation (50 g/ml), and before labelling, medium was changed and DMEM (lacking serum,
proline and glycine), supplemented with ascorbic acid (50 g/ml), was added. Cells were labelled 4 h with 20
Ci [3H]-proline and 20 Ci [3H]-glycine, and then chased with fresh DMEM supplemented with 2 mM cold proline
and 2 mM cold glycine. The medium (= "M" in the figure) and cell (= "C" in the figure) layers were harvested
separately for each sample at 5 min, 30 min, 1h, 2h and 4h chases, and digested with pepsin (50 g/ml) overnight
at 4◦C. Purified collagens were separated on 5% SDS-PAGE. Note that the fibroblasts of the healthy control
individual and of our patient #3 almost completely secreted the α 1(I) and α2(I) chains within the first hour,
whereas fibroblasts from the positive control still retained collagens intracellularly, a portion of which formed
α1(I) di-sulfid bonded dimers.315
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Chapter 8: A de novo paradigm for mental retardation
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Figure S19: Coverage plots of all 30 individuals
Coverage for all exons targeted by enrichment was evaluated. The median coverage for all 30 individuals was
42-fold, with on average 90% of all targets covered at least 10-fold. The numbers in the figure legends refer to
the corresponding MR trios; M: Mother; F: Father; C: Child
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Figure S20: Variant calling per trio
Schematic representation of number of variants identified per individual, per trio. On average, 22,272 variants
are identified per individual, of which 19,212 are located in genes (intronic and exonic together), and 12,341 are
located within the exons and/or canonical splice-sites. The number on the x-axis refer to the corresponding MR
trios, whereas M to Mother, F to Father and C to child.
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(a) DYNC1H1 - trio 1 (b) ZNF599 - trio 1
(c) RAB39B - trio 2 (d) YY1 - trio 3
(e) BPIL3 - trio 3 (f) PGA5 - trio 4
(g) DEAF1 - trio 5 (h) CIC - trio 6
(i) SYNGAP1 - trio 8 (j) JARID1C - trio 10
Figure S21: IGV browser plots for the nine de novo and one X-linked inherited mutations
identified in the patients with mental retardation
21(a); 21(b); 21(c); 21(d); 21(e); 21(f); 21(g); 21(h); 21(i); 21(j);. For each overview, top panel show chromosome
with mutation location indicated by a red box. The second panel from the top shows the relative coverage per
base pair for patient, mother and father. Colored coverage columns indicate the location of the mutation with
the relative height of the color representing the percentage of variant reads observed. Middle panels show the
individual reads (zoom-in to ∼10-15 reads of all reads) with bases deviant from the wildtype sequence highlighted
in colors. Lower panel shows wildtype sequence and translated amino acids.
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Figure S22: Sanger validation of de novo mutations
Partial electropherograms showing the de novo occurrence for the nine mutations identified. Mutations are
highlighted in yellow. 22(a), left panel DYNC1H1 with mutation c.11465A>C leading to p.His3822Pro and right
panel ZNF599 with mutation c.532C>T leading to p.Leu187Phe. 22(b), RAB39B with mutation c.557G>A leading
to a premature stop p.Trp186X. 22(c), left panel YY1 with mutation c.1138G>T leading to p.Asp380Tyr and right
panel BPIL3 with mutation c.887G>A leading to p.Arg269His. 22(d) with mutation c. 1058T>C in PGA5, leading
to Val353Ala. 22(e), with mutation c.683T>G in DEAF1 leading to p.Ile228Ser. 22(f), with mutation c.1474C>T
in CIC leading to p.Arg492Trp and 22(g), with mutation c.998_999del in SYNGAP1 leading to p.Val333Alsfs70X.
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Figure S23: Distribution of PhyloP and Grantham scores for dbSNP, HGMD and the de novo
mutations identified in this study
A) Relative distribution of PhyloP scores for non-synonymous in dbSNP (green surface) and HGMD (red surface)
to represent evolutionary scores observed for benign and pathogenic variants. B) Evolutionary conservations for
the 3 functionally benign (green diamonds) and 4 functionally pathogenic de novo mutations, as well as the X-
linked inherited mutation (red diamonds). This analysis was further extended to analyse these combined scores
for all non-synonymous variants in dbSNP and HGMD to visualize the probability for the de novo variants to be
pathogenic or benign. Heat maps for distribution and frequency for the combined PhyloP and Grantham scores
in dbSNP C) and HGMD D). Functionally benign and pathogenic de novo mutations, as well as the inherited
JARID1C mutation, are represented by squares and triangles respectively. Benign de novo variants show a
better overlap with dbSNP as indicated by the their location mostly restricted to dark green areas in c and not
in d, whereas the pathogenic de novo variants show a better overlap with HGMD, as indicated by their location
mostly being in dark green areas in d and not in c. Statistical probability scores for these analyses are provided
in Table 8.2. Note: Two de novo mutations, a nonsense and frameshift mutation, identified in our patient cohort
are not depicted because such mutations do not have representative Grantham scores. Their functional impact
on the protein level will however be most severe and both are located in known mental retardation genes.
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Chapter 9: Next generation genetic testing for Retinis Pigmentosa
Sanger sequencing o n 124 RP probands:
Sanger sequencing o n 124 RP probands:
Sanger sequencing o n 8 RP probands
originating from an isolated region segregating
an founder mutation:
ABCA4
CRB1
RPE65
RPE65
6 probands solved
7 probands solved
2 probands solved
234 probands with isolated or autosomal recessive RP
219 RP probands
APEX arRP analysis in 67 RP probands: 5 probands solved
214 RP probands High-resolution homozygosity mapping in
186 RP probands and aected relatives
:
:
Identication of EYS and subsequent Sanger
sequence of EYS in 179 RP probands
Identication of C2ORF71 and IMPG2:
Sanger sequencing of known retinal disease
genes residing in homozygous regions
11 probands solved
2 probands solved
24 probands solved
177 RP probands
Targeted NGS of 111 retinal dystrophy genes in 100 RP probands
Figure S24: Overview of previous genetic analyses of our RP cohort
A total of 234 RP patient samples has been collected over the last 15 years. Several of these patients were
screened for mutations in ABCA4, CRB1, and RPE65 by Sanger sequencing, resulting in a molecular diagnosis
in 20 patients. In 186 of the probands a genome-wide homozygosity mapping was performed, leading to the
discovery of the disease-causing mutations in additional 37 patients. From the group of remaining RP probands,
100 were selected for the targeted NGS analysis of 111 retinal dystrophy genes.
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Figure S25: Systematic classification system for missense changes as well as for non-
canonical splice site variants
A systematic pipeline for the determination of pathogenicity was developed based on A) in silico evidence and
B) combined evidence of two mutations in a recessive gene. A) With regard to in silico evidence three different
features were considered important: (a) missense prediction software, (b) evolutionary conservation, and (c)
population frequencies. In the case of prediction programs, the scores for three different tools were combined
resulting in a single classification as "probably pathogenic", "unknown" or "probably benign" using a majority
vote. In case of three different predictions that variant was classified as "unknown". B) The final classification for
recessive genes was established by accounting for combinations of variants.
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A Results NGS analysis in selected group of 100 RP probands
B Results NGS analysis and all prescreening data in total cohort of 234 RP probands
Autosomal
recessive
X-linked
recessive
Autosomal dominant /
de novo
Figure S26: Summary of the genetic analysis on our complete RP cohort and estimated
prevalence of causative genes
A) Pie chart showing the results of the NGS analysis of 100 RP patients in this study. Pathogenic variants were
identified in 39 patients, and were present in 22 different genes, underscoring the extreme heterogeneity of RP.
Mutations in 14 genes follow an autosomal recessive inheritance model, six are autosomal dominant or de novo,
and two are x-linked. B) Pie-chart summarizing the combined results of the prescreening analyses (described in
Supplementary Figure S24) and the targeted NGS analysis performed in this study. Seventy-seven patients have
not undergone targeted NGS analysis. We calculated that 30 of these patients will also carry mutations in one
of the known retinal dystrophy genes.
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Chapter 2: Massively parallel sequencing of ataxia genes after array-based enrichment
Table S1: Coverage of coding and non-coding regions of targeted disease genes
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Control 1 Control 2 Average
ATM coding sequences 40.2 18.8 18.2 40.3 20.1 27.1 23.5 26.9
ATM non-coding sequences 35.9 15.1 18.1 34.7 19.3 23.6 21.3 24
APTX coding sequences 40.4 16.5 30.3 44.3 28 26.4 25.2 30.2
APTX non-coding sequences 34.1 17.3 19.3 30.9 27.9 24.4 23.2 25.3
FXN coding sequences 21.1 13.2 8.6 23.3 16.5 15.2 17.4 16.5
FXN non-coding sequences 25.4 12 12.9 18.7 18.9 15 14.2 16.7
SACS coding sequences 74 33.2 30.9 57.6 35.7 41.7 39.3 44.6
SACS non-coding sequences 36.8 17.2 19.2 31.3 24.1 23.3 21.4 24.8
SETX coding sequences 60.9 25 25.6 43.8 28.2 33 36.6 36.1
SETX non-coding sequences 37.7 17.7 19.6 30.2 24.1 24.1 22.5 25.2
SYNE1 coding sequences 53 23 23.4 41.2 30 29.7 28.3 32.7
SYNE1 non-coding sequences 40.5 18.9 21.3 37 23.7 26.1 24.4 27.4
TDP1 coding sequences 43.4 23 24.4 41.3 30.6 28.9 26.2 31.1
TDP1 non-coding sequences 42.3 18.5 22 34.4 27 27.1 23.2 27.8
Values depicted are average fold coverage per target type.
Table S2: Percentage of coding and non-coding regions in disease genes without sequence
coverage
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Control 1 Control 2 Average
ATM coding sequences - - - - - - -
APTX coding sequences - - - - - - - -
FXN coding sequences 25.7 25.54 21.21 23.07 25.7 14.55 25.7 23.07
SACS coding sequences 1.08 1.06 1.08 1.08 1.07 1.1 1.08 1.08
SETX coding sequences - - - - - - - -
SYNE1 coding sequences - - - - - - - -
TDP1 coding sequences - - - - - - - -
ATM non-coding sequences 0.56 2.58 0.67 0.07 0.65 0.39 0.84 0.83
APTX non-coding sequences 0.88 2.87 - 0.35 0.31 - 0.88 0.76
FXN non-coding sequences 1.37 4.53 1.15 1.71 1.64 1.57 1.85 1.97
SACS non-coding sequences 1.09 3.66 1.69 1.78 1.32 1.25 2.02 1.83
SETX non-coding sequences 0.92 2.26 0.83 0.55 0.4 0.6 1.3 0.98
SYNE1 non-coding sequences 1.04 2.02 0.7 0.7 0.79 0.93 1.05 1.03
TDP1 non-coding sequences 1.27 2.12 1.39 0.73 1.12 0.87 1.18 1.24
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Table S3: SNP calling error rate depending on read coverage
5x 10x 15x 20x
Patient 1
Conflicting Heterozygous Calls 1.93% 0.89% 0.73% 0.34%
Conflicting Homozygous Calls 0.12% 0.09% 0.09% 0.06%
Sum of Conflicting Calls 2.05% 0.98% 0.83% 0.40%
Patient 2
Conflicting Heterozygous Calls 2.15% 1.01% 0.60% 0.30%
Conflicting Homozygous Calls 0.06% 0.00% 0.00% 0.00%
Sum of Conflicting Calls 2.21% 1.01% 0.60% 0.30%
Patient 3
Conflicting Heterozygous Calls 0.93% 0.45% 0.25% 0.12%
Conflicting Homozygous Calls 0.04% 0.04% 0.02% 0.02%
Sum of Conflicting Calls 0.96% 0.48% 0.27% 0.14%
Patient 4
Conflicting Heterozygous Calls 2.97% 1.43% 0.65% 0.30%
Conflicting Homozygous Calls 0.12% 0.06% 0.06% 0.00%
Sum of Conflicting Calls 3.09% 1.49% 0.71% 0.30%
Patient 5
Control 1
Conflicting Heterozygous Calls 1.27% 0.91% 0.56% 0.36%
Conflicting Homozygous Calls 0.24% 0.24% 0.16% 0.16%
Sum of Conflicting Calls 1.51% 1.15% 0.72% 0.52%
Control 2
Conflicting Heterozygous Calls 2.05% 0.93% 0.54% 0.24%
Conflicting Homozygous Calls 0.34% 0.29% 0.24% 0.15%
Sum of Conflicting Calls 2.40% 1.22% 0.78% 0.39%
Average Conflicting Heterozygous Calls 1.88% 0.94% 0.55% 0.28%
Average Conflicting Homozygous Calls 0.15% 0.12% 0.10% 0.06%
Average Sum of Conflicting Calls 2.04% 1.06% 0.65% 0.34%
A comparison was performed between the number of SNP genotypes identified the 6 of the 7 samples using an
Affymetrix 6.0 array and those called in the sequenced genotypes (on average 3867 SNP markers).
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Table S5: Known genes for ataxia
Chromosome Start Position End Position Common Name RefSeq Name Number of Coding Exons Number of Coding Bases
chr1 45089036 45224869 EIF2B3 NM_020365 11 2056
chr1 201729894 201744700 AXPC1,OPTC NM_014359 6 1359
chr10 13359801 13382136 PHYH NM_006214 10 1645
chr10 50334496 50417153 ERCC6 NM_000124 20 5682
chr10 102737302 102744148 PEO1,C10orf2 NM_021830 5 2370
chr11 47193069 47217345 XPE,DDB2 NM_000107 10 1969
chr11 66209296 66245446 SPTBN2 NM_006946 36 9337
chr11 107598768 107745036 ATM NM_000051 62 12903
chr12 4889333 4897683 KCNA1 NM_000217 1 1548
chr12 6903887 6921745 ATN NM_001007026 9 4113
chr12 110374400 110521863 ATXN2 NM_002973 26 5755
chr12 122671522 122684200 EIF2B1 NM_001414 9 1464
chr12 123828127 123914472 CLA1,SCARB1 NM_005505 13 2691
chr13 22800964 22905841 SACS NM_014363 10 14408
chr13 51404805 51483631 ATP7B NM_000053 21 5658
chr13 69172726 69580460 KLHL1AS,KLHL1 NM_020866 11 2907
chr13 101171205 101852125 FGF14 NM_175929 6 1312
chr13 102296175 102326346 SAX1,ERCC5 NM_000123 48 12902
chr14 74539364 74546045 EIF2B2 NM_014239 8 1536
chr14 87469110 87529660 GALC NM_000153 17 3141
chr14 89491998 89580861 TDP1 NM_018319 16 3066
chr14 91594648 91642718 ATXN3 NM_030660 11 1746
chr15 40823835 41000299 TTBK2 NM_173500 14 4603
chr15 70422831 70455574 HEXA NM_000520 14 2438
chr16 8799170 8850695 PMM2 NM_000303 8 1221
chr16 13921515 13953706 XPF,ERCC4 NM_005236 11 3428
chr16 56211411 56256445 BFPP,GPR56 NM_005682 13 2877
chr16 65868913 65880904 PLEKHG4 NM_015432 21 4836
chr18 12319107 12367194 AFG3L2 NM_006796 17 3414
chr18 19365462 19420579 NPC1 NM_000271 25 5337
chr19 3831617 3879080 ATCAY NM_033064 13 1924
chr19 13178256 13478274 CACNA1A NM_001127222 96 21020
chr19 46595543 46622750 BCKDHA NM_000709 10 2148
chr19 50546489 50565685 XPD,ERCC2 NM_000400 24 3973
chr19 55510576 55524446 KCNC3 NM_004977 5 2591
chr19 59077278 59102713 PRKCG NM_002739 18 3225
chr2 21077806 21120450 Apo-B VLDL and LDL NM_000384 29 15432
chr2 27440722 27446828 EIF2B4 NM_001034116 13 2485
chr2 127731336 127768222 XPB,ERCC3 NM_000122 15 3249
chr2 152397533 152663839 CACNB4 NM_000726 16 2904
chr2 219354715 219388260 CYP27A1 NM_000784 9 2136
chr21 44018258 44020687 CSTB NM_000100 3 477
chr22 44446350 44619493 ATXN10 NM_013236 12 2148
chr22 49410314 49413473 ARSA NM_001085428 7 2057
chr3 2117247 3074645 SCA16,CNTN4 NM_175607 22 4409
chr3 4510033 4864286 ITPR1 NM_001099952 60 11913
chr3 14161650 14195176 XPC NM_004628 16 3786
chr3 15618258 15662329 BTD NM_000060 4 1872
chr3 63825272 63964176 ATXN7 NM_000333 13 3704
chr3 185335503 185345793 EIF2B5 NM_003907 16 3194
chr5 36642213 36724193 SLC1A3 NM_004172 9 2256
chr5 60205415 60276662 CKN1,ERCC8 NM_000082 12 1979
chr5 138310308 138561964 SIL1 NM_022464 18 3852
chr5 145949260 146441226 PPP2R2B NM_181678 12 2178
chr6 16407321 16869700 ATXN1 NM_001128164 2 2568
chr6 53470098 53517790 GCLC NM_001498 16 2880
chr6 137185394 137276764 PEX7 NM_000288 10 1572
chr6 152484514 153000227 SYNE1 NM_182961 148 36498
chr6 170705395 170723872 TBP NM_003194 7 1440
chr8 64135984 64161166 TTPA NM_000370 5 1137
chr8 91014740 91066075 NBS1,NBS,NBN NM_002485 16 3225
chr9 32962607 32991626 APTX NM_175069 8 1591
chr9 70840298 70904914 FXN NM_001161706 6 1035
chr9 78982181 79222219 CHAC,VPS13A NM_033305 74 14100
chr9 99477011 99499512 XPA NM_000380 6 1182
chr9 130896895 130912891 CRAT NR_028048 15 2811
chr9 134126647 134220193 SETX NM_015046 25 9621
chrX 19271932 19289723 PDHE1A,PDHA1 NM_000284 12 2007
chrX 74189830 74292857 ABC7,ABCB7 NM_004299 16 3222
chrX 146801200 146840333 FMR1 NM_002024 17 2919
Data were obtained from the Gene Reviews pages on Hereditary Ataxias available at the Gene Tests website
(date of access 24/08/2009), supplemented a PubMed search for published Literature reviews. All these will be
considered for a 2nd generation array.
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Chapter 3: Next generation sequencing of a 40 Mb linkage interval reveals TSPAN12
mutations in patients with familial exudative vitreoretinopathy
Table S6: General statistics of the sequencing run
Coverage statistics Variant statistics
Number of bases sequenced 51,440,891 Number of variants detected 1,915
% bases mapped 94.4% Known SNPs (dbSNP130) 1,749
% bases mapped to or near
(500 bp) targets
90.5% Unknown variants in genes 106
Average coverage of the tar-
gets
13.2x Unknown variants in exons 21
% targets covered at least 1x 94.8% Unknown missense variants 17
% targets covered at least 5x 79.8% Unknown variants in splice
sites
2
% targets covered at least 10x 56.5% Unknown substitutions 139
% targets covered at least 20x 20.9% Unknown indels 27
Left side: statistics on the target sequence coverage for the complete run. Right side: statistics on the detected
variants in the region on chromosome 7 by the Roche 454 software.
Table S7: Primer sequences of TSPAN12
Exon Forward (5′ > 3′) Reverse (5′ > 3′) Amplicon Length (bp)
1A ggagggcaacaaagcaataa cagctgcacaaactctcagc 397
1B ctgggtgagagggacaagaa gtcattcaaaccccgcttc 645
2 gatgaggcgatgtctcgaat gtggctgcagaaaaccagag 332
3 ttcaagatgcagcaaatggt ccaaaagatcaaggaagagca 307
4 tgctatgtcttgggtgcatt tcactgctccctaatcttgtga 291
5 caagtctgtctttgaggagccta gcggagtgaaaatgaactaaca 230
5 cgaagagagtcatttggcaat ccagagacagggagaaaatatga 393
6 tgcagttgcttcaaagagca caggcttaatttttcagcacag 631
7 gccatggtgttcctttactaca ggccttttacatttagacagagaag 430
8 tctcatcagctttccctgaga tgtccaggtggtgacttatgac 646
Primers used for amplification and sequence analysis of human TSPAN12.
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Chapter 4: Targeted next generation sequencing of a 12.5 Mb homozygous region
reveals ANO10 mutations in patients with autosomal recessive cerebellar ataxia
Table S8: Targeted regions of the array-analysis: targeted regions
Chromosome start end size
Chr.1 77,105,773 78,116,669 1,010,896
Chr.1 91,918,489 93,199,672 1,281,183
Chr.2 140,705,465 142,605,740 1,900,275
Chr.3 17,173,658 17,869,885 696,227
Chr.3 32,123,105 33,009,854 886,749
Chr.3 34,355,326 44,599,977 10,244,651
Chr.3 78,729,077 80,456,380 1,727,303
Chr.3 126,284,169 127,489,262 1,205,093
Chr.3 131,245,012 131,313,041 68,029
Chr.4 147,394,586 147,692,007 297,421
Chr.14 59,132,446 59,624,078 491,632
Sum 19,809,459
Table S9: Targeted regions of the array-analysis: base pairs targeted
Total bp targeted
1,905,376
Table S10: Targeted regions of the array-analysis: Total base pairs targeted after probe se-
lection
Total bp tiled
2,178,492
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Table S11: General statistics of the sequencing run
Coverage statistics Variant statistics
Number of bases sequenced 109,790,683 Number of variants detected 3,917
% bases mapped 93.50% Known SNPs (dbSNP130) 3,521
% bases mapped to or near
(500 bp) targets
32.28% Novel variants of those: 396
Average coverage of the tar-
gets
32.28x Splice site (SS) or coding vari-
ants
10
% targets covered at least 1x 99.01% Non synonymous (NS) or SS 8
% targets covered at least 5x 98.48% Homozygous SS or NS 4
% targets covered at least 10x 95.80%
% targets covered at least 15x 89.77%
% targets covered at least 20x 79.66%
Left side: statistics on the sequence coverage. Right side: statistics on the detected variants by the Roche 454
software. Known SNPs are only variants with the exact nucleotide change as described in dbSNP.
Table S12: Overview of variants after initial prioritization
Chr Position Ref Var % Var Gene Gene Id Ref AA Mut AA PhyloP Grantham
chr2 1.41E+08 A - 89 LRP1B NM_018557 SS 0.40 0
chr3 36754018 C G 98 DCLK3 NM_033403 R S 0.24 0
chr3 43571913 A C 94 ANO10 NM_018075 L R 5.26 145
chr3 43718918 G T 100 ABHD5 NM_016006 R L 2.65 102
Columns are from left to right: chromosome (Chr), position of the variant (Position), reference allele on the
plus strand (Ref), variant allele on the plus strand (Var), percentage of reads with the variant allele (% Var),
gene name in which the variant is located (Gene), RefSeq gene id (Gene Id), reference amino acid, where "SS"
indicates a canonical splice site (Ref AA), variant amino acid (Mut AA), PhyloP log odds ratio for evolutionary
conservation (PhyloP)229 and Grantam score for the amino acid substitution (Grantham). The variant in italics
was reported in our internal variant database. The causative mutation is indicated in bold.
184
Supplementary Tables
Table S13: Primers used for amplification and sequence analysis of human ANO10
Exon Forward (5’ > 3’) Reverse (5’ > 3’) Amplicon Lenght (bp)
1 TACGATCGCCCAGTGAGG GCTCTGTGGCTGCAAGG 340
2 TGCTTTTATCTTGGAAGCCAG GGGAGGCTGAGCATACAGTG 327
3 AAAGAACTGCCATCCCTAATG AAAAAGTTTGCTGATCCCTGA 457
4 CATACTGCTTTCTGCTCATTGG ATTTTCATGTACAATGTTAGGGC 744
5 TGAAGCGTATCATGCACAATC ATATCTGCCCAAGGGAGCTG 275
6-1 AGGGTTGAATGATCCCCAC AAATGCGCAACTGTCTCTTG 459
6-2 AACATGACCTACAGGTGGGG TGTGAATCCCATGATCTAGGC 435
7 GACTGAGGCTCTGATGTTGG TCAATCCTTGCCTATTTGCAC 304
8 AGGCTGGGAGCTGTAGACTG GCATAATACACAATGCCATTCC 399
9 GAAACACCATTCTAACACCTAGC AGCAGTGCTTCAATGCAAAG 569
10 AGAGGCCACAGCTTTGATTAG TTTCCCTGTCATAACACCTCG 341
11 AGGATGAGGAAATATGGAAGC TTGCTCAATTGTCAGTCATGG 290
12 GGCCTGCTTGGTCTTTGATAC TCCTGAACTGGAGTCCTCTG 404
13-1 GCTTCCACAGAGAGCAGAGG ACTGCTATGAGGGGAACGTG 490
13-2 CCTTCTCAGTTTCGCAGTGG ATCTCACCGCTCCACCTTC 499
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Chapter 5: De novo mutations of SETBP1 cause Schinzel-Giedion syndrome
Table S14: Overview of exome-sequencing performance
Patient Total reads Uniquely mapped Reads overlapping Unique reads Mean coverage Number of
reads with targets called bases
Patient 1 89949891 58189014 46075589 29610185 47.32 196123687
Patient 2 86104150 55453009 45014396 27565627 47.43 178688964
Patient 3 88542531 52783914 40266883 28586694 40.43 195062516
Patient 4 61480688 52684110 38528450 27384374 36.71 213431228
Table S15: Overview of all variants identified by exome sequencing in 4 patients with Schinzel-
Giedion syndrome
Patient 1 Patient 2 Patient 3 Patient 4 Mean No. of genes with vari-
ants in all 4 samples
Total variants called 22916 22602 22152 19528 21800 4735
Exonic + SpliceSites (SS) (+/- 2nts in-
tronic) variants
12196 12255 11796 10498 11686 3331
Non-synonymous (NS) + SS variants 5556 5618 5427 4802 5351 1634
Unknown SNP variants (dbSNP130) 405 401 390 387 396 35
Unknown variants (in-house database) 299 289 275 288 288 12
Genes showing variants in at least 2 differ-
ent genomic positions
2
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Chapter 6: Exome sequencing identifies WDR35 variants involved in Sensenbrenner
syndrome
Table S17: Overview of exome-sequencing performance
Patient Total reads Uniquely mapped
reads
Reads overlapping
with targets
Unique reads Mean coverage
Patient 1 102,407,996 66,897,339 45,849,038 27,324,198 67.45
Patient 2 95,313,421 62,810,337 40,561,381 28,243,645 59.70
Table S18: Overview of all variants identified by exome sequencing in 2 patients with cranio-
ectodermal dysplasia
Patient 1 Patient 2 No. of genes
with variants in
both patients
Total variants called 22,723 22,094 6,446
Exonic + SpliceSites (SS) (+/- 2nts intronic) vari-
ants
12,243 13,230 4,684
Non-synonymous (NS) + SS variants + frameshifts 5,559 5,488 2,473
Unknown SNP variants (dbSNP130) 416 439 69
Unknown variants (in-house database) 169 211 6
Quality filtering (>= 4 and >= 20% variant reads) 139 158 6
Candidate genes according to a recessive disease
model. (compound heterozygous / homozygous)
3/0 4/0 1/0
Segregation analysis 2 2* 1
∗ One not conserved variant in USH2A was inherited maternally (Supplementary Table S19).
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Chapter 7: Exome sequencing identifies truncating mutations in human SERPINF1 in
autosomal-recessive osteogenesis imperfecta
Table S20: Exome sequencing statistics
Statistic Value
Total number of sequenced reads 94,888,765
Total number of mapped reads 77,281,481 (81.44%)
Total number of bases mapped 3,727,327,393
Total bases uniquely mapped 3,135,079,346 (84.11%)
Total bases mapping to targets 2,639,906,551 (70.83%)
% Targets with 10x coverage 92.90%
Mean target coverage 65.47
Table S21: Prioritization scheme for exome data analysis
Type of prioritization filter Number of remaining
variants
All variants 26922
Coding and canonical splice site (SS) variants after quality filtering (>5
variant reads, >15% variation)
13487
Non-synonymous variants, SS variants 6298
Not in dbSNP130 657
Not in in-house database 318
Homozygous variants (>80% variation reads) 20
(of which autosomal) (17)
Of which overlap homozygous regions 3
The in-house database consists of data from in-house exome resequencing projects of patients with rare
syndromes (425,529 variants), from the 1000 genomes project, and of published data from various studies
(3,097,878 variants in total).1,213,214
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Table S22: Homozygous Regions Identified when Considering all SNP (dbSNP 130) Geno-
types Covered >15-Fold by Exome Sequencing Data
Chromosome Start Position
[hg 18, bp
position]
End Position
[hg 18, bp
position]
Number of SNP markers
(tolerated mismatches)
Size [bp]
Chr1 58,869,327 89,371,625 1,918 (6) 30,502,298
Chr6 8,007,840 11,293,519 1,526 (4) 3,285,679
Chr6 37,039,286 42,774,142 698 (2) 5,734,856
Chr11 5,109,976 5,301,257 555 (2) 191,281
Chr11 97,942,525 110,164,199 969 (2) 12,221,674
Chr17 97,058 3,091,589 568 (2) 2,994,531
Chr17 3,299,188 4,983,922 663 (2) 1,684,734
Table S23: Three Novel Homozygous Variants that are Non-Synonymous and Overlap with
Homozygous Regions
Chrom. position reference mutation reads variation
reads
% varia-
tion
Abberation Gene
name
Gene id Ref-
erence
Amino
Acid
Mutation
Amino
Acid
phyloP Grantham
Score
chr1 62,399,185 C T 39 39 100 substitution INADL NM_176877 T M -0.94 81
chr1 82,181,925 A G 103 103 100 substitution LPHN2 NM_012302 Q R 2.58 43
chr17 1,625,154 C G 18 18 100 substitution SERPINF1 NM_002615 Y X 0.99 NA
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Chapter 8: A de novo paradigm for mental retardation
Table S24: Overview of exome-sequencing performance
reads sequenced reads mapped bps mapped % mapping to targeted
sequence∗
MR trio 1
Mother 75,539,970 62,421,598 2,994,163,125 84.3
Father 60,482,344 49,757,641 2,359,196,222 79.7
Patient 83,750,821 63,968,695 2,993,659,326 82.4
MR trio 2
Mother 61,213,042 45,635,581 2,129,184,998 79.5
Father 81,822,660 64,920,388 3,101,222,088 83.8
Patient 81,274,402 63,413,997 2,998,226,897 80.1
MR trio 3
Mother 91,218,082 65,444,907 3,111,727,311 82.4
Father 90,482,575 66,637,781 3,174,885,071 83.4
Patient 89,089,332 63,253,491 2,987,977,994 82.5
MR trio 4
Mother 89,715,373 63,797,713 3,045,658,184 83.3
Father 80,613,693 64,548,447 3,100,745,735 82.7
Patient 84,917,415 65,900,711 3,147,306,800 83.7
MR trio 5
Mother 95,997,554 75,047,477 3,635,298,749 77.3
Father 85,743,467 61,089,261 2,939,733,902 74.3
Patient 72,400,831 55,557,595 2,658,661,406 71.5
MR trio 6
Mother 77,312,957 66,715,554 3,208,045,277 70.1
Father 82,262,575 63,187,587 3,006,761,015 71.8
Patient 74,889,401 57,633,832 2,769,859,304 71.7
MR trio 7
Mother 88,884,506 67,665,146 3,207,116,037 76.3
Father 93,174,731 72,970,692 3,483,792,759 81.0
Patient 76,030,490 58,908,643 2,789,555,317 81.2
MR trio 8
Mother 82,506,855 66,109,620 3,185,522,297 70.4
Father 55,116,325 45,653,877 2,163,335,572 76.5
Patient 81,579,330 63,654,731 3,047,698,346 69.9
MR trio 9
Mother 88,622,619 69,950,138 3,363,461,864 76.3
Father 95,568,766 82,036,334 3,985,154,541 77.9
Patient 83,296,156 62,687,172 3,032,856,030 77.4
MR trio 10
Mother 90,342,631 73,134,022 3,537,828,588 77.8
Father 95,285,830 79,698,200 3,875,693,431 81.6
Patient 87,139,147 67,783,275 3,255,909,349 80.6
Over all 30 individuals
Median 83,523,489 64,258,571 3,074,222,041 79.6
Min 55,116,325 45,635,581 2,129,184,998 69.9
Max 95,997,554 82,036,334 3,985,154,541 84.3
∗Defined as the sum of bases mapping to the SureSelect bait and one read length (50 bp) away from the Sure
Select bait.
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Supplementary Tables
Chapter 9: Next generation genetic testing for Retinis Pigmentosa
Table S27: Known disease-causing mutations in 12 DNA samples of patients with autosomal
recessive retinal dystrophy
sample gene allele 1 - cDNA allele 1 - protein allele 2 - cDNA allele 2 - protein phenotype
10064 RDH5 c.214_215insGTGG p.A72GfsX15 c.914C>G p.C267W FAP
10559 CNGB3 c.1148delC p.T383IfsX13 c.819_826del8bp p.R274VfsX12 ACHM
10719 CNGA3 c.1565T>C p.I522T c.1641C>A p.F547L ACHM
13079 NPHP5 c.424_425delTT p.F142fsX146 c.1535_1536insATAGC p.Q512X LCA/SLS
18459 RPE65 c.1102T>C p.Y368H c.11+5G>A splice defect LCA
18872 CEP290 c.2991+1655G>A p.C998X/wt c.451C>T p.R151X/∆Exon7/∆Exon7+8 LCA
21067 GUCY2D c.2302C>T p.R768W c.2837C>T p.A946V LCA
21933 RP1 c.4241_4242delTA p.H1414QfsX5 c.368_369dupGC p.P124AfsX20 arRP
21974 GRM6 c.57_75dupl19 p.V26X c.172G>C p.G58R arCSNB
29964 CFH c.1222C>T p.Q408X c.1204T>C p.Y402H arBLD
36392 KCNV2 c.556_571del16 p.G186GfsX20 c.1381G>A p.G461R arCD
44010 PDE6C c.633G>C splice defect c.1363A>G p.M455V ACHM
Abbreviations: ACHM, achromatopsia; arBLD, autosomal recessive basal laminar drusen; arCD, autosomal re-
cessive cone dystrophy; arCSNB, autosomal recessive congenital stationary night blindness; arRP, autosomal
recessive RP; FAP, fundus albipunctatus; LCA, Leber congenital amaurosis; SLS, Senior Loken syndrome.
Table S31: Clinical characteristics of all RP patients
Proband Gender Age of onset RD (yrs) Retinal phenotype Extra-ocular abnormalities (Probable) causative gene Unknown
7554* F 7 CRD - ABCA4
8322 M 38 RP - TOPORS (potentially de novo)
8625 F 16 RP - IMPG2
9398 M 20 RP Hearing loss
9402 M 1st decade RP - CC2D2A
9437** M 20 RP Hearing loss USH2A
9444 M 20 RP -
9470 M 22 RP - RP2
9472 M 6 RP - PDE6B
9493 M unknown RP - PDE6B
9506 M 15 RP Congenital hearing loss
9509 F unknown RP Unilateral hearing loss
9511 M 35 RP - RP1
9518 M unknown RP - RP1
9520 F 25 RP -
9527 M unknown RP -
9528 M 26 RP -
9537 F 31 RP -
9539 M unknown RP -
9543 M unknown RP -
9552 F 36 RP -
11005 M 37 RP -
11319 M unknown RP - RPGRIP1L, SNRNP200
11893 M 68 RP -
11919 F 25 RP -
13023 F 49 RP Neurosensory hearing loss
13480 M unknown RP - RPE65
14181 F unknown RP -
14182 F 25 RP -
14192 M 29 RP -
14267 M unknown RP -
14428 F unknown RP -
14705 F 35 RP -
14812 M unknown RP -
15569 F 50 RP - PRPH2 SNRNP200
16389 M unknown Secundary photore-
ceptor damage due to
uveïtis ODS
-
16430 F 15 RP -
17593 M unknown RP
17597 F 44 RP - USH2A
17792 F unknown RP RHO (potentially de novo)
18060 F 9 RP - SPATA7
18130 F unknown RP -
18336 M 27 RP - PDE6B
18351 F 16 RP -
18390 F 10 Juvenile MD ABCA4
18777 F 5 Early-onset RP Mild intellectual disability, obesitas SNRNP200
19081 F unknown RP - TOPORS (ad)
Continued on next page
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Proband Gender Age of onset RD (yrs) Retinal phenotype Extra-ocular abnormalities (Probable) causative gene Unknown
19531 F 8 RP
19689 F unknown RP -
19693 M 12 RP - PDE6B
19733 F 61 RP - USH2A
19735 F Childhood LCA / EOSRD Tinnitus: BAE normal RPE65
20703 M 4 RP Wilm’s tumor ABCA4
20984 F 10 RP - PDE6B
21010 M 6 EOSRD -
21017 M 6 EOSRD -
21141** M Congenital LCA / EOSRD (Mild) intellectual disability CEP290
21213 F 50 RP -
21334* M Congenital CSNB - CACNA1F
21384 F 9 RP -
21642 F 20 RP -
21933 M unknown RP Hypertension RP1 SEMA4A
22312 M 15 RP - GUCY2D (potentially de novo)
22315 M 10 RP - RHO (de novo)
22383 M 16 RP - USH2A
22393 M 10 RP Age-related mild hearing loss,
psoriasis
PDE6B
22731 F 43 RP Diabetes mellitus, hypertension,
hearing loss
22777 F 39 RP - USH2A
23224 M 7 RP -
23422 F 28 RP -
27528 M 11 RP -
27585 M unknown RP -
27790 M 18 RP - PRPF31 (de novo)
28064 M 45 RP Mantle cell lymphoma
28557 F 35 RP - USH2A(one allele de novo)
28692 F 58 RP Malignant hypertension with renal
failure, followed by transplant
29883 M 18 RP -
30364 M 26 RP -
31035 M 45 RP - NR2E3 (potentially de novo)
31124 M 29 RP - USH2A
31343 F 34 RP Epilepsy USH2A
31494 F 34 RP Subtle hearing loss, fibromyalgia CRX
31723** F 9 RP Obesity, familial hypercholes-
terolemia, recurrent cystitis (5
yrs), heart murmur
ARL6
31910 F 58 RP Cardiomyopathy (hypertrophic) EYS
31933 M 19 RP - CRB1
31994 M 40 RP Secundary diabetes mellitus type
1 (due to pancreatitis)
RHO
32111 F 58 RP Diabetes mellitus type 2
32594 M 1 Early-onset CPRD Ferriprive anemia NRL
32655 M 4 EOSRD - RP2
32825 F 28 RP -
33626 F 29 RP - USH2A
33672 M 26 RP - RDH12
33884 F 33 RP -
34624 M Childhood RP -
34886 F unknown RP Hyperornithemia
36832 F 65 RP -
37360 M 18 RP -
37370 F 4 EOSRD - RLBP1
38290 F 8 RP -
41611 F unknown RP - TRPM1
Clinical characteristics of all 100 RP patients that were analyzed in this study. *Although these patients were
initially diagnosed with RP, clinical reassessment upon identification of the genetic causes led to a re-appreasal
of the retinal phenotype as indicated in the fourth column. ** Upon identification of the causative gene, patients
were diagnosed with extra-ocular features previously reported to be associated with the corresponding genes.
Abbreviations: CPRD: clumped pigmentary retinal degeneration; CSNB: congenital stationary night blindness;
EOSRD:early-onset severe retinal degeneration; LCA: Leber congenital amaurosis; MD; macular dystrophy; RP;
retinitis pigmentosa.
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Supplementary Tables
Table S32: Pathogenic missense mutations identified by exome sequencing studies, with their
evolutionary conservation
Chromosome Position (hg18) Gene Conservation
(PhyloP)
Position within
codon
Nucleotide
change
Wild type amino
acid
Mutated amino
acid
chr11 69729915 FADD -0.67 3 T>G C W
chr6 44380227 AARS2 0.27 1 C>T R W
chr12 47712152 MLL2 0.36 3 C>T Q STOP
chr12 47718918 MLL2 0.56 1 C>T R STOP
chr12 47706398 MLL2 0.76 3 T>G Y STOP
chr16 70613786 DHODH 0.90 1 C>T R W
chr5 118890750 HSD17B4 0.99 3 T>A Y STOP
chr10 121419383 BAG3 1.08 1 C>T R W
chr5 148386628 CMT 1.08 1 C>T R STOP
chr10 121419602 BAG3 1.16 1 A>G T A
chr3 130111584 ACAD9 1.44 1 C>T R W
chr5 148402474 CMT 1.47 1 T>C Y H
chr3 130107753 ACAD9 1.60 1 C>T R C
chr12 47711008 MLL2 1.68 1 C>T R STOP
chr12 47717445 MLL2 1.92 1 C>T R STOP
chr12 47702113 MLL2 2.22 1 C>T R STOP
chr8 99222235 POP1 2.29 1 C>T R STOP
chr12 47707306 MLL2 2.29 1 C>T R STOP
chr10 121419452 BAG3 2.39 1 A>T I F
chr10 121421902 BAG3 2.40 2 G>A R Q
chr12 47712058 MLL2 2.51 1 C>T Q STOP
chr20 2346091 TGM6 2.65 2 T>G L W
chr16 70612601 DHODH 2.70 1 C>T R C
chr3 130081354 ACAD9 2.76 1 T>A F I
chr12 47712514 MLL2 2.76 1 C>T Q STOP
chr8 58053250 IMPAD1 2.88 1 C>T R STOP
chr10 121422033 BAG3 3.06 1 G>A A T
chr10 121419498 BAG3 3.35 2 A>G H R
chr1 26994134 PIGV 3.57 2 C>A/C>T A V/E
chr16 70606041 DHODH 3.62 1 C>T R C
chr12 47706480 MLL2 3.69 2 G>A R H
chr16 70615586 DHODH 3.95 2 A>G D G
chr16 70603484 DHODH 3.95 2 G>A G E
chr16 70614936 DHODH 4.00 1 C>T R W
chr8 58055151 IMPAD1 4.04 1 A>C T P
chr16 70614596 DHODH 4.17 2 C>T T I
chr20 2329081 TGM6 4.28 2 A>G D G
chr12 47711035 MLL2 4.40 1 A>T K STOP
chr19 14536653 TECR 4.53 2 C>T P L
chr8 58055169 IMPAD1 4.67 1 G>A D N
chr2 20009029 WDR35 4.90 2 A>G E G
chr12 47706821 MLL2 4.97 3 G>A W STOP
chr1 26994266 PIGV 4.99 2 A>C H P
chr12 47706690 MLL2 5.06 2 G>T C F
chr5 118852813 HSD17B4 5.08 2 A>G Y C
chr6 44387222 AARS2 5.10 2 T>G L R
chr18 40785915 SETBP1 5.13 2 T>C I T
chr1 26993878 PIGV 5.23 1 C>A Q K
chr12 47706375 MLL2 5.24 2 G>A R H
chr12 47704661 MLL2 5.29 2 G>T R L
chr1 26637306 DHDDS 5.36 1 A>G K E
chr18 40785906 SETBP1 5.65 2 A>C D A
chr2 19996711 WDR35 5.70 1 G>A A T
chr12 47713606 MLL2 5.78 1 C>T Q STOP
chr3 130105612 ACAD9 5.86 1 G>A A P
chr12 47706799 MLL2 5.88 1 C>T Q STOP
chr12 47721525 MLL2 5.89 1 C>T R STOP
chr8 99230256 POP1 5.89 2 G>A G E
chr11 65527331 BANF1 5.94 1 G>A A T
chr12 47711365 MLL2 5.99 1 C>T Q STOP
chr12 47724914 MLL2 6.13 1 C>T R STOP
chr3 130100983 ACAD9 6.18 2 G>A R Q
chr12 47702351 MLL2 6.21 2 C>T T M
chr12 47702382 MLL2 6.21 1 C>T R STOP
chr12 47722238 MLL2 6.29 1 C>T Q STOP
chr12 47714119 MLL2 6.36 1 C>T Q STOP
chr10 121426486 BAG3 6.39 2 G>A R H
chr16 70608443 DHODH 6.68 1 G>A G R
chr16 70612611 DHODH 6.70 2 G>C G A
chr18 40785905 SETBP1 7.13 1 G>A D N
chr18 40785911 SETBP1 7.13 1 G>A G S
chr18 40785912 SETBP1 7.13 2 G>A G D
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Disease gene identification through Next Generation
Sequencing
Identifying genes which when damaged lead to disease is of importance for many reasons.
When the genetic cause for a disease has been identified patients can be diagnosed, thereby
giving definite answers concerning their exact disorder and the cause of it. Hereby it is pos-
sible to (1) predict the course of the disease on the basis of other diagnosed patients; (2) to
screen embryos preventively for the disorder, and (3) to start studies into possible treatments
for the disorder. Identifying the genetic cause for heritable disorders is very difficult and
time-intensive with traditional techniques and in many cases these methods will be unable
to identify the genetic cause. The introduction of a new technology called Next Generation
Sequencing (NGS) makes it possible to read the DNA much faster than before. In this the-
sis I examine the possibilities of using this technique for the identification of genes that are
responsible for diseases with different genetic backgrounds.
We first evaluate NGS in Chapter 2 by screening the DNA of 7 known genes in 10 patients
with a recessive form of ataxia, a neurological disorder that causes difficulties in muscle coor-
dination. By sequencing these known genes we successfully identified the known pathogenic
mutations in these patients, proving the feasibility of this approach for the identification of
pathogenic DNA mutations.
In the following chapters (3 and 4) we use NGS to screen regions in the genome that were
previously implicated in the disease by classical techniques, but for which no pathogenic mu-
tation was identified. In both cases this screen yielded several thousands of genomic variants.
By using prioritization strategies we found that dominant mutations in TSPAN12 are involved in
a blindness disorder called familial exudative vitreoretinopathy (Chapter 3), and that recessive
mutations in ANO10 are a new cause of ataxia (Chapter 4).
In Chapter 5 we screened all genes in the DNA (i.e., the exome) of four sporadic patients
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with a rare dominant developmental disorder called Schinzel-Giedion syndrome. In this case
there was no additional information about a specific genomic locus that was implicated in the
disease. Screening the exome resulted in several ten thousands of variants, but by comparing
all genomic variants from multiple patients we identified de novo changes in a single gene,
SETBP1, as the cause for this disorder. Because of the very confined location of these mu-
tations we speculated that these mutations do not inhibit the production of this protein, but
change its function. We were the first to show that it is possible to screen all genes simulta-
neously and identify the causative gene for a dominant disorder without any prior knowledge.
In Chapter 6 we showed that this unbiased approach, in which we look at all genes simultane-
ously, also works when using only a single patient with a recessive disorder. In this analysis we
focused specifically on variants that fit the recessive inheritance of Sensenbrenner syndrome,
another rare developmental disorder. In doing so we identify mutations in gene WDR35 as a
cause for Sensenbrenner syndrome. Interestingly in both patients we identified a combination
of a truncating and missense variant, and it now turns out that the combination of two truncat-
ing mutations in this gene leads to a more severe disorder, namely short-rib polydactyly.
In Chapter 7 we screen the exome of a patient with a recessive form of osteogenesis imper-
fecta, a condition causing extremely fragile bones. The patient’s parents are consanguine and
we hypothesize that the genetic cause lies in a genomic region that is shared by both parents.
By selecting variants in the patient that come from these shared regions we identify mutations
in the gene SERPINF1 as a new genetic cause for osteogenesis imperfecta. We were the first
to use such an approach, based solely on NGS data.
In Chapter 8 we investigate the DNA of 10 sporadic patients with intellectual disability and
that of their parents. In no less than 6 of these patients we identify new mutations that were
not inherited from the parents and likely underly the disease. Thereby we conclude that these
so called de novo mutations are an important cause of reproductively lethal diseases such as
intellectual disability.
The importance of these findings for diagnostic applications is confirmed in Chapter 11 where
we apply NGS as a diagnostic tool to identify the genetic cause in 100 patients with a geneti-
cally heterogenous disorder, namely blindness. We screen the DNA of more than 100 known
blindness genes after which we apply a methodological variant calling and interpretation pro-
cedure. Within this cohort of 100 patients we identify mutations that have likely occurred de
novo in 7 patients. In total we identify the genetic cause of the disease in 37% of the patients.
This is a much higher diagnostic yield than with any existing diagnostic test for this disease,
thereby showing the potential for diagnostic applications of NGS.
In the final chapters we review the different strategies that underly the successful application of
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NGS technology for the identification of disease genes (Chapter 10), and discuss the influence
of new insights that were gained with this technology in the last two years (Chapter 11). The
final discussion looks ahead into the future of this technology and how it will change genetic
research, genetic diagnosis and perhaps society, in the next 10 years.
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Samenvatting
De identificatie van ziekte genen door middel van een
nieuwe generatie sequentie technologieën
Het identificeren van genen die, wanneer ze beschadigd zijn, tot ziekte leiden is om veel rede-
nen belangrijk. Wanneer de genetische oorzaak voor een ziekte eenmaal bepaald is kunnen
patiënten gediagnosticeerd worden, daarbij uitsluitsel gevend over hun precieze aandoening
en de oorzaak ervan. Hierdoor is het mogelijk om (1) voor patiënten het verloop van de ziekte
te voorspellen op basis van andere gediagnosticeerde patiënten; (2) embryo’s preventief te
controleren op deze ziekte, en (3) onderzoek te starten naar eventuele behandelingen voor de
aandoening. Het identificeren van de genetisch oorzaak voor erfelijke aandoeningen is met
traditionele technieken erg moeilijk en tijdsintensief. In vele gevallen zullen deze methoden
zelfs niet in staat zijn om de genetisch oorzaak te achterhalen. De introductie van een nieuwe
technologie genaamd "Next generation sequencing" (NGS) heeft er echter toe geleid dat het
uitlezen van DNA nu veel sneller kan. In dit proefschrift onderzoek ik de mogelijkheden om
deze techniek te gebruiken voor het identificeren van genen die verantwoordelijk zijn voor
ziektes met verschillende genetisch achtergronden.
Eerst evalueren we NGS in hoofdstuk 2 en bekijken we het DNA van 7 bekende genen van
10 patiënten met een recessieve vorm van ataxie, een neuronale aandoening die leidt tot
problemen bij het coördineren van spieren. Door het uitlezen (sequencen) van deze bekende
genen vinden we de vooraf bekende pathogene mutaties terug in deze patiënten, waarmee
we aantonen dat deze methode geschikt is voor het vinden van causatieve mutaties in het
DNA.
In de daaropvolgende hoofdstukken (3 en 4) gebruiken we NGS voor het bekijken van regio’s
in het genoom die eerder al betrokken waren bij de aandoening door middel van klassieke
technieken, maar waarvoor nog geen causatieve mutatie was gevonden. In beide gevallen
vonden we enkele duizenden genetische varianten. Door het toepassen van prioritizerings
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methoden vonden we dat dominante mutaties in gen TSPAN12 betrokken zijn bij een familiare
blindheids aandoening (hoofdstuk 3) en dat recessieve mutaties in gen ANO10 een nieuwe
oorzaak zijn voor ataxie (hoofdstuk 4).
In hoofdstuk 5 kijken we naar alle genen in het DNA (het exoom) voor 4 patiënten met een
zeldzame dominante ontwikkelingsaandoening genaamd Schinzel-Giedion syndroom. In dit
geval was er geen extra informatie beschikbaar over een specifieke genomische regio die
betrokken was bij de ziekte. Het bekijken van alle genen resulteerde in enkele tienduizenden
varianten, maar doormiddel van het vergelijken van de varianten van meerdere patiënten
vonden we nieuw ontstane (de novo) mutaties in een enkel gen, SETBP1, als de oorzaak
voor deze ziekte. Omdat alle mutaties heel dicht bij elkaar lagen op het genoom vermoeden
we dat deze mutaties het gen niet uitschakelen maar de functie van het resulterende proteïne
veranderen. Met deze bevindingen waren we de eersten die aantoonden dat het mogelijk is
om doormiddel van het bekijken van alle genen, en zonder voorkennis, de genetische oorzaak
voor een dominante aandoening te vinden.
In hoofdstuk 6 laten we zien deze aanpak, om zonder voorkennis alle genen te bekijken, ook
werkt voor een enkele patiënt met een recessieve aandoening. We richtten ons op varianten
die passen bij de recessieve overerving van Sensenbrenner syndroom, een andere zeldzame
ontwikkelingsaandoening. Hiermee vonden we dat mutaties in gen WDR35 een oorzaak kun-
nen zijn voor Sensenbrenner syndroom. Opvallend genoeg vonden we in beide patiënten
een combinatie van een truncerende mutatie en een missense mutatie, en het blijkt nu dat
de combinatie van twee truncerende mutaties in dit gen leidt tot een veel ernstigere ziekte,
namelijk "short-rib polydactyly".
In hoofdstuk 7 bekijken we het exoom van een patiënt met een recessieve vorm van osteo-
genesis imperfecta, een aandoening die zorgt voor extreem breekbare botten. Omdat de
ouders van de patiënt familie van elkaar zijn vermoeden we dat de genetische oorzaak in een
genomische regio ligt die beide ouders delen. Door het selecteren van varianten in de patiënt,
die liggen in deze gedeelde regio’s vonden we mutaties in gen SERPINF1 als een nieuwe
oorzaak voor osteogenesis imperfecta. We waren de eersten die een dergelijke methode
gebruikten enkel met behulp van NGS data.
In hoofdstuk 8 bekijken we het DNA van 10 patiënten met verstandelijke handicap en het
DNA van hun ouders. In maar liefst 6 van deze patiënten vinden we nieuwe mutaties die niet
overerft zijn van de ouders, en die waarschijnlijk een rol spelen in de aandoening. Hierdoor
concluderen we dat deze de novo mutaties een belangrijke oorzaak zijn van aandoeningen
die vanwege hun ernst niet vaak overerft worden, zoals verstandelijke handicap.
Het belang van deze bevindingen voor diagnostische toepassingen wordt bevestigd in hoofd-
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stuk 9 waar we NGS gebruiken als diagnostisch instrument om de genetische oorzaak te
achterhalen in 100 patiënten met een genetisch heterogene ziekte, namelijk blindheid. We
doorzochten het DNA van meer dan 100 bekende blindheids genen waarna we op methodol-
ogische wijze varianten identificeerden en interpreteerden. In ons cohort van 100 patiënten
vonden we 7 patiënten met mutaties die naar alle waarschijnlijkheid nieuw ontstaan zijn. In
totaal vonden we de genetische oorzaak in 37% van onze patiënten. Dit is een veel betere
diagnostische opbrengst dan met bestaande diagnostische testen voor deze aandoening,
waarmee we de grote mogelijkheden van NGS als diagnostisch middel aantonen.
In de laatste hoofdstukken beschrijven we verschillende strategieën die ten grondslag liggen
aan het succesvol toepassen van NGS technologie, voor het vinden van nieuwe ziekte genen
(hoofdstuk 10) en bespreken we de invloed van de bevindingen die met deze technologie
in de laatste twee jaar gedaan zijn, op onze visie van Mendeliaanse genetisch aandoeningen
(hoofdstuk 11). De discussie blikt vervolgens vooruit op de verdere technologisch ontwikkelin-
gen voor beter uitlezen van DNA, en de invloed hiervan op toekomstig genetisch onderzoek,
genetische diagnostiek, en de invloed die dit wellicht zal hebben op onze samenleving, in de
komende 10 jaar.
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